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SUMMARY
Cysteine conjugate p-lyase (CS-lyase) [glutamine transam inase K 
(GTK) / kynurenine am inotransferase (KAT)] is involved in  the toxicity of 
certain halogenated alkenes by metabolising their corresponding cysteine S- 
conjugates into reactive metabolites. These are know n to produce m arked 
nephrotoxicity and neurotoxicity in  experimental animals. The KAT 
activity has been linked to neurom odulatory pathways which are the target 
of therapeutic strategies for the treatm ent of neurodegenerative disorders. 
There is substantial evidence to suggest that CS-lyase/GTK/KAT is 
horm onally m odulated following reports of differences in the levels of 
activity of this enzyme between male and female rodents, and between 
young and m ature anim als. Therefore, to understand in greater depth the 
regulation of CS-lyase/GTK/KAT gene expression, the ability of horm ones 
to m odulate this enzyme was studied.
The ability of the glucocorticoid and sex horm ones to m odulate CS- 
lyase/GTK/KAT activity in  male rat brain and kidney, during post-natal 
developm ent, was studied. Corticosterone treatm ent significantly increased 
GTK specific activity in  both kidney and brain tissue. This induction was 
observed at post-natal days 19,21,23,25 and 30. Following adm inistration of 
dexamethasone, induction was also observed, however, this was restricted 
to post-natal day 21 in both tissues. Progesterone was the only sex horm one 
found to induce GTK activity in  post-natal day 21 m ale rat kidney and brain. 
The pattern of induction was comparable to the effect produced by
dexamethasone treatm ent. GTK activity was induced at post-natal day 21 in 
the kidney and post-natal days 21,23 and 25 in the brain. This study clearly 
dem onstrated an age-related influence on the susceptibility of GTK to 
induction by these horm ones which supports the proposal that CS- 
lyase/ GTK/KAT is developm entally m odulated in  the post-natal m ale rat.
Long distance PGR techniques have been employed to isolate and sequence 
the upstream  regulatory region from the rat CS-lyase/GTK/KAT gene and 
to identify horm one response elements. Using gene-specific primers, 
designed against the non-coding region of the know n rat renal CS-lyase 
cDNA sequence, 'genom ewalking' experiments yielded a Ikb sequence. 
Following, cloning into a pCR®2.1-TOPO TA vector and DNA sequencing 
of the Ikb insert, no horm one response elements or other regulatory motifs 
were identified. TATA and CAAT boxes were present in  the sequence, 
indicating that a region of the upstream  sequence had been isolated. This 
suggests that the regulatory sequence motifs are located further upstream .
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CHAPTER 1 
INTRODUCTION
1.1. GENERAL INTRODUCTION
Halogenated hydrocarbons have received m uch attention from toxicologists 
over the last few decades following the finding that exposure to these 
compounds can lead to toxicity in rodents (Lock, 1988). Halogenated 
hydrocarbons are m ajor constituents of many industrial preparations including 
dry-cleaning fluids, industrial solvents, and degreasers. The exact m echanism  
of toxicity resulting from exposure to these com pounds has yet to be fully 
confirmed but several theories are under investigation. This in troduction will 
discuss the evidence supporting the involvem ent of cysteine conjugate P-lyase 
(CS-lyase) in halogenated hydrocarbon toxicity and in the general m etabolism  
of xenobiotics. In addition, the function of CS-Lyase/Glutamine 
Transam inase K /K ynurenine Am inotransferase (CS-lyase/GTK/KAT) in the 
central nervous system (CNS) and its role in  the developm ent of several 
neuropathologies will be reviewed.
1.1.1. The Detoxification of Xenobiotics
Foreign chemicals which can enter the body are collectively know n as 
xenobiotics and many are capable of inducing toxicity through conversion to 
highly reactive compounds containing electrophiles, free radicals (Aust et ah, 
1993), nucleophiles, or redox-active reactants (Kappus, 1986). In order to combat
1
these bioactivations, m echanism s exist m v ivo  to detoxicate the compounds by 
a series of reactions know n as biotransformations, which ultim ately elim inate 
the toxin from the body, or prevent their formation. Generally, 
biotransform ation reactions detoxify xenobiotics w ith functional groups, 
nucleophiles, electrophiles, free radicals or protein toxins, converting them  
from highly lipophilic compounds (which favour absorption) to water soluble 
com pounds (which favour excretion in  the urine and faeces). A standard 
review of drug m etabolism from a historical perspective is given in Conti and 
Bickel (1977). A m ore recent review of xenobiotic metabolism can be found in 
Sheweita (2000).
The m ajor organ involved in biotransform ation reactions is the liver, m ainly 
due to it containing very high levels of the drug-metabolising enzymes, but 
also because it is the first organ to receive blood from the intestine and, 
transported w ithin that, xenobiotics which have been absorbed orally (Jakoby, 
1980; Jakoby & Ziegler, 1990; Sheweita, 2000). Some biotransform ations do 
occur in  extra-hepatic tissues although in  relatively sm aller quantities. This 
has toxicological significance to the organism as the highly reactive 
interm ediates generated from the biotransform ations may accumulate in  the 
organ in which they were produced, or they may be transported to target organs 
causing various degrees of toxicity. These biotransform ation reactions can be 
divided into two phases, I and II.
The reactions which feature prom inently in the first phase of xenobiotic 
m etabolism are hydrolysis, reduction, oxidation, hydration and some 
isom érisation reactions (see Sheweita, 2000). The m ajority of these are 
catalysed by enzyme systems which are commonly referred to as mixed 
function oxidase systems (MFOs). MFOs, including the cytochrome P450s, are 
located on the sm ooth endoplasmic reticulum  of many cells, especially of the 
liver, kidney, lung and intestines, and are induced by a vast range of 
xenobiotics (see Om ura & Sato, 1962; Sheweita, 2000; Thomas et al., 1976). The 
activity of MFOs results in  functionalisation of the xenobiotic rendering it a 
favourable substrate for Phase 11 detoxification reactions, typically through the 
introduction of functional groups to the molecule.
Phase 1 metabolism results in an increase in hydrophilicity of the compound, 
but the greatest change structurally to the xenobiotic is the conjugation of an 
endogenous, highly polar, molecule to the toxin in Phase 11 m etabolism  (see 
Sheweita, 2000). One of the most im portant conjugations is glucuronidation, 
but sulphation, méthylation, acétylation, am ino acid conjugation and 
glutathione conjugation all play a role in broadening the range of xenobiotics 
that the body is capable of biotransforming. A com m on feature of all of these 
conjugation reactions is the interaction between the cofactors required for 
reactivity and the functional groups which can be present either on the 
xenobiotic originally, or which are introduced or exposed during the Phase 1 
reactions.
The Phase II reactions of glucuronidation, sulphation, m éthylation and 
acétylation all involve high energy cofactors or active interm ediates (see 
Sheweita, 2000). Conversely, amino add  conjugation and glutathione 
conjugation involve interaction w ith the reactive or activated xenobiotic. The 
conjugation of glutathione in  Phase II metabolism will be focused on here as 
this pathway is im portant in the events preceding the role of CS-lyase.
1.1.2. Biosynthesis of Glutathione S-Conjugates
Glutathione has several functions w ithin the body including the storage of 
cysteine and enzyme regulation, but the m ost relevant to this study is cellular 
defence (Meister & Tate, 1976). This function is mediated by the intrinsic action 
of glutathione in protection against oxidative stress and free radicals (Meister, 
1992). G lutathione is a small tripeptide composed of glydne, cysteine and 
glutamic add, where the glutamic acid is conjugated to cysteine via the y- 
carboxyl group rather than the usual a-carboxyl group (Meister, 1988; Meister & 
Tate, 1976). The reaction m echanism  for the synthesis of glutathione is show n 
in Figure 1.1. As shown, y -glutamylcysteine synthetase forms a peptide linkage 
between cysteine and glutamic acid, followed by the addition of glydne due to 
the activity of glutathione synthetase in an ATP-dependent reaction.
Conjugation to glutathione occurs preferentially w ith electrophilic xenobiotics 
or those compounds which can be readily transform ed to electrophiles and is 
facilitated by the high concentration of glutathione (0.5-12mM) in  m ost tissues 
(see Jakoby, 1980). Conjugation of glutathione is catalysed by glutathione S-
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transferases (GSTs) (Chasseaud, 1979; Jakoby, 1980) which are located in the 
majority of tissues, w ith high activity in  the liver, kidney, intestine, testis, 
adrenal glands and the lungs. This activity is highest in the cytosolic, 
microsomal, m itochondrial and peroxisomal m em brane fractions (reviewed in 
Armstrong, 1997).
Cytosolic GSTs can be hom o- or heterodim eric in structure and are widely 
distributed throughout the body (see Armstrong, 1997). There are five 
m ultigene families of cytosolic GST, namely alpha, m u, pi, kappa and theta and 
they catalyse the reaction of the thiolate of glutathione to xenobiotics w ith 
electronegative atoms (Anders & Dekant, 1998). Cytosolic GSTs generally 
catalyse addition and addition-élim ination reactions, examples of w hich are 
show n in Figure 1.2.
H O O a .N K
cysteine
COOH
HOOC
glutamic acid
y-glutamylcysteine synthetase
COOH
HOOC
NHgCHgCOOH
glycine glutathione
synthetase
HOOC
ADP + Pi
COOH
glutathione
Figure 1.1. Synthesis and structure of glutathione.
As illustrated, the activity of y-glutamylcysteine synthetase results in  the 
form ation of a peptide bond between cysteine and glutam ic acid. Finally, 
glycine is attached to the dipeptide in  an ATP-dependent reaction catalysed by 
glutathione synthetase (Meister & Tate, 1976).
Reaction 1 : addition-élimination reaction
I'
1,1 -dichloroalkene
GSH/GST
X.
GS
X.
Cl
S-( 1,2,2-trihaloalkenyl) 
glutathione)
Reaction 2: addition and addition-élimination reactions
X.
F
1,1 -difluoroalkene
GSH/GST GS GS
^1. X.
H
S-( 1,2,2-trihaloalkenyl) S-( 1,1 -difluoro-2,2-dihalo- 
glutathione) alkenyl)glutathione)
Reaction 3: addition reaction
.Cl
Cl"
dichloroethane
GSH/GST
Cl
GS
H
Cl
S-( 1,2-dichloro vinyl) 
glutathione)
Figure 1.2. A ddition and addition-élim ination reactions of g lutathione 
catalysed by glutathione S-transf erase.
Reactions 1 and 2. Reaction of glutathione w ith haloalkenes. Reaction 3. 
Reaction of glutathione w ith dichloroethane. Figure adapted from Anders and 
Dekant (1998).
Microsomal GSTs are structurally unrelated to the cytosolic isoenzymes as they 
are predom inantly trim eric and are m em brane bound (Andersson et al., 1994). 
They catalyse addition reactions such as the reaction of glutathione w ith 
1,1-difluoroalkenes (Figure 1.2.) and have significant am ino acid identity w ith 
5-lipoxygenase-activating protein (FLAP) and to leukotriene Q  synthase 
(Jakobsson et ah, 1996). The m ain catalytic difference, compared to the cytosolic 
GSTs, is that microsomal GSTs are regio-specific and stereoselective, whereas 
cytosolic GSTs do not show such enantioselectivity. This difference has been 
used to define the relative contribution of microsomal and cytosolic GSTs to 
cellular glutathione S-conjugate form ation using chlorotrifluoroethene as the 
model substrate (Hargus et ah, 1991). It was already know n that microsom al 
GSTs selectively produce a 25 diastereomer {i.e. the molecule has two chiral 
carbons of S configuration). Using rat hepatic microsomes, rat hepatocytes or 
purified microsomal GST, an 80% excess of 2S diastereom er was found, 
indicating that intracellular glutathione S-conjugation is selectively catalysed 
by m icrosomal GSTs.
1.1.3. Enzymatic Processing of Glutathione S-Conjugates and Mercapturic Acid 
Biosynthesis
Mercapturic acid biosynthesis occurs predom inantly in the liver but can also 
take place in the proximal tubule of the kidney (see Jakoby, 1980). The 
biosynthesis of mercapturic acids involves the sequential hydrolysis of the 
peptide bonds in the xenobiotic glutathione conjugate (Meister & Tate, 1976).
Glutathione S-conjugates are excreted in  the bile to the small intestine due to 
their high molecular weight and the presence of an active transport system in 
the canalicular m em brane of the hepatocyte (Inoue et al., 1984; Vore, 1993). 
However, in the bile duct and the small intestinal epithelial cells, some 
glutathione S-conjugates are hydrolysed to the corresponding L-cysteinylglycine 
and L-cysteine S-conjugates (Gietl & Anders, 1991). The reaction m echanism  
show n in Figure 1.3. illustrates the biosynthesis of mercapturic acids w ith the 
initial step being the processing of the glutathione S-conjugate.
I.I.3.I. Hydrolysis of the y-Glutamyl Group of Glutathione
The first step in the conversion of glutathione S-conjugates to cysteine 
S-conjugates is the hydrolysis or transfer of the y-glutamyl group of the 
glutathione moiety to an appropriate acceptor by y-glutamyl transferase 
(Taniguchi & Dceda, 1998; Tate & Meister, 1974). Serine hydrolase y-glutamyl 
transferase catalyses the transfer of the D- or L-y-glutamyl group from  
y-glutamyl di- and tripeptides (such as glutathione) to acceptor am ino acids or 
dipeptides, y-Glutamyl transferase is the only know n enzyme to cleave 
glutathione and glutathione S-conjugates and was first identified in  kidney, 
where the highest levels are found (Tate & Meister, 1985). It is also present in  
the pancreas which displays 20% of the renal enzyme activity.
OOC'
o coo
'hs^  °
Glutathione
0 0 0 ' "N 
H
RS"
Glutathione S-conjugate 
Amino acid  ^
y-Glutamyl amino acid
0 0 0 ' "N 
H
L-Cysteinylglycine conjugateCysteine conjugate 
P-lyase pathway
Glycine
“O
AcetateRS'
/"'L-Cysteinyl conjugate 
Acetyl C o A j/^
V y l^  ^ Co ASH
OH"O
R S '
Mercapturate
Mercapturate sulphoxide
Cysteinyl S-conjugate 
sulphoxide
■OH3OOOOO- + NH4+ +RS-OH  
cysteine 
conjugate
Figure 1.3. Simplified illustration of the biosynthesis of mercapturic acids, 
from glutathione conjugates, and the alternative metabolic pathways of the L- 
cysteinyl conjugate.
1. glutathione S-transferase; 2. y-glutamyl transferase; 3. cysteinyl-glydne 
dipeptidase; 4. cysteine S-conjugate N-acetyltransferase; 5. cysteine conjugate 
P-lyase; 6. deacylase; 7. S-oxidase; 8. cysteine S-conjugate sulphoxide P-lyase.
Figure adapted from Cooper (1998).
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In the kidney, y-glutamyl transferase activity is present in the brush border of 
the proximal tubules, in the renal vasculature, and in  the basolateral 
m em branes of the P3 region of the renal proximal tubule (Goldberg, 1980; 
H inchm an & Ballatori, 1990). The enzyme is a heterodim eric glycoprotein 
composed of subunits of 22kDa and 46-51kDa (Goldberg, 1980; H inchm an & 
Ballatori, 1990). The heavy subunit is anchored to the lum enal surface of brush 
border m em branes through the hydrophobic N -term inal domain, w ith the 
active site oriented in the outer surface of cell m em branes (Horiuchi et al., 1978; 
Tate & Meister, 1985).
y-Glutamyl transferase activity has also been reported to be present in the 
intestinal m icrovilli (Kozak & Tate, 1982). Bile duct epithelia and the bile 
canaliculi of rat liver are also reported to have activity, but there is no activity 
in  the sinusoidal cells. However, in guinea pig, the bile canaliculi have very 
low levels of y-glutamyl transferase and the sinusoidal cells have very high 
activity, suggesting that there may be species differences in  the disposition of 
glutathione S-conjugates (Hinchm an & Ballatori, 1990).
I.I.3.2. Removal of Glycine from L-Cysteinylglycine S-Conjugates by
Peptidases
The next step in mercapturic acid biosynthesis is the conversion of the L- 
cysteinylglycine S-conjugate to a cysteine S-conjugate in  a hydrolysis reaction, 
catalysed by microsomal alanyl am inopeptidase (am inopeptidase M) or 
cysteinylglycine dipeptidase, w ith the latter being the m ost active (McIntyre &
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Curthoys, 1982). Am inopeptidase M is a zinc-containing protein of 
hom odim eric structure w ith a molecular weight of ISOkDa, which catalyses the 
cleavage of unblocked N -term inus am ino acids from dipeptides and 
oligopeptides and is located in liver, kidney, intestinal epithelia and the 
lum enal surface of m icrovillus m em branes (McIntyre & Curthoys, 1982; Tate, 
1985). It was later discovered that epididymal mem branes, which lack 
aminopeptidase M, could hydrolyse S-methylglutathione and this initiated the 
search for an additional dipeptidase (McIntyre & Curthoys, 1982). 
Cysteinylglycine dipeptidase, which is also a zinc-containing, hom odim eric 
protein of 50kDa subunit molecular weight was found to catalyse this reaction. 
The activity of cysteinylglycine dipeptidase is highest in  the kidney, followed by 
the liver, w ith lower levels found in  the intestines (Hughey et al., 1978). 
Significant activity has also been observed in the canalicular m em branes of rat 
hepatocytes, the lum enal m em brane of the biliary epithelia and also in 
pancreatic secretions (Ballatori et al., 1986).
I.I.3.3. Form ation of Mercapturic Acids by N -Acétylation of Cysteine S-
Conjugates
Norm ally in the biotransform ation of xenobiotics, cysteine conjugates will then  
be further converted into a m ercapturic acid derivative in an acétylation step 
which is catalysed by cysteine S-conjugate N-acetyltransferase (Figure 1.3.) and 
will finally be elim inated from the body in the urine (Duffel & Jakoby, 1982; 
Jakoby et al., 1984). N -Acetyltransferases are predom inantly located in  the 
endoplasmic reticulum  of kidney and liver cells (Green & Elce, 1975), but lower
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activities are found in  m any other tissues, as w ith other enzymes involved in 
xenobiotic biotransform ation. For catalysis, N-acetyltransferases require the 
co-substrate acetyl coenzyme A, but this reaction may be reversed via enzymatic 
deacetylation by deacetylase to regenerate the cysteine S-conjugate (Okajima et 
al., 1984). The conversion of the cysteine conjugate into a mercapturic acid is 
preferable for the purposes of excretion because there are active transporters 
available to aid the detoxification of organic acids. A standard review of the 
biosynthesis and processing of glutathione S-conjugates to mercapturic acids is 
given in  Anders and Dekant (1998).
1.1.4. Cysteine Conjugate p-Lyase and the Thiomethyl Shunt
The excretory pathway, described in the previous section, does not always occur 
and the further metabolism of some compounds, such as the haloalkenes, CS- 
lyase enzymes can cause undesirable effects in rodents in vivo  (Lash & Anders, 
1989; Lock, 1988; Lock & Ishmael, 1998; Lock & Ishmael, 1979; N ash et al., 1984). 
CS-lyase activity has been found in the gastrointestinal tract, liver, kidney and 
m ost recently in the brain (see Cooper, 1994). H um an toxicity due to CS-lyase 
activity was first indicated following the discovery that individuals w ho were 
working w ith industrial solvents, dry-cleaning fluids and degreasers, were 
suffering from nephropathologies (Mutti et al., 1992). The observed 
pathologies were proposed as being due to the metabolic processing of these 
compounds by CS-lyase and, subsequently, the probable specific localisation of 
these products generated this regional toxicity.
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In order to fully understand the toxic inducing effects of this enzyme, it is firstly 
vital to understand its m echanism  of action. Figure 1.4., Reaction 1, illustrates 
this alternative pathway (Elfarra & Anders, 1984; Stevens et al., 1986a). The 
toxic consequences of CS-lyase activity will be reviewed later. As show n also in 
Figure 1.3., rather than  undergoing the norm al pathway of m ercapturate 
formation, the cysteine S-conjugate, generated by the action of am inopeptidase 
M, liberating glycine and producing the cysteine S-conjugate, or by the action of 
deacetylase on the mercapturate, can then undergo conversion by CS-lyase and 
result in the form ation of am m onium , pyruvate and a thiol interm ediate, in a 
reaction know n as P-elim ination (Elfarra & Anders, 1984).
CS-lyase has been show n to be active w ith several com pounds bearing non ­
polar leaving groups on the P-carbon of an am ino acid substrate such as 
aromatic thioethers of cysteine, and aliphatic am ino acid derivatives of S-(l,2- 
dichlorovinyl)-L-cysteine (DCVC) and other haloalkenes (Dekant et al., 1994; 
Dekant et al., 1990; Koob & Dekant, 1991). All forms of CS-lyase have a 
pyridoxal phosphate (PLP) cofactor which is essential to m any functions of the 
enzyme (see Cooper, 1994).
The cysteine S-conjugate binds to the PLP via a free am ine group which forms a 
Schiff base (substituted imine) and opens up the active site of the enzym e 
(Stevens et ah, 1986b). Schiff bases are formed as an alternative to an 
unsubstituted im ine which are unstable and often polymerise on standing. 
The more stable Schiff base, however, is formed from a prim ary am ine w ith
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the am ino acid instead of amm onia. Following the ^-elim ination reaction, the 
PLP returns to an internal Schiff base, w ith a lysine residue w ithin  the active 
site, switching it off. One protective agent against the toxicity of CS-lyase is the 
com pound aminooxyacetic acid (AGAA) which is a PLP-dependent enzyme 
inhibitor and can, therefore, decrease the toxic effect of cysteine S-conjugates 
(Elfarra et al., 1986). The thiol resulting from this pathway can then  be further 
processed in a pathway know n as the "thiomethyl shunt" (Jakoby, 1978; Jakoby et 
al., 1984; W eisiger & Jakoby, 1979).
The purpose of the "thiomethyl shunt" pathway (Jakoby, 1978; Jakoby et al., 1984; 
Weisiger & Jakoby, 1979) in  xenobiotic metabolism is not fully understood as it 
shunts some mercapturic adds and cysteine S-conjugates away from the 
direction of the detoxification pathway, thereby avoiding elim ination from the 
body. The thiom ethyl shunt is catalysed by thiol-S-methyltransferase w hich 
converts the free thiol produced from the CS-lyase reaction into a thiom ethyl 
group. Figure 1.4., Reaction 2 (Jakoby, 1978; Weisiger & Jakoby, 1979). This 
thiom ethyl derivative is even less water soluble and can localise in areas of 
high fat content, such as adipose tissue and brain (Jakoby & Stevens, 1984). It is 
the unstable reactive electrophiles of the thiol which have been implicated in  
nephrotoxicity in the rat, and selective hum an  neurotoxicity, in  areas w here 
there are elevated levels of CS-lyase and other predisposing factors. Thus, 
metabolism by both the CS-lyase pathway and the "thiomethyl shunt" can 
increase the potential for xenobiotic toxicity in tissues expressing high levels of 
the enzymes involved in these pathways.
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Figure 1.4. The cysteine conjugate P-lyase pathway and the th iom ethyl shunt. 
Reaction 1 . The cysteine conjugate P-lyase (CS-lyase) pathway. The activity of 
CS-lyase yields pyruvate, am m onium  and a reactive thiol th rough  the cleavage 
of the cysteine S-conjugate.
Reaction 2. The thiom ethyl shunt pathway. Thiol-S-m ethyltransferase 
catalyses the m éthylation of the free thiol to produce the thiom ethyl group.
Figure adapted from Jakoby and Stevens (1984).
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1.2. GLUTATHIONE CONJUGATION AND XENOBIOHC BIOACTIVATION
Generally, the m ercapturate pathway is beneficial to the organism in rem oving 
potentially harm ful xenobiotics from the system, however, it can also act as a 
branch point for deleterious reactions. These bioactivation reactions occur 
particularly during the m etabolism of certain chemicals such as the 
haloalkenes and haloalkanes.
1 .2 .1 . Directly Toxic G lutathione S-Conjugates
Toxic glutathione S-conjugates which are direct-acting tend to be generated 
from vicinal dihaloalkanes through the form ation of electrophilic su lphur 
m ustards (Monks et aL, 1990). One good example is in the metabolism  of 
ethylene dibromide. This vicinal dihaloalkane can be metabolised to 
bromoacetaldehyde by cytochrome P450 and is thought to account for protein- 
binding of ethylene dibromide metabolites. G lutathione-dependent 
metabolism, on the other hand, is responsible for the binding of metabolites of 
ethylene dibromide to DNA (Shih & Hill, 1981) and therefore the mutagenicity 
of ethylene dibromide (Figure 1.5.). Ethylene dibromide is metabolised to 
S-(2-bromoethyl)-glutathione, a half su lphur m ustard, which non- 
enzymatically forms an episulphonium  ion for reaction w ith DNA (Koga et aL, 
1986; Peterson et al., 1988).
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GSH + Br
GST GS.
r Br
Ethylene dibromide S-(2-bromoethyl)glutathione
ADNA GS
NH O
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N
Figure 1.5. The glutathione-dependent bioactivation of ethylene dibromide.
The product of bioactivation, S-(2-bromoethyl)-glutathione, non-enzym atically 
forms an episu lphonium  ion which readily binds to DNA form ing an adduct, 
such as S-[2-(N^-guanyl)-ethyI]glutathione, as show n (see M onks et aL, 1990; 
Peterson et al., 1988).
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Geminal dihaloalkanes can also undergo glutathione-dependent bioactivation 
(Ahmed & Anders, 1978). The m etabolism of dichlorom ethane yields an initial 
metabolite, S-chloromethyl-glutathione, which is non-enzymatically converted 
into S-hydroxymethyl-glutathione. This is the hemim ercaptal of glutathione 
and formaldehyde which has been implicated in the developm ent of tum ours 
in dichloromethane-treated anim als (Reitz et al., 1989)
1.2.2. Glutathione S-Conjugates Acting as Transport and Targeting Metabolites
Glutathione S-conjugates can partake in 'redox cycling' w ith quinones and 
thereby contribute to the developm ent of oxidative stress state (Kappus, 1986). 
This is due to the ability of quinones to react directly w ith cellular nucleophiles, 
such as protein and non-protein sulphydryls, where glutathione is the m ajor 
cellular non-protein sulphydryl. One example is in the epithelial cells of the 
bovine lens, here a stable 2 ,6 -dim ethoxyquinone-glutathione free radical has 
been show n to cause cataracts (Wolff & Spector, 1987). In addition, it has been 
discovered that during the peroxidase-catalysed oxidation of p-phenetidine, 
three glutathione S-conjugates were present in  oxidised and reduced forms 
which were interchangeable during redox processes (Ross et al., 1985).
1.2.3. Glutathione S-Conjugates Requiring Further Bioactivation
The activity of y-glutamyl transferase can convert some glutathione 
S-conjugates to toxic metabolites (Monks & Lau, 1990). G lutathione 
S-conjugates of quinones and hydroquinones can act as transporters to tissues 
rich in y-glutamyl transferase, such as the kidney. Here they can be
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metabolised by y-glutamyl transferase to their corresponding cysteine 
S-conjugates, which are m ore easily oxidised to toxic quinone metabolites than  
the original hydroquinone. Additionally, the CS-lyase pathway can lead to 
nephrotoxicity and nephrocarcinogenicity in the m etabolism and bioactivation 
of the cysteine S-conjugates of haloalkanes and haloalkenes (see below).
1.3. TOXICITY OF GLUTATHIONE AND CYSTEINE S-CONJUGATES OF 
HALOGENATED ALKENES
Halogenated alkenes were originally show n to cause toxicity in cattle which 
had been fed trichloroethylene-extracted soybean oil meal (Stockman, 1916), 
and some forty years later DCVC was identified as the toxic factor (McKinney et 
aL, 1959). It is now know n that, following metabolism via CS-lyase, m any 
halogenated alkenes (haloalkenes) produce m arked toxicity (notably 
nephrotoxicity) in experimental animals, particularly rodents (Bernauer et aL, 
1996; Birner et aL, 1998; Com m andeur et aL, 1987; Dohn et aL, 1985; Elfarra et aL, 
1986; Finkelstein et aL, 1992; Jaffe et aL, 1983; Lock, 1988; Odum  & Green, 1984).
Analogues of S-haloalkyl glutathione and cysteine conjugates; S-(2-bromo-2- 
chloro-l,l-difluoroethyl)-glutathione and S-(2-bromo-2-chloro-l,l-difluoro- 
ethyl)-L-cysteine, are nephrotoxic in Fischer 344 rats (Finkelstein et aL, 1992). 
A dm inistration of these compounds results in diuresis, increased glucose and 
protein in urine, increased blood urea nitrogen (BUN), and increased 
kidneyrbody weight ratio. The proximal tubule cytotoxicity was prevented by 
the CS-lyase inhibitor AGAA (Finkelstein et aL, 1992). In hum ans, the finding
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that industrial workers exposed to trichloroethylene at high doses, over long 
time periods, developed cranial nerve palsies (Buxton & Hayward, 1967) was a 
further spur to work on this topic.
1.3.1. Interorgan Transport of S-Conjugates
Interorgan transport of S-conjugates from the liver (Figure 1.6.) (Com m andeur 
et al., 1991), and accumulation in the kidney, is necessary for the developm ent 
of nephrotoxicity and nephrocarcinogenicity following haloalkene and 
haloalkane exposure (Monks et al., 1990; Stevens & Jones, 1989). G lutathione 
S-conjugates formed in  the liver are secreted in  the bile via the small intestine 
(W ahllaender & Sies, 1979), due to their increased m olecular mass and the 
presence of active transport systems (Inoue et ah, 1981; Inoue et al., 1982; Vore,
1993). y-Glutamyl transferases and dipeptidases convert the hydrophilic
glutathione S-conjugate to a more lipophilic cysteine S-conjugate in  the bile 
and intestine (Figure 1.6.), which may be reabsorbed from the small intestine 
into the liver (Schaeffer & Stevens, 1987). Some glutathione S-conjugates are 
released into the general circulation and are hydrolysed by renal peptidases to 
their equivalent cysteine S-conjugate (Monks & Lau, 1987).
Also, cysteine S-conjugates can be N-acetylated by microsom al cysteine 
S-conjugate N-acetyltransferases to their corresponding m ercapturic acids 
(Com mandeur et al., 1991). The liver is the m ajor organ responsible for the 
metabolism of compounds which have been reabsorbed from the sm all 
intestine. Since this organ has high N-acetyltransferase activity, the m ajority of
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reabsorbed cysteine S-conjugates are N-acetylated here (Inoue et al., 1981; Inoue 
et al., 1982). These m ercapturic acids are then transported to the kidney and 
concentrated by an organic anion transporter (Lock & Ishmael, 1985). The 
majority of m ercapturic acids are then  excreted in the urine, however, the 
mercapturates of the haloalkenes are substrates for deacetylase (Com m andeur 
et al., 1989; Pratt & Lock, 1988). Ultimately, the nephrotoxic effect is produced by 
the bioactivation of the cysteine S-conjugate to reactive thiol interm ediates 
which can covalently bind to proteins (Anderson & Schultze, 1965; Hayden et 
al., 1991) and DNA (Bhattacharya & Schultze, 1972; Koga et al., 1986; M uller et 
al., 1998) leading to nephrotoxicity (Boogaard et al., 1989; C om m andeur et al., 
1996).
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Figure 1.6. Interorgan transport of glutathione and cysteine S-conjugates.
The diagram illustrates the interorgan transport of S-conjugates during the 
metabolism of a difluoroalkene.
1. glutathione S-transferase; 2. y -glutamyl transferases and dipeptidases; 
3. N-acetyl transferase; 4. deacetylase; 5. CS-lyase; = organic anion transporter. 
Figure adapted from Com m andeur et al (1991).
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1.3.2. Toxicity of Chlorinated Haloalkenes
Hexachloro-l,3-butadiene (HCBD) is a by-product in  the m anufacture of 
trichloroethylene and tetrachloroethylene (Hook et aL, 1983) and is metabolised 
to S-(l,2,3,4,4-pentachlorobutadienyl)glutathione (PCBDG) (Birner et aL, 1995; 
Birner et aL, 1998; Nash et aL, 1984). HCBD toxicity has been extensively 
studied in rat kidney, where an intraperitoneal (i.p.) dose of 2 0 0m g/kg was 
show n to result in necrosis of the pars recta (S3) section of the proximal tubule 
only eight hours after adm inistration (Birner et al., 1995; Ishmael et al., 1982). 
HCBD has been reported to selectively damage the renal organic anion uptake 
system and treatm ent w ith the inhibitor of organic anion uptake, probenecid, 
did not protect against nephrotoxicity (Hook et aL, 1982). A distinct band of 
proximal tubule necrosis was observed in the outer stripe of the m edulla after 
16 hours, and this persisted to 1 -2  days w ith no apparent damage to the distal 
tubules. Three days post treatm ent, nuclear vacuolisation was observed w ith  
some tubular regeneration five days after initial adm inistration (Hook et al., 
1982). A dult male rats have been show n to be less susceptible to nephrotoxicity 
than  adult females and young males, which has been proposed as being due to 
related differences in the hepatic and renal enzymes involved in detoxification, 
or activation, of HCBD (Birner et aL, 1995; Hook et aL, 1983).
The toxicity of HCBD metabolites has also been examined. Using isolated rabbit 
renal tubules, S-(l,2,3,4,4-pentachlorobutadienyl)-L-cysteine (PCBDC) treatm ent 
caused a dose-dependent decrease in acid and base transport (Jaffe et aL, 1983). 
Also, in Swiss Webster mice, adm inistration of PCBDC results in dose-
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dependent damage to the pars recta region of the proximal tubule in vivo  (Jaffe 
et aL, 1983). In addition, the toxicity of PCBDC has been investigated in  isolated 
rat renal cortical respiring m itochondria. Increasing doses of PCBDC correlated 
w ith a dose-dependent loss of ability to retain calcium, and a subsequent 
collapse of the m itochondrial m em brane potential (W allin et aL, 1987). This 
respiratory insufficiency was thought to lead to the observed nephrotoxicity 
(Hayden & Stevens, 1989; W allin et aL, 1987). The PLP-dependent enzyme 
inhibitor AOAA blocks this ability to inhibit respiration, but PCBDC is able to 
uncouple oxidative phosphorylation (Hayden & Stevens, 1989). Using PS]- 
labelled PCBDC, binding was observed to macromolecules and AOAA was also 
able to prevent this binding. A small proportion of this binding was rem oved 
by the disulphide reducing agent dithiothreitol (DTT) suggesting that some of 
this macromolecular binding is via mixed disulphides (Hayden & Stevens, 
1989).
The metabolite of PCBDC, N-acetyl-S-(l,2,3,4,4-pentachlorobutadienyl)-L- 
cysteine (NAc-PCBDC) at a dose of 3m g/kg leads to a 1.5 to 3-fold increase in 
CS-lyase activity and elevated CS-lyase m RNA levels (MacFarlane et aL, 1993). 
Conversely, nephrotoxic doses of lOmg/kg NAc-PCBDC lower the enzym e 
activity and mRNA levels. The m ost likely process of HCBD toxicity is via the 
eventual metabolism to NAc-PCBDC, which is cleaved by renal acylases back to 
PCBDC, a renal CS-lyase substrate. This possibly results in the form ation of a 
reactive thioketene which binds to macromolecules (Birner et aL, 1995). Birner 
et al (1995) have postulated that the form ation of a mercapturic acid sulphoxide
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in males (which is not detected in females) may explain the sex differences in 
toxicity.
The nephrotoxicity of DCVC has been observed in several anim al models, 
including rats, mice, guinea pigs, and rabbits, as tubular necrosis and enlarged 
nuclei in the epithelial cells of the proximal convoluted tubule (Anders et al., 
1988; Terracini & Parker, 1965). Elfarra et al (1986) studied the involvem ent of 
CS-lyase in DCVC toxicity by examining the effects of keto-acids (which may 
convert pyridoxamine phosphate (PMP) to PLP). a-Keto-y-methiobutyric acid 
(a-KMB) and phenylpyruvate potentiated the cytotoxicity of DCVC in  rat renal 
proximal tubule cells and the inhibition of m itochondrial respiration (Elfarra et 
ah, 1986). The latter authors also showed that the m itochondrial activity of 
CS-lyase was present in the outer m itochondrial m em brane, rather than  the 
inner m itochondrial m em brane.
The accumulation and toxicity of DCVC in m ouse kidney has been compared 
in relation to developm ental changes in basal activities of organic anion  
transport in vitro, and of CS-lyase activity (Darnerud et al., 1991). Higher levels 
of radiolabelled DCVC were apparent in female adult kidney following 5m g/kg 
dose of DCVC, compared to non-treated female mice. W ith 25mg/kg dose, the 
male kidney was m ost affected. The changes in  anion transport and CS-lyase 
activity did not directly m irror the age-dependent increase in  kidney 
radioactivity. Therefore, it was proposed that there may be a sex difference in  
gastrointestinal bioactivation or absorption of DCVC (Darnerud et ah, 1991).
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The findings of Darnerud et al (1991) supported previous work on the 
metabolism of DCVC and N-acetyl-S-(l,2-dichlorovinyl)-L-cysteine (NAc- 
DCVC) by the proximal tubule (Zhang & Stevens, 1989). It has been reported 
that the inhibition of DCVC-induced toxicity by probenecid is not due to 
inhibition of transport (Zhang & Stevens, 1989). NAc-DCVC, on the other 
hand, is transported by the probenecid-sensitive organic anion transporter 
(Zhang & Stevens, 1989). DCVC is metabolised to inorganic sulphate and NAc- 
DCVC very rapidly and is excreted in the urine (Finkelstein et aL, 1995b). 
Further studies into DCVC toxicity have show n that both DCVC and S-(l,2- 
dichlorovinyl)-L-homocysteine (DCVHC) treatm ent causes severe elevation of 
intracellular calcium, prior to bleb form ation and cell death, in the porcine 
kidney cell line, LLC-PKl (Vamvakas et aL, 1990). By combining DCVC 
treatm ent w ith AOAA, lipid peroxidation and therefore binding is decreased by 
60-70% w ith no effect on cell death and so it has been postulated that DCVC is 
bioactivated by other means (Groves et aL, 1993).
1.3.3. Toxicity of Fluorinated Haloalkenes
1,1,2,2-Tetrafluoroethylene (TFE) is used industrially to produce polytetra- 
fluoroethylene (PTFE) and it has been reported to produce damage to the rat 
kidney proximal tubule with no adverse effects on the liver (Odum & Green,
1984). TFE is metabolised to 1,1,2,2-tetrafluoroethyl-glutathione (TFEG) in  rat 
liver fractions (Odum & Green, 1984). However, w hen metabolised to S- 
(l,l,2,2-tetrafluoroethyl)-L-cysteine (TFEC) and the corresponding m ercapturate, 
toxicity results in  the rat kidney (Boogaard et aL, 1989). The effects of TFEC on
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m itochondria have also been investigated (Bruschi et aL, 1993). M itochondrial 
heat shock proteins (hsp) are m ajor targets for m odification during TFEC- 
induced toxicity. The hsp60 and hsp70 families are im portant participants in  
protein folding, transport targeting, and may also have a role in  the 
recognition/prevention of dénaturation, and degradation of abnormal proteins 
(Bruschi et aL, 1993). TFEC also covalently modifies select m itochondrial 
respiration proteins, including dehydrogenase m ultienzym e complexes, prior 
to cell death (Bruschi & Lindsay, 1994). TFEC has also been proven to inactivate 
the a-ketoglutarate dehydrogenase complex in the presence of CS-lyase (Park et 
aL, 1999).
2-Chloro-l,l,2-trifluoroethylene (CTFE) is a m onom er for the industrial 
production of the fluoropolym er polychlorofluoroethylene (Krespan, 1965). 
Hexafluoropropene (HFP) is formed during the hydrolysis of PTFE. Both of 
these com pounds caused dose related proximal tubular necrosis, diuresis and 
increased BUN concentration in rats following two days exposure by inhalation  
(Potter et al., 1981). Potter et al (1981) reported CTFE to be the m ore potent renal 
toxin of the two, affecting the pars recta specifically. The effects of HFP were 
slightly broader as the pars recta and pars convoluta were both targets for 
toxicity.
2-(Fluoromethoxy)-l,l,3,3,3-pentafluoro-l-propene (Compound A) is a fluoro- 
alkene derived from the degradation of fluoromethyl-2 ,2 ,2 -trifluoro-l- 
(trifluoromethyl)ethyl ether (Sevoflurane) which is an inhalation  anaesthetic
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(Iyer & Anders, 1997). Com pound A is a structural analogue of other 
nephrotoxic haloalkenes and has been reported to damage the renal 
corticomedullary stripe, increase BUN and glucose, proteins and ketone bodies 
in urine (Iyer & Anders, 1997). The m echanism  of toxicity of Com pound A is 
unclear, although there have been reports that it is not due to CS-lyase activity 
(Martin et aL, 1996). It has also been proposed that the m echanism  of toxicity 
may be due to unstable a-fluorothiolates losing inorganic fluoride yielding 
thioacylating agents which react w ith macromolecules and damage cells (Iyer & 
Anders, 1997). Since probenecid and AOAA dim inish the histological and 
biochemical evidence of toxicity, the m echanism  of toxicity is mediated, at least 
in part, by CS-lyase (Kharasch et aL, 1998; Kharasch et aL, 1997).
1.3.4. Mutagenicity and Carcinogenicity of S-Conjugates of Haloalkenes
The carcinogenicity of haloalkenes has been reported where 1,2-dibromoethane 
and l,2-dibromo-3-chloropropane treatm ent leads to the developm ent of 
stomach tum ours (Weisburger, 1977). Research has now  been carried out to 
determ ine the nephrocarcinogenicity of S-conjugates of haloalkenes. 
Nephrocarcinogenicity has been show n in rats, where HCBD exposure leads to 
an increased incidence of renal tum ours, adenomas and adenocarcinomas 
(Lock, 1988). The S-conjugates of the chloroalkenes and fluoroalkenes are 
nephrotoxic, as discussed earlier, but chloroalkenes are also capable of inducing 
carcinogenesis, unlike their fluorinated counterparts (Green & Odum, 1985). 
DCVC mutagenicity has been evaluated using the Ames Test and was revealed
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to be a strong direct-acting mutagen, and y-glutamyl transferase and CS-lyase 
are im portant in this process (Vamvakas et aL, 1988).
In 1989, Vamvakas et al studied DNA repair following exposure to S-conjugates 
which they m easured as unscheduled DNA synthesis (UDS). DCVC, trichloro- 
vinyl-L-cysteine (TCVC) and PCBDC all dose-dependently increased UDS in 
LLC-PKl cells w ithout im pairing viability. At higher doses, all conjugates were 
cytotoxic, including S-(2-chloro-l,l,2-trifluoroethyl)-L-cysteine (CTFEC), 
although genotoxicity was not observed w ith this fluorinated haloalkene 
cysteine S-conjugate (Vamvakas et aL, 1989). PCBDC also affects rat kidney 
m itochondrial DNA, RNA and protein synthesis (Banki & Anders, 1989).
CS-lyase activity results in the form ation of thioacylchlorides and thioketenes, 
and the interaction of these potent electrophiles w ith DNA leads to 
mutagenicity in bacteria, genotoxicity in  cultured renal cells and cytotoxicity in  
kidney cells (Dekant et aL, 1990). The ability of the kidney to concentrate 
glutathione and cysteine S-conjugates and the capacity of this organ to 
metabolise glutathione S-conjugates to cysteine S-conjugates is the m ajor 
contributor of the observed organ-specific carcinogenicity (Dekant et aL, 1990).
The DCVC metabolite, chlorothioketene, derived from CS-lyase activity, forms 
cytosine adducts in organic solvents but not in aqueous solution (Volkel & 
Dekant, 1998). Therefore, it was proposed that these DNA adducts were 
unlikely to be produced under physiological conditions and so may not prove
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effective as a biomarker of trichloroethylene exposure (Volkel & Dekant, 1998). 
Adenine adducts, however, have been reported in intact calf thym us DNA 
following 1 -halovinylcysteine-S-conjugate exposure via the generation of 
reactive thioketenes (Muller et ah, 1998).
1.4. MECHANISMS OF HALOALKENE TOXICITY
It is know n that haloalkene toxicity is m ediated through the initial generation 
of a glutathione S-conjugate, transport to the kidney where it is converted to a 
cysteine S-conjugate substrate for CS-lyase (Elfarra et al., 1986; Jaffe et ah, 1983; 
Lock, 1988; Odum  & Green, 1984). CS-lyase activity can yield unstable thiols, or 
electrophilic sulphonium  ions can be generated from sulphur m ustards non- 
enzymatically (Peterson et al., 1988).
1.4.1. Sulphoxidatîon in Nephrotoxicity
In order to assess the role of sulphoxidation in the m echanism  of toxicity of 
cysteine S-conjugates, DCVC and DCVC sulphoxide (DCVCO) were 
adm inistered in equim olar doses to rats (Lash et al., 1994). DCVCO was found 
to be a m ore potent nephrotoxin in vivo  than  DCVC, w ith a greater increase in  
BUN, and more severe and widespread proximal tubule necrosis and distal 
tubule necrosis. W hen treated in conjunction w ith AOAA, some protection 
against DCVC toxicity was observed but no protection was afforded against 
DCVCO toxicity. From this work. Lash et al (1994) implicated sulphoxidase in  
the toxicity of DCVCO. In addition, the HCBD metabolite, NAc-PCBDC 
sulphoxide, has also been found to cause nephrotoxicity w ithout CS-lyase
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activity as it is able to act as a Michael acceptor substrate w ith cellular 
macromolecules (Birner et aL, 1998). Sulphoxidation of mercapturic acids 
derived from tri- and tetrachloroethylene by cytochrome P450 3A has also been 
reported (W erner et aL, 1996). This demonstrates a bioactivation reaction in
addition to deacetylation and CS-lyase m ediated cleavage.
1.4.2. Direct-Acting Nephrotoxins
As m entioned earlier, the vicinal dihaloalkanes, such as ethylene dibromide 
(Figure 1.5.) can be transform ed by GSTs into m utagenic and nephrotoxic 
glutathione S-conjugates via episulphonium  ion (or thiirane, three-m em bered 
sulphur heterocycle containing compound) form ation (Weisburger, 1977). In a 
sim ilar way, direct-acting toxins are involved in the toxicity of the cysteine 
S-conjugate of dichloroethane, S-2-chloroethyl-DL-cysteine (CEC) (Figure 1.2., 
Reaction 3). A dm inistration of CEC to rats results in m arked nephrotoxicity, 
both functionally, and histopathologically (Elfarra et aL, 1985). Since CEC is not 
a substrate for CS-lyase, the m echanism  of toxicity is proposed as being related 
to the form ation of the th iiran ium  ion (Elfarra et aL, 1985).
1.4.3. Formation of Reactive Thiols
The generation of reactive thiols has been show n to be one factor contributing 
to haloalkene toxicity following CS-lyase metabolism. Studies on the 
bioactivation of CTFEC has show n that initially an unstable thiol is formed, 
namely 2-chloro-l,l,2-trifluoroethanethiol (Dekant et aL, 1987). They also 
showed that this latter interm ediate loses hydrogen fluoride to form  an
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acylating agent, chlorofluorothionacetyl fluoride. Further hydrolysis of the 
thionacyl fluoride generates the stable products of chlorofluoroacetic acid and 
inorganic fluoride. The interm ediate in this reaction has been considered as 
the m ain contributor to toxicity of CTFEC (Dekant et aL, 1987). Using a PLP 
model, DCVC and TCVC, w hen incubated w ith CS-lyase and N-dodecyl 
pyridoxal bromide, produce N, N-diethylchloro-thioacetamide and N ,N -  
diethyldichlorothioacetamide, respectively (Dekant et aL, 1988). The form ation 
of thioacylating agents from these enethiols is thought to result in  toxicity.
Com m andeur et al (1996) have also reported thionacylating species to be 
formed w ith TCVC and TFEC. They have show n that the form ation of 
thiiranes are generated as interm ediates rather than thionacyl fluorides in the 
metabolism of CTFEC (Com m andeur et aL, 1996). After an initial alkylation 
step, the products formed from dihalothionacylating species and thiiranes still 
contain an electrophilic centre which is capable of a second alkylation. These 
electrophiles may be involved in cross-linking of biomolecules.
More recent findings using S-(2-bromo-l,l,2-trifluoroethyl)-N-acetylcysteine 
methyl ester, S-(2 -chloro-l,l,2 -trifluoroethyl)-N-acetylcysteine m ethyl ester and 
S-(2 -fluoro-l,l,2 -trifluoroethyl)-N-acetylcysteine m ethyl ester as substrates for 
CS-lyase, have reported the form ation of thiolates and thiiranes (Luu et aL, 
2 0 0 0 ). S-(2 -brom o-l,l,2 -trifluoroethyl)-N-acetylcysteine m ethyl ester has 
mutagenic properties which coincides w ith an increased propensity to produce 
thiiranes on reaction w ith hydroxide, m ethoxide and ethoxide (Luu et aL, 2000).
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1.4.4. Reactive Intermediates of Bromine-Containing Cysteine S-Conjugates
The form ation of thiiranes has also been associated w ith brom ine containing 
cysteine S-conjugates in the form of 2,2-difluoro-3-halothiiranes (Finkelstein et 
aL, 1996). A m olecular m echanism  of thiirane form ation from brom ine- 
containing 1,1 -difluoroalkene-derived cysteine S-conjugates is show n in Figure 
1.7.
CS-lyase has also been show n to catalyse the conversion of S-(p-bromophenyl)- 
L-cysteine to p-brom othiophenol and S-(p-bromophenyl)-L-cysteine (Tomisawa 
et aL, 1993). Using an isotope dilution study, they reported that C-S bond 
cleavage liberates a sulphenic acid and a thiol which play a role in the 
generation of toxic interm ediates in v ivo .  a-Thiolactones have also been 
proposed as participating in  the developm ent of toxicity as their production has 
been demonstrated in the bioactivation of brom ine-containing cysteine S- 
conjugates (Finkelstein et aL, 1995a).
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Figure 1.7. Reaction mechanism for the formation of l,l-difluoro-2- 
haloethenes from bromine-containing 1,1-difluoroalkene-derived cysteine 
S-conjugates via elimination of sulphur from 2,2-difluoro-3-halothiiranes.
Figure adapted from (Finkelstein et aL, 1996).
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1.5. THE CYSTEINE CONJUGATE g-LYASE (CS-LYASE) ENZYME FAMILY
The metabolism of cysteine S-conjugates to reactive thiols is catalysed by CS- 
lyases, a general terminology for enzymes which are capable of metabolising 
cysteine conjugates via p-elim ination reactions. As reviewed above, the P- 
cleavage of some cysteine conjugates can lead to toxicity (Anders & Dekant, 
1998; Anders et aL, 1988). CS-lyase activity has been dem onstrated in several 
tissues including liver, brain, heart, muscle, pancreas, testes and lung, but the 
highest levels are found in the kidney (Cooper et aL, 1993; Jones et aL, 1988; 
Stevens et aL, 1986b; Tateishi et aL, 1978). It should be noted that the 
m etabolism of cysteine S-conjugates is not the m ain metabolic function of 
these enzymes in v ivo .  Thus, CS-lyase activity is expressed by a wide variety of 
enzymes, m ainly transaminases, whose shared feature is the presence of the 
co-factor PLP in the active site.
1.5.1. N on-M am m alian CS-Lyases
I.5.I.I. Bacterial CS-Lyase
The presence of a bacterial form of CS-lyase in the m am m alian gastrointestinal 
tract flora was established in 1985 by Larsen and Stevens. This CS-lyase form  
was thought to be responsible for the biotransform ation of xenobiotics w hich 
are secreted in the bile or consumed in  the diet. Larsen and Stevens (1985) 
found that CS-lyase activity was present in 27 of the 43 intestinal bacteria they 
examined.
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CS-lyase activities have since been characterised and partially purified from 
Fusobacterium necrophorum  (Larsen et aL, 1983) and Fusobacterium varium  
(Tomisawa et aL, 1984). The enzyme purified from F. varium  was responsible 
for the carbon-sulphur bond cleavage of several S-aryl, S-aralkyl, and S-alkyl 
cysteines (Larsen, 1985). By studying the incubation of the enzyme w ith 
p-bromobenzene, Tomisawa et al (1984) discovered that pyruvate, am m onium  
and a thiolated derivative of p-bromobenzene were generated from the activity 
of this 70kDa protein. Since these products were consistent w ith the reaction 
products of the CS-lyase activity the reaction was concluded as being CS-lyase 
catalysed. The activity of the enzyme was inhibited by potassium  cyanide or 
hydroxylamine and stabilized by PLP, the latter being the cofactor in  all CS-lyase 
catalysed reactions. The enzyme was found to display a very broad substrate 
specificity, an im portant aspect in  the role of gut flora in the form ation of 
m ethylthio-containing metabolites of various xenobiotics (Larsen & Stevens,
1985).
Larsen and Stevens (1985) also reported the isolation and characterisation of 
CS-lyase from Eubacterium limosum  which resides in the intestines of 
hum ans, poultry, and rum inants. The enzyme was hom odim eric and
composed of two 38kDa subunits. This form of CS-lyase appeared to be 
different to that isolated from F. varium  as it showed approximately 16-fold 
higher specific activity. The naturally occurring substrate cystathionine was 
also cleaved by the enzyme, indicating that it had P-cystathionase activity and 
may be im portant in the metabolism of several cysteine conjugated xenobiotics
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into their thiol containing derivatives (Larsen & Stevens, 1985). A CS-lyase has 
since been purified from Peptostreptococcus magnus (Kataoka et aL, 1995) and 
has been show n to have the same properties as the CS-lyase of F. varium . 
However, FPLC analysis showed it to be a m uch larger protein of approximately 
150kDa. Vamvakas et al (1988) showed in metabolic studies that Salmonella 
typh im urium  also contained a CS-lyase activity and that synthetic cysteine 
S-conjugates, such as CTFEC, were cleaved to produce pyruvate, am m onium  
and a thiol.
It has been proposed that bacterial CS-lyase activity in the gut could contribute 
to the production of toxic species from cysteine conjugates which m ight 
damage the gut locally (see Cooper, 1994). It has also been proposed that stable 
thiol products produced by CS-lyase activity in enteric bacteria m ight be 
transported and distributed in  the circulation and cause toxicity elsewhere. 
However, it is unlikely that sufficient localised concentrations of bacterially- 
derived reactive thiols could be achieved and thus CS-lyase-mediated toxicity is 
only associated w ith concentrating tissues, such as the kidney proximal tubule.
l.S.1 .2 . Parasitic CS-Lyase
Recently, CS-lyase activity has been found in the three m ajor groups of the 
parasitic helm in th  species: cestodes {Moniezia expansa) (Adcock et aL, 2000), 
digeneans {Fasciola hepatica) and nem atodes (Necator americanus and 
Heligmosoides polygyrus) (Adcock et aL, 1999). GSTs had previously been 
found in  helm inths (Brophy & Barrett, 1990). Aspartate and alanine
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aminotransferase activity was detected in all four species, and y -glutamyl 
transferase activity was detected in M. expansa and N. americanus (Adcock et 
aL, 1999). It has been proposed that these enzymes can play the same 
detoxification roles in  parasites as they do in m am m als.
1.5.2. M am m alian CS-Lyases
I.5.2.I. Hepatic CS-Lyase/Kynureninase
Tateishi et al (1978) purified CS-lyase from rat liver cytosol after it was show n to 
catalyse the cleavage of the thioether linkage in the cysteine S-conjugates of 
aromatic com pounds such as 2,4-dinitrobenzene. This hepatic enzyme was also 
show n to be active w ith a num ber of com pounds bearing non-polar leaving 
groups on the ^-carbon of an am ino acid substrate, and that this reaction was 
dependent on PLP (Stevens & Jakoby, 1982). CS-lyase was later purified to 
hom ogeneity (Stevens, 1985). The enzyme, shown to be active as a lOOkDa 
dimer, was reported to be identical to kynureninase.
Kynureninase was found to represent the m ajor CS-lyase activity of the rat 
liver, particularly w hen DCVC was used as the assay substrate (Stonard, 1973; 
Stonard & Parker, 1971). Kynureninase is involved in tryptophan m etabolism  
and leads to the production of 3-hydroxyanthranilate from 3-hydroxy- 
kynurenine (see Stone, 2001a). Quinolinic acid is an interm ediate in the 
kynurenine pathway leading to the synthesis of nicotinam ide ribonucleotides, 
via nicotinate nicotinamide, although the diet is the m ajor source of this. The 
kynurenine pathway is illustrated later in Figure 1.10. (section 1.7.).
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One m ajor difference between kynureninase and CS-lyase activity is in the 
reaction m echanisms, where kynureninase activity involves a ^-replacement 
m echanism  and CS-lyase activity a ^-elim ination reaction (Pearson et al., 1995). 
The differences between the kynureninase and CS-lyase reactions are depicted 
in Figure 1.8. The kynureninase reaction of p-replacement leaves a partial 
carbanion ^-carbon interm ediate bound to the enzyme PLP complex, whereas 
the CS-lyase reaction of ^-elim ination leaves an eneam ine interm ediate w ith 
partial carbonium (carbocation) character (Figure 1.8.).
Following hydrolytic cleavage and protonation of the carbanionic cofactor 
intermediate, the resulting interm ediate is alanine bound as a Schiff s base to 
the PLP cofactor. This is subsequently hydrolysed to free alanine (see Cooper,
1994). During the catalytic cycle, the rat liver enzyme is though t to be 
inactivated by nucleophilic attack of an enzyme bound nucleophile on the p- 
carbon of the eneam ine (Stevens, 1985), or by an aldol-type condensation 
reaction between the eneam ine interm ediate and the enzyme-Schiff base 
complex. In addition, inactivation of the enzyme by substrates which progress 
to the P-elim ination reaction leads to a loss of kynureninase activity, bu t 
kynurenine does not inactivate the enzyme (see Stone, 1993).
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Figure 1.8. Differences between the reaction m echanism s of kynureninase and 
CS-lyase.
Equation 1, The kynureninase reaction. Equation 2 , The CS-lyase reaction. 
Equations 3 and 4, show the partial carbanion nature of the eneam ine PLP 
interm ediate resulting from kynureninase cleavage, and the partial carbonium  
(carbocation) nature of the eneam ine PLP interm ediate resulting from  CS-lyase 
activity, respectively.
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CS-lyase is also found in hum an  liver and Tomisawa et al (1986) purified the 
enzyme from post mortem  liver. They reported that hum an  liver CS-lyase was 
active w ith S-aryl cysteines but not w ith simple S-alkylcysteines. In addition, 
they revealed that hum an  hepatic CS-lyase was not reactive w ith L- 
cystathionine or L-kynurenine, indicating that it did not have kynureninase 
activity. The enzyme was show n to have SSkDa native m olecular weight and 
required PLP for full activity at an optim um  pH of 8.5. The cDNA encoding the 
hum an  liver kynureninase has now been isolated (Alberati-Giani et aL, 1996a; 
Toma et aL, 1997). The sequence was found to be 70% hom ologous to rat 
kynureninase at the nucleotide level, and 85% hom ologous at the protein 
level. Toma et al (1997) further confirmed that this was indeed the correct 
cDNA by cloning the cDNA into an expression vector and transfecting into 
COSl cells. However, the expressed enzyme did not show CS-lyase activity 
towards the standard substrates. A KAT activity has since been found in  
hum an  liver which has identity w ith hum an  hepatic CS-lyase and it has been 
proposed that in hum an  liver KAT is the m ain enzyme displaying CS-lyase 
activity (Buckberry et aL, 1992).
I.5.2.2. Renal CS-Lyase/GTK/KAT
CS-lyase activity has been purified from rat kidney cytosol (MacFarlane et aL, 
1989; Stevens et aL, 1986b) using a m ethod similar to that for the purification of 
GTK activity from rat kidney (Cooper & Meister, 1985). Using the substrate, 
S-(2-benzothiazolyl)-L-cysteine, Lash et al (1986) showed that in the rat kidney 
two-thirds of the CS-lyase activity occurred in the cytosol of cells from  the
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cortical region (Stevens et al., 1986b). The rem aining third was present in the 
outer m itochondrial m em brane of the proximal tubular cells (Lash et aL, 1986). 
Rat kidney cytosolic CS-lyase and GTK co-purify (Cooper & Anders, 1990) and it 
has been demonstrated that a single protein displays both activities using 
stringent m ethods such as hydrophobic interaction HPLC and gel perm eation 
FPLC (Yamauchi et aL, 1993).
The enzyme isolated from the rat kidney was found to be distinct from the 
CS-lyase/  kynureninase previously isolated from rat liver (Blagbrough et aL, 
1990). Antibodies raised to the liver form did not cross-react w ith the enzym e 
from rat kidney (MacFarlane et aL, 1989). Unlike the liver, the kidney enzym e 
did not accept aliphatic cysteine conjugates and required com pounds w ith  
strong leaving groups on the p-carbon of cysteine (MacFarlane et aL, 1989).
It was also show n that rat liver, skeletal muscle and heart possess a CS- 
lyase/ GTK activity identical to that of purified rat renal GTK (Abraham & 
Cooper, 1991). An additional CS-lyase band of 330kDa was present in  rat kidney 
hom ogenate (Abraham & Cooper, 1991). This high m olecular weight CS-lyase 
activity was isolated from rat kidney cytosol and displayed endogenous 
metabolic activity w ith leukotriene (Abraham et aL, 1995a). This cytosolic 
form was found to preferentially metabolise DCVC and TFEC (Abraham et al., 
1995a). The metabolism of DCVC required a-KMB or a protein factor know n as 
L-amino acid oxidase containing flavin which is present in  the cytosol of the rat 
kidney cortex (Abraham et aL, 1995b). Abraham  et al (1995) showed that the a -
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KMB transam inase activity found was identical to GTK in the rat kidney 
cytosol.
A highly purified m itochondrial GTK has since been purified and show n to 
display little activity as a CS-lyase. There has been evidence that a high 
m olecular weight enzyme is responsible for the CS-lyase activity in rat kidney 
m itochondria (Abraham et ah, 1995b). A further difference found between the 
m itochondrial and cytosolic forms was that the m itochondrial form is m ore 
sensitive to inhibition by the PLP-dependent enzyme inhibitor AOAA, than  
the cytosolic form, w ith the Ki of the m itochondrial form at 0.4pM and the 
cytosolic 20-fold higher at 8 juM (Abraham et aL, 1995b).
In 1993, the full length cDNA for the rat kidney cytosolic CS-lyase was isolated 
using im m unological and hybridisation screening of rat kidney cDNA libraries 
(Perry et aL, 1993). The full length cDNA was confirmed as being that for CS- 
lyase from the deduced am ino acid composition, the deduced m olecular 
weight, the presence of a consensus PLP binding site in the am ino acid 
sequence, the kidney specific expression of the corresponding m RNA and the 
detection of elevated CS-lyase and GTK activity in COSl cells transfected w ith  
the cDNA (Perry et aL, 1993).
Analysis of the open reading frame of the cDNA showed that the cDNA was 
capable of coding for a 47.8kDa protein (Perry et aL, 1993) which was consistent 
w ith previous studies on the m olecular weight of the enzyme. The PLP
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binding site was reported as being composed of residues Ser-Ala-Gly-Lys-Ser- 
Phe, which was consistent w ith the binding site on other PLP-dependent 
proteins. The amino acid sequence also contained the conserved am ino acids 
lys267, tyr216 and arg387, which have been proposed as having a role in the 
m echanism  of action of PLP dependent enzymes. The authors also postulated 
that the 5' non-coding region of the 2.1kb mRNA may actually be involved in 
regulating the expression of CS-lyase protein, through the form ation of a 
secondary loop structure that m ight affect the progression of the ribosome 
along the m RNA during translation. A nother point raised by Perry et al (1993) 
was that it was yet to be determ ined if the rat kidney m itochondrial enzyme 
was coded separately, or w hether it was merely a modified version of the 
cytoplasmic form. This could occur by the alternative splicing of the CS-lyase 
pre-mRNA to introduce coding sequences for N -term inal targeting am ino 
acids.
In 1995, the am ino acid sequences of four tryptic peptides from  rat kidney 
cytosolic KAT were determ ined (Alberati-Giani et al., 1995). This followed 
studies on the purification of KAT from rat kidney (Mawal et ah, 1991). These 
am ino acid sequences were identical to sequences in CS-lyase/GTK (Alberati- 
Giani et al., 1995). Thus, CS-lyase/ GTK also shows transam inase activity 
towards kynurenine converting it to kynurenic acid. This was subsequently 
confirmed when the cDNA for rat brain KAT was isolated (Alberati-Giani et al.,
1995), see later. For comparison, the reactions catalysed by each of the enzym e 
activities (CS-lyase/GTK/KAT) is given (Figure 1.9.).
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Reaction A: Cysteine conjugate p-lyase (CS-lyase) 
NHo^ . 0 0 0
S'
I
R
COO
pyruvate
+ R-SH + NH4
thiol ammonium ion
Reaction B: Glutamine transaminase K (GTK)
N H l. .0 0 0 "
0 0 0
COO’
COO"NK
O ^ C O O -
coo
Reaction C: Kynurenine aminotransferase (KAT)
O OOOH 
NH2 
NH. N ^^C O O H
kynurenine kynurenic acid
Figure 1.9. Reactions catalysed by CS-lyase, glutamine transaminase K and 
kynurenine aminotransferase.
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In 1995, the full length cDNA for hum an  kidney CS-lyase/GTK/KAT was 
isolated using hybridisation screening and RT-PCR (Perry et aL, 1995). W hen 
the open reading frame was examined it was found to be capable of encoding a 
polypeptide of 422 am ino acids in length, corresponding to a 47.9kDa protein. 
The deduced am ino acid sequence was 82% similar to that of the rat cytosolic 
enzyme, w ith 90% similarity in  the PLP binding site region (amino acids 185- 
287). It was also found that of the 78 am ino acids which varied between the 
hum an  and the rat sequences, 23 of the changes were conservative. The gene 
encoding hum an  kidney cytosolic CS-lyase was show n to be situated on h u m an  
chrom osome 9. Subsequently, the H um an Genome Sequencing Project 
localised the gene to chrom osome 9q 34.1 (H um an Genome Sequencing 
Consortium, 2001).
1.5.2.3, CS-Lyase/GTK/KAT of the Central N ervous System
In 1977, rat brain glutam ine transam inase was reported to be identical to that of 
the hepatic enzyme (Cooper & Gross, 1977). Early studies into the levels of 
kynurenine pathway metabolites in rat brain regions showed that the 
cerebellum expressed the lowest levels, w ith higher levels observed in  the sub- 
cortical areas, including the thalam us, hypothalam us, basal ganglia and septum  
(Gal & Sherman, 1978). Generally, rat brain CS-lyase/GTK/KAT levels have 
been reported as being lower than those found in  kidney and liver (Abraham  & 
Cooper, 1991). Using activity staining for CS-lyase/  GTK/ KAT in  rat kidney, 
liver and brain samples, the activities were compared to that of purified GTK 
and it was show n that all tissues displayed a 95kDa band. In the kidney sample.
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an additional band of 330kDa was present and, to a lesser extent, in the liver 
also.
Two KAT activities had been partially characterised from hum an  brain and 
show n to be distinct from the rat brain enzyme (Okuno et aL, 1991a). Using 
pH]-kynurenine as a substrate, the two forms of hum an  KAT activity were 
characterised and the kinetic analyses performed have indicated that 
biosynthesis of kynurenic acid, derived from the activity of either KAT 1 or 
KAT 11, is dependent on physiological conditions (Baran et aL, 1994; Schmidt et 
aL, 1993). These kinetic studies are discussed later (section 1.7.2.).
More recently, KAT 1 and KAT 11 activities have been purified and 
characterised from rat brain (Guidetti et aL, 1997). High activity of KAT 1 was 
present in the cerebellum and KAT 11 in  the olfactory bulb, w ith lowest levels 
of KAT 11 observed in the cerebellum. The kinetics of rat KAT 1 and KAT 11 
have also been studied in rat cortical tissue slices, which will be discussed later 
(Hodgkins et aL, 1999). In 1995, the cDNA for rat brain cytosolic KAT was 
cloned (Alberati-Giani et al,, 1995) and found to be identical to that for rat renal 
CS-lyase/GTK/KAT (Perry et aL, 1993). This was further confirmed by 
N orthern  Blotting. Subsequently, another cDNA was cloned from rat brain 
encoding a m itochondrial form of CS-lyase/GTK/KAT which included an 
additional 32 am ino acid N -term inal (Malherbe et aL, 1995; Mosca et al,, 1996). 
This additional am ino acid sequence had structural aspects w hich strongly 
resembled a leader peptide for m itochondrial import.
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The location of CS-lyase/GTK/KAT mRNA expression has now been mapped 
during post-natal developm ent in rat brain (Plant et aL, 1997). Using in situ  
hybridisation techniques, m RNA was located and quantified on post-natal days 
14, 21, 28, 35, 42 and in adult male rats and was show n to increase steadily in 
m ost of the 42 neuroanatom ical regions quantified. However, in some regions, 
such as the medial forebrain bundle and cerebral penduncle, adult levels were 
reached by post-natal day 35. Also, in the fronto-parietal cortex and basolateral 
amygdaloid nuclei, levels of mRNA were substantially higher at day 28 than in  
adults, then decreased to adult levels by post-natal day 32, indicating 
physiological m odulation. Tam burin et al (1999) have also employed in situ  
hybridisation to m ap CS-lyase/GTK/KAT mRNA in adult rat brain. They have 
show n also that the m RNA is widely expressed throughout adult rat brain, 
w ith the highest levels observed in the hippocampus, piriform  cortex and the 
choroid plexus (Tamburin et aL, 1999). In addition, the m itochondrial form of 
the enzyme was reported to be expressed not only in astrocytes, but also in  
hippocampal neurones and choroid plexus epithelial cells (Tam burin et aL, 
1999).
Im m unohistochem ical techniques have localised CS-lyase/GTK/KAT in  
neurodegenerative states following in v ivo  adm inistration of sodium  azide 
(Knyihar-Csillik et aL, 1999). It was show n that KAT im m unoreactivity  was 
decreased in the glial cells of the striatum , dentate gyrus and tem poral cortex 
and in hippocampal astrocytes following i.p. sodium  azide treatm ent. In 
addition, the authors reported low levels of KAT im m unoreactivity  in  nerve
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cells. More invasive techniques have recently been employed to study the in 
v ivo  effects of co-substrates, specifically straight chain (e.g. pyruvate) and 
branched chain (a-ketoisocaproate) 2 -oxoacids on extracellular kynurenic acid 
levels (Hodgkins et aL, 1999). In v ivo  microdialysis on the dorsal hippocam pus 
of unanaesthetised rats showed that both oxoacids resulted in  dose-dependent 
increases in kynurenic acid levels which returned to basal levels w hen the co­
substrates were rem oved.
Since KAT has a role in the m etabolism of tryptophan in  the brain, the 
m odulation of this pathway has been implicated in the pathology of certain 
neurodegenerative disorders (see Stone, 1993; Stone, 2001a; Stone, 2001b) and 
this has lead to an increase in research on brain CS-lyase/GTK/KAT. The 
neurom odulatory function of KAT will be discussed in m ore detail in  section 
1.7.
1.6. CS-LYASE-MEDIATED TOXICITY: TARGET ORGAN SPECIFICITY
A lthough CS-lyase activity has been detected in m any tissues, the pars recta (S3 
segment) of the rat renal proximal tubule rem ains most susceptible to toxicity 
from the bioactivation of cysteine S-conjugates of haloalkenes by CS-lyase. It 
has been reported that i.p. adm inistration of HCBD to rats results in necrosis of 
the pars recta (Ishmael et aL, 1982). Renal injury and fatal aplastic anaem ia has 
been found in calves treated with haloalkane cysteine S-conjugates such as 
DCVC, TFEC and HCBD (Bruning et aL, 1996; Lock et aL, 1996). Early signs of 
m ild nephropathies, such as high m olecular weight proteinuria, shedding of
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epithelial m em brane components from tubular cells, and increased release of 
lam inin  fragments, fibronectin and glycosaminoglycans, have also been 
observed in hum ans exposed to perchloroethylene in dry cleaning fluids (Mutti 
et aL, 1992). The effect of trichloroethylene on the renal cells of exposed 
cardboard workers received attention in 1995, w hen it was published that there 
was an increased incidence of renal tum ours in workers exposed to this 
com pound (Henschler et aL, 1995a). Haloalkene bioactivation by CS-lyase has 
also been implicated in  neuropathologies including trigem inal analgesia, facial 
paresis and dysphagia following exposure to trichloroethylene.
Several factors may be involved in the specific targeting of organs for toxicity, 
such as the location of the enzymes responsible for bioactivation of the 
xenobiotic in the target tissues. Alternatively, the location of detoxification 
enzymes is also im portant in affording protection against the harm ful reactive 
interm ediates generated during m etabolism of such compounds.
1.6.1. Hepatotoxicity
Prior to the discovery that CS-lyase catalysed the m etabolism  of DCVC, early 
studies using rat liver m itochondria, indicated that the liver may be susceptible 
to DCVC-induced damage. This proposal was derived from studies (Stonard & 
Parker, 1971) which reported that DCVC was metabolised to pyruvic acid, 
am m onium  and an unknow n com pound which possessed alkylating 
properties, now know n to be a thiol. However, the liver was show n not to be a 
m ajor target for cysteine 5-conjugate-mediated toxicity, although decreased
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kynureninase activity caused by cysteine S-conjugate inhibition has been 
proposed as contributing towards any toxic effects in the liver. Also, 
cytomorphological changes have been observed in RL-4 rat liver cells w hen 
treated w ith glutathione and cysteine S-conjugates of allyl and benzyl 
isothiocyanates (Tem m ink et aL, 1986). In addition, cysteine S-conjugate 
toxicity has been observed in vitro  using hum an  Chang liver cells (Buckberry et 
aL, 1993).
1.6.2. Nephrotoxicity
The rodent and hum an  kidney is the m ajor target organ for cysteine 
S-conjugate-mediated toxicity for several reasons (Dekant et aL, 1990). 
Receiving around 25% of the cardiac output, the kidney is the prim ary organ 
for the elim ination of xenobiotics and their metabolites. The presence of m ost 
of the drug metabolising enzymes in the kidney also contributes to the 
bioactivation of certain com pounds in situ. However, one of the m ajor 
contributory factors to this localised toxicity is the ability of the kidney to 
concentrate glutathione and cysteine S-conjugates and the capacity of this organ 
to metabolise glutathione S-conjugates to cysteine S-conjugates.
An organic anion transporter, present on the basolateral side of proxim al 
tubule cells, is the m ain factor in  the accum ulation of S-conjugates in  the 
proximal tubule cells (Lock & Ishmael, 1985). This transporter is sensitive to 
probenecid which can selectively inhibit organic anion transport w ithout 
affecting energy metabolism. Haloalkane- and haloalkene-derived
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mercapturates have the highest affinity for this transporter but glutathione and 
cysteine S-conjugates w ith lipophilic substituents on the su lphur are also 
substrates. Probenecid is capable of preventing the toxic effect of haloalkene 
cysteine S-conjugates which supports the role of the renal organic anion 
transporter in S-conjugate accumulation. The toxicity of DCVC has been partly 
explained by its m etabolism to NAc-DCVC, which is transported into proximal 
tubule cells via this transporter (Boogaard et aL, 1989; Zhang & Stevens, 1989). 
The availability of renal proximal tubular cell cultures has aided in vitro  
research on haloalkene toxicity specific to the pars recta (Boogaard et aL, 1990).
I .6 .2 .I. Nephrotoxicity in  Rodents
The activity of CS-lyase has been localised by im m unohistochem ical staining 
which revealed that no enzyme was present in  the glom eruli or distal tubular 
elements of the kidney, and that the renal proximal tubule epithelia was the 
only area to display CS-lyase activity (Jones et aL, 1988). This has been
confirmed by toxicity studies where the exact location of nephrotoxicity 
coincides w ith im m unohistochem ical localisation of CS-lyase (MacFarlane et 
aL, 1989). The cysteine S-conjugates of several haloalkenes have been show n to 
produce nephrotoxicity specific to the pars recta region (MacFarlane et aL, 1989). 
The involvem ent of CS-lyase has also been proven in the toxicity of 
haloalkenes, including DCVC (Lash & Anders, 1989; MacFarlane et al., 1989), 
TFEC (Boogaard et aL, 1989; MacFarlane et aL, 1989), CTFEC (Hayden & Stevens, 
1989), and HCBD (Ishmael et aL, 1982).
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More recently, Kim et al (1997) have examined the activities of CS-lyase and L- 
am ino oxidase in various nephron segments, namely glom erulus, Sj, Sg and S3 
portions of the proximal tubule, thick ascending limb, distal tubule and the 
collecting tubule. Following isolation of the aforem entioned nephron 
segments by microdissection, the segments were solubilised and 
electrophoresed on polyacrylamide gels which were then incubated w ith 
DCVC. After incubation, three bands were present; band 1 was 330kDa and was 
a high m olecular weight CS-lyase, band 11 was a 240kDa L-amino acid oxidase, 
and band 111 a 90kDa CS-lyase which was identical to cytosolic GTK (Kim et aL, 
1997). They detected CS-lyase activity only in  the S^  to S3 segments of the 
kidney. Studies have also been carried out into the toxicity of HCBD and 
mercuric chloride (both S3 specific nephrotoxins) and potassium  dichrom ate 
(S1-S2 specific) by m easuring GTK in  the urine. The detection of GTK in urine 
has been show n to be a m easure of mercuric chloride site-specific 
nephrotoxicity (Trevisan et aL, 1996). Increased urinary GTK was found after 
treatm ent w ith the S1-S2 specific and the S3 specific nephrotoxins, indicating 
that GTK is located along the whole length of the proximal tubule (Trevisan et 
aL, 1998).
Cell regeneration, following DCVC exposure, has been reported in rabbit renal 
proximal tubule cells in vitro  (Kays et aL, 1993). The proximal tubule cells were 
grown to confluency and then treated w ith DCVC (lOOpM for two hours). 
Viable cells had depleted to 55% after 24 hours, and further to 37% after 48
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hours. However, 96 hours post exposure, the cells had regenerated to 57% 
confluency, returning to full confluency after 8 days (Kays et al., 1993).
I.6.2.2. Nephrotoxicity in Humans
Nephrotoxicity has been found in hum ans following exposure to com pounds 
such as perchloroethylene (Mutti et al., 1992) and trichloroethylene (Bruning et 
al., 1996; Henschler et al., 1995b). The toxicity of S-(l,2-dichlorovinyl)-L- 
glutathione (DCVC) and DCVC has been studied in hum an  renal proximal 
tubule cells, w ith the cysteine S-conjugate proving to be m ore toxic than  DCVC 
(Chen et al., 1990a). However, on adm inistration of DCVG w ith y-glutamyl 
transferase the toxicity is increased indicating that the metabolism to the 
cysteine S-conjugate is the rate lim iting step. PCBDC, CTFEC and TFEC were 
also found to be toxic in vitro, and the inhibitory effects observed w ith AOAA 
reinforce the involvem ent of CS-lyase in  this toxicity (Chen et aL, 1990a; Chen 
et aL, 1990b). In addition, CS-lyase activity has been reported to be at least 50% 
lower in hum an  renal carcinoma samples than in norm al tissue (Nelson et aL,
1995).
1.6.3. Neurotoxicity
It has been suggested that the brain CS-lyase/GTK/KAT activity, discussed 
previously, may be involved in the recycling of glutam ine in astrocytes and 
m ight contribute to an overall role in  neurotoxicity (Makar et aL, 1994). There 
are some active transport systems present in the blood-brain barrier w hich are 
also present in the kidney, and it has been show n that the glutathione and
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cysteine S-conjugates of dichloroacetone are taken up and that the DCVC 
carrier is analogous to the neutral am ino acid (l) transporter (Patel et al., 1994). 
HCBD possesses a structure sim ilar to that of dichloroacetylene, and it has been 
proposed that inhalation of either haloalkene can lead to their conversion in 
the lung to the glutathione S-conjugate by m icrosomal GSTs and then  pass 
readily to cerebellar regions and elicit neurotoxic effects. However, the 
localisation of CS-lyase/GTK/KAT in the brain does not correlate w ith areas of 
damage and so this suggests that other factors m ust be required for site-specific 
toxicity (Patel et al., 1993).
The toxic effects which have been observed in rodents following exposure to 
haloalkenes has been researched m ore fully than  in  m an. W hen exposed to 
trichloroethylene and dichloroacetylene (Reichert et al., 1976), rabbits show 
signs of neurotoxicity and neurodegeneration in  the sensory trigem inal 
nucleus, facial and oculom otor nerves and m otor trigem inal nucleus. Very 
recent data indicates that HCBD can produce toxicity in the choroid plexus of rat 
brain (M. T. Boroushaki, personal communication). In hum ans, the effects of 
haloalkene neurotoxicity include facial paresis, dysarthria, dysphagia, vocal 
chord paralysis and visual im pairm ent (see Schaumberg, 1992). On post 
m ortem  studies of severely affected individuals there was evidence of brain 
stem neurodegeneration of the trigeminal nucleus and the axons w ith in  its 
tract. Taken together, these results suggest that the regional neurotoxicity may 
be associated w ith localised toxic thiol form ation due to regional localisation of 
the activating enzyme CS-lyase/GTK/KAT.
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1.7. THE ROLE OF KYNURENINE AMINOTRANSFERASE IN 
NEUROMODULATION AND NEURODEGENERATION
1.7.1. The Kynurenine Pathway
KAT is the enzyme responsible for the production of kynurenic acid in the 
kynurenine pathway (Figure 1.10.) (Gal & Sherm an, 1978; Guidetti et ah, 1995). 
As illustrated, tryptophan is metabolised by tryptophan 2,3-dioxygenase to 
form yIkynurenine. This is the substrate for kynurenine formylase which 
produces L-kynurenine. At this point L-kynurenine can have one of two fates 
via metabolism by one of two enzymes. W hen metabolised by KAT, kynurenic 
acid is produced (Okuno et al., 1991b). Kynurenic acid is an antagonist of N - 
methyl-D-aspartate (NMDA) receptors and has been show n to have 
neuroprotective properties (Moroni et al., 1988a; Perkins & Stone, 1982). It is 
unique as it is capable of blocking all three ionotropic EAA receptors w ith a 
high affinity for the NMDA receptor complex (Okuno et al., 1991a). This infers 
that kynurenic acid may affect physiological and pathological processes because 
EAA receptors are highly im portant in brain developm ent, m em ory and 
learning, and the m ediation of neurodegeneration. Kynurenic acid is present 
in slightly higher am ounts in the hum an  brain than in the rat brain, and it has 
been show n to have neuroprotective and anticonvulsant properties 
(Gramsbergen et al., 1992). The localisation of KAT using im m unoreactiv ity  
techniques have detected KAT in rat striatum  (Roberts et al., 1992), m edulla 
and spinal cord (Kapoor et al., 1997). Kynurenic acid and KAT have been 
studied in heart tissue also, as blocking of NMDA receptors affects cardiac 
function (Baran et al., 1997).
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Alternatively, L-kynurenine can be metabolised by kynurenine 3-hydroxylase 
leading to a series of reactions culm inating in the production of quinolinic acid 
(an agonist of NMDA receptors and a neurotoxin) (Beal et al., 1986; Harris et al., 
1998; Heyes et al., 1993; M eldrum  & Garthwaite, 1990). The m odulation of this 
pathway between neuroprotectant or neurotoxin production has aroused m uch 
interest as a potential m eans of discovering the m olecular m echanism s 
involved in several neurodegenerative diseases. These neurodegenerative 
disorders will be covered later. The implications of the tryptophan pathway 
w ith regards to the developm ent of therapies for these disorders will also be 
discussed (see Stone, 1993; Stone, 2001b).
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Figure 1.10. Diagram illustrating the pathways of kynurenine synthesis and 
metabolism.
Figure adapted from Stone (2001b).
59
1.7.2. Kynurenine Aminotransferase I and Kynurenine Aminotransferase II in  
Human Brain
In hum an  brain there are know n to be two KATs present, KAT I and KAT II, 
which can be separated physically using DEAE-sepharose (Guidetti et aL, 1997; 
Okuno et al., 1991a) and kinetically using pH]-kynurenine as a substrate 
(Schmidt et al., 1993). These two forms differ in  their selectivity for various 
am ino adds and it has been postulated that KAT I (identical to GTK) which 
functions at an optim um  pH of 9.5 to 10, contributes very modestly to 
kynurenic add  production under physiological conditions (Guidetti et al., 1997). 
The activity of KAT I is markedly inhibited by the presence of the am ino acids 
glutamine, tryptophan and phenylalanine (Schmidt et al., 1993). KAT II (which 
also has activity as an L-a-aminoadipate transam inase) has an optim um  pH  of 
7.4 and it is not inhibited by glutam ine, tryptophan or phenylalanine (Okuno et 
al., 1991a; Schmidt et al., 1993). A cDNA encoding KAT/ L-a-aminoadipate 
transam inase was cloned from rat kidney (Buchli et al., 1995). It has been 
suggested that KAT II produces the majority of kynurenic add  under 
physiological conditions (Guidetti et al., 1997; Okuno et al., 1996). Thus, it has 
been proposed that KAT I may synthesise kynurenic add  during pathological 
conditions where decreased brain concentrations of glutam ine, decreased 
endogenous enzyme inhibitors, or cellular alkylosis are a feature (Baran et al., 
1994). This theory has prom oted interest in KAT I and has lead to its 
purification and the structure determ ined to be hom odim eric, composed of two 
identical 60kDa m onom ers (Baran et ah, 1994; Guidetti et al., 1997). Further 
study using im m unotitration  and im m unoblotting techniques has allowed
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confirm ation that KAT I is a different protein to both hum an  KAT II and rat 
KAT (Baran et aL, 1994).
Following cloning of hum an  KAT I, it has been revealed that the deduced 
am ino acid sequence has 82% homology to the rat enzyme (Mosca et aL, 1996). 
Using autoradiography, KAT I has recently been localised in adult rat brain 
using in situ  hybridisation techniques (Tamburin et aL, 1999). It was show n 
that KAT I mRNA is widely expressed throughout the adult male brain, w ith 
high levels in the hippocampus, piriform  cortex and the choroid plexus.
1.7.3. Excitatory A m ino Acids, the Kynurenine Pathway and 
N eurodegeneration
Over the past twenty years, the involvem ent of EAAs in the developm ent of 
acute neurodegenerative diseases has been well established (Schwarcz et aL, 
1984; M eldrum  & Garthwaite, 1990). W hen mice were treated w ith increased 
levels of glutamate (the m ajor EAA), degeneration of regions of the brain 
which were not protected by the blood-brain barrier was induced via 
overstim ulation of the NMDA receptor (M eldrum & Garthwaite, 1990). For 
chronic neurodegenerative disease and neurotoxicity, the role played by EAAs 
is not fully know n although there have been several proposals.
Quinolinic acid has been strongly implicated in neurodegenerative processes 
(Blight et aL, 1995; Heyes et aL, 1993) as quinolinic acid-induced lesions have 
been reported in rat hippocampus (Wu et aL, 1992). It is the m ost potent
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endogenous excitotoxin and is capable of producing neuropathologies sim ilar 
to several hum an  brain disorders (Beal et aL, 1986; Harris et al., 1998; Heyes et 
al., 1993; M eldrum  & Garthwaite, 1990; Schwarcz et al., 1984). It has been 
proposed that activated invading macrophages may contribute the m ajor 
source of cerebral quinolinic acid during neuroinflam m ation (Alberati-Giani et 
aL, 1996b). Levels of quinolinic acid, L-kynurenine, kynurenic acid and activity 
of KAT have also been found to be elevated in disorders such as H untington 's 
disease and Alzheim er's disease (Ceresoli et aL, 1996; Du et aL, 1993; Pearson et 
aL, 1995; Schwarcz et aL, 1992; Stone, 1993). The activation of NMDA receptors 
by quinolinic acid leads to excessive stim ulation of neurones and eventually 
toxicity due to elevated intracellular calcium levels (reviewed in  Stone, 2000b; 
Stone, 2001a). Increases in intracellular calcium levels can lead to the 
overexpression or activation of various enzymes such as phospholipases and 
proteases or trigger amplification cascades leading to excessive production of 
free radicals and lipid peroxidants (Vergun et aL, 1999). Indeed, inhibition of 
calcium uptake, in cultured neurones, by nifedipine has been show n to prevent 
damage caused by EAAs (see Stone, 1993).
In an anim al model of neurodegeneration, using ibotenate injection to produce 
neuronal injury and CNS lesions, the m etabolism of L-kynurenine was 
investigated in developing rat brain (Ceresoli et aL, 1997). It was show n that 
age-dependent changes occur in  the levels of metabolites of the L-kynurenine 
pathway in response to neurotoxicity. This age-dependent change reinforced 
several previous findings where kynurenic acid production was reported to
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increase w ith age in rat brain (Baran & Schwarcz, 1993; Beal et aL, 1992; 
Gramsbergen et aL, 1992). The L-kynurenine metabolic pathway has also been 
implicated in schizophrenia (Schwarcz et aL, 1997) and epilepsy (Du et aL, 1993) 
but the evidence for involvem ent w ith these conditions is not as abundant as 
for other neuropathologies.
1.7.4. Huntington's Disease
H untington's disease (HD) is a neurodegenerative disorder which is 
characterised by psychiatric disturbance, progressive cognitive dysfunction, 
m ovem ent disorder w ith chorea, dystonia, bradykinesia and rigidity, w ith the 
onset of the disease appearing in m id-adult life (Andrews et aL, 1999). 
Neuropathologically, HD selectively targets the y-am inobutyric acid-ergic 
(GABAergic) striatopallidal projection neurones, which constitute 90% of all 
striatal neurones, but the adjacent large spiny cholinergic in terneurons are 
preserved late into the progression of disease. It has been show n (H untington 's 
Disease Collaborative Research Group, 1993) that HD is an autosom al 
dom inant inherited neurodegenerative disorder w ith the genetic anom aly 
being located on chrom osome 4 as a GAG repeat in the hun ting tin  gene. 
However, the exact molecular m echanism  of the observed neuronal 
degeneration rem ains unknow n. Quinolinic acid injection had been show n to 
produce axon-sparing lesions in rat brain similar to those observed in  HD, 
theoretically providing a good anim al model (Beal et aL, 1986; Ellison et aL, 
1987; Schwarcz et aL, 1984). It was reported that the striatum , globus pallidus 
and hippocampus of experimental animals were all vulnerable to the
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developm ent of lesions following quinolinic acid treatm ent (Beal et aL, 1991). 
In hum ans, the most pathologically affected brain area in HD was also the 
striatum . These lesions lead to the depletion of neurotransm itters contained in 
the striatopallidal projection neurones, namely GABA and substance P (Beal et 
aL, 1986; Beal et aL, 1989). The levels of som atostatin and neuropeptide Y, were 
not decreased, instead it was reported that the levels of these com pounds were 
increased three- to five-fold in HD striatum  (Beal et aL, 1986; Beal et aL, 1989).
Since quinolinic acid had been show n to produce neurotoxicity (Beal et aL, 
1991; Heyes et aL, 1993; M eldrum  & Garthwaite, 1990), perhaps through over­
activation of NMDA, it was the m ost likely candidate for causing 
neurodegeneration via excitotoxicity. W ith this hypothesis, it was possible that 
glutamate could produce this same effect. However, post m ortem  analysis of 
HD brains revealed that the levels of quinolinic acid and glutam ate were 
norm al, or decreased in  the striatum  (Ellison et aL, 1987). As kynurenic acid 
was capable of antagonising this toxicity, it had also been proposed that levels of 
this neuroprotectant were decreased in HD brains, enhancing the toxicity of 
quinolinic acid (Beal et aL, 1992). Indeed, the levels of kynurenic acid were 
show n to be considerably reduced in  several regions of HD brain. To support 
the involvem ent of kynurenic acid in  HD neuropathophysiology, it was also 
show n that the activities of KAT I and KAT II were reduced in the striatum  of 
HD brain (Jauch et aL, 1995). A possible factor in the pathophysiology of HD has 
been postulated in a m ouse model as involving the disruption of the KAT II 
gene (Yu et aL, 1999a; Yu et aL, 1999b). Further work is required to fully
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elucidate the m echanism  of toxicity in HD and to establish w hether disruption 
of the kynurenine pathway in some form leads to the observed 
neurodegeneration.
1.7.5. Alzheimer's Disease and Kynurenine Metabolism
The neurodegenerative disorder A lzheim er's disease (AD) is the m ost 
com m on cause of dementia, a m ajor health  problem in the elderly (see Baran 
et aL, 1999). AD patients present w ith progressive im pairm ent of m em ory and 
cognition (McKhann et aL, 1984) which is accompanied by neuropathologies 
including neuronal loss, prim arily the cholinergic neurons of the basal 
forebrain and the glutamatergic neurons of the hippocampus, the deposition of 
extracellular amyloid plaques, and in traneuronal neurofibrillary tangles (M ann 
& Yates, 1986).
Baran et al (1999) m easured the levels of L-kynurenine, 3-hydroxykynurenine, 
and the NMDA receptor antagonist, kynurenic add in  the frontal cortex, 
caudate nucleus, putam en, hippocam pus and cerebellum of post m ortem  
confirmed AD brains. Kynurenic add  has a high affinity for the strychnine- 
insensitive glycine site of the NMDA receptor (Baron et aL, 1990; W u ef aL, 
1997). A trend of a decrease in levels of L-kynurenine and 3- 
hydroxykynurenine in all regions of AD brain w hen compared to the post 
m ortem  confirmed non-dem entia controls was reported (Baran et aL, 1999). 
Significant increases in  kynurenic acid levels in the putam en and caudate 
nucleus were observed w hen compared to controls. The increased kynurenic
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add  in these areas was found to correlate w ith significant increases in KAT I 
activity in the caudate nucleus and putam en, respectively. The other brain 
regions studied displayed only small increases in kynurenic add  content. It is 
thus clear from this research that kynurenine m etabolism is modified in the 
brains of AD patients, and that this leads to regiospecific increased levels of 
kynurenic add  in the brain, and elevated levels of KAT I in these regions also 
(Baran et aL, 1999). Despite the antagonistic properties of kynurenic add, 
neuronal damage still occurs in AD brains due to an altered strychnine- 
insensitive glycine recognition site on the NMDA receptors involved in  
glutamatergic transmission. This combined w ith the elevated levels of 
kynurenic add  may be a m ajor contributor to the m em ory and cognition 
defidts observed in  AD patients.
1.7.6. Parkinson's Disease
The neuropathology associated w ith Parkinson's disease (PD) is the progressive 
loss of dopaminergic neurones of the substantia nigra leading to the 
degeneration of the nigrostriatal dopaminergic pathway (Ogawa et aL, 1992). 
Exposure to the com pound l-methyl-4-phenyl-l,2,5,6-tetrahydropyridine 
(MPTP) results in the developm ent of clinical symptoms sim ilar to those found 
in patients w ith PD (Langston et aL, 1983). Studies of the invo lvem ent of the 
kynurenine pathway w ith PD followed from a study w hich showed that 1- 
m ethyl-4-phenylpyridinium  (MPP^) the metabolite of MPTP, was capable of 
blocking the nicotinam ide-adenine dinucleotide (NADH): ubiquinone
oxidoreductase (complex I) in the m itochondrial electron transport chain
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(Ramsay & Singer, 1986). Since the kynurenine pathway leads to the 
production of nicotinam ide and nicotinic acid, Ogawa et al (1992) studied the 
levels of tryptophan metabolites in PD and control brains. They showed that 
the L-kynurenine and kynurenic acid concentrations were significantly lower 
in the frontal cortex of brains from PD patients who had received 3,4- 
dihydroxyphenylalanine (L-dopa) therapy, w hen compared to control brains 
w ith no neurologic or psychiatric disorder. They also found that the overall 
level of L-kynurenine in  the PD brains of L-dopa-treated patients was lower 
than in  PD brains from individuals who had not received L-dopa treatm ent. In 
addition, a two- to three-fold increase in  the level of 3-hydroxykynurenine in  
the putam en and substantia nigra of PD patients, w hen compared to the 
control, was observed (Ogawa gf aL, 1992).
Ogawa et al (1992) postulated that the altered levels of L-kynurenine, kynurenic 
add  and 3-hydroxykynurenine may have been due to an increase in  
metabolism of L-kynurenine to 3-hydroxykynurenine, or a decrease in  the 
metabolism of 3-hydroxykynurenine to 3-hydroxyanthranilic add. Turski et al 
(1991) reported that NMDA antagonists, such as EAAs, can block the toxidty 
produced by MPP^ in the substantia nigra. Since kynurenic add  is an EAA 
antagonist and it can protect against quinolinic acid-induced toxicity in  
nigrostriatal dopaminergic neurons (Miranda et aL, 1997), Ogawa et al (1992) 
proposed that the decreased concentration of kynurenic acid in PD brains may 
accelerate the neuronal degeneration associated w ith this disease.
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1.7.7. Down's Syndrome
The L-kynurenine pathway and the levels of the pathway metabolites have also 
been show n to be altered in Down's syndrome (DS) patients (Baran et aL, 1996). 
DS (Trisomy 21) is a disorder which affects learning and m em ory and studies 
on post m ortem  DS brains have revealed that they display neuropathologies 
which are observed in AD brains, such as neurofibrillary tangles, neuronal loss 
and senile plaques (Ball & Nuttall, 1980; Ball & Nuttall, 1981). It has been 
reported that the level of kynurenic add  in the frontal cortex of DS patients is 
significantly increased compared to controls (Baran et aL, 1996). Also, the 
activity of KAT I is reduced in  the frontal and tem poral cortex of DS brains 
although the exact implications of this in DS rem ains unclear. The m olecular 
m echanism s of the observed neuropathologies are not fully understood and 
further research is required.
1.7.8. Cerebral Ischaemia
The tryptophan metabolic pathway was linked to cerebral ischaemia following 
the finding that quinolinic add  levels were altered in gerbils following a short 
period of cerebral ischaemia lasting only 5-15 m inutes (Heyes & Nowak, 1990). 
After 24 hours, no change in quinolinic add  level was observed, how ever, 
several days after ischaemia the levels in hippocam pus rose to 50-fold the basal 
level (Saito et aL, 1992). The changes observed were accompanied w ith  
increased activity of all the enzymes involved in kynurenine m etabolism, w ith  
the exception of KAT. It is the ischaemia-induced increase in quinolinic add
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compared to kynurenic acid that has been proposed as contributing to brain 
damage following ischaemia (Wood et al., 1993).
1.7.9. Therapeutic Approaches to Neuroprotection
The L-kynurenine pathway has been a principal target in the developm ent of 
therapies for the treatm ent of neurodegenerative disorders (see Stone, 2000a; 
Stone, 2001b). Several directions have been taken in the pharmacological 
m anipulation of this pathway to develop analogues of kynurenic acid or its 
precursor L-kynurenine, and to generate effective inhibitors of kynurenine-3- 
hydroxylase or kynureninase to divert m etabolism away from quinolinic acid 
production (see Stone, 2000a; Stone, 2000b). This approach was reinforced by 
the dem onstration that adm inistration of L-kynurenine and probenecid to rat 
brain dim inished NMDA-induced seizures (Vecsei et al., 1992). However, to 
date, attempts to develop an effective therapy have proved unsuccessful at the 
clinical trial stage due to psychomimetic effects and neuronal vacuolisation (see 
Stone, 2000a).
I.7.9.I. Antagonism of Glutamate Receptors by Kynurenic Acid Analogues
Initially, kynurenic acid analogue design focused around the addition of 
halogen atoms, as in  5,7-dichlorokynurenic acid (Figure 1.10.), to give a higher 
affinity for the strychnine-insensitive glycine site (Baron et al., 1990; Stone, 
2000a), and the 7-chloro- or 5,7-chloro- structure has featured in  m any 
analogues developed since. Examples of kynurenic acid analogues are show n 
in Figure 1.11. (Baron et al., 1990; Bristow et al., 1996). In addition, the inclusion
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of lipophilic substituents to the analogue has been studied to increase the lipid 
solubility, thereby im proving blood-brain barrier penetration by the potential 
drug, as w ith L701324 (Bristow et aL, 1996). Derivatives such as L701324 have 
proved to be the m ost effective in  clinical trials at m inim ising seizures and 
neurotoxicity in v ivo  following oral or systemic adm inistration.
I.7.9.2. Kynurenic Acid Pro-Drugs
4-Chlorokynurenine is transported into astrocytes where it is converted into 
7-chlorokynurenic acid by KAT (see structures in Figure 1.12.) (Hokari, 1996; 
Salituro et aL, 1994). Studies have revealed that intracerebral infusion of 
4-chlorokynurenine significantly reduced quinolinic acid-induced 
neurotoxicity in rat hippocampal regions, via the NMDA receptor antagonistic 
properties of 7-chlorokynurenic acid (Wu et aL, 1997). The glycine site NMDA 
receptor blockers are less associated w ith the neuropathological side effects, 
including changes in the posterior cingulate cortex and other brain regions, 
apparent w ith other NMDA receptor antagonists (Hargreaves et aL, 1993).
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Cl OH
N'^GOOH
Kynurenic acid
N^^ ^^COOH
5,7-Dichlorokynurenic acid
OH
L701324
Figure 1.11. Chemical structures of kynurenic acid and the analogues; 5,7- 
dichlorokynurenic acid (Baron et ah, 1990) and L701324 (Bristow et ah, 1996).
COOH
4-Chlorokynurenine
N^^^^COOH
7-Chlorokynurenic acid
Figure 1.12. Structures of the potential kynurenic acid pro-drugs; 4- 
chlorokynurenine and its active metabolite 7-chlorokynurenic acid (Hokari,
1996).
71
1.7.9.3, Modulation of CNS Kynurenic Acid and Quinolinic Acid 
Concentration via Enzyme Inhibition
The m ost recent therapeutic approach involves m odulation of endogenous 
kynurenic acid and quinolinic acid concentrations. By inhibition of 
kynurenine 3-hydroxylase and kynureninase, metabolism of L-kynurenine can 
be diverted towards production of kynurenic acid rather than  quinolinic acid, 
leading to elevated levels of neuroprotective kynurenic acid and depletion of 
neurotoxic quinolinic acid. The regulation of kynurenine 3-hydroxylase 
(Hayaishi & Okamoto, 1971) and KAT (Mason, 1954; Mason, 1974; Mason & 
Tobes, 1977; Mason et aL, 1975) has been studied for over four decades. In 1997, 
it was reported that kynurenine 3-hydroxylase was consistently deficient in 
hum an  cells w ith a decreased capacity to synthesise quinolinic acid (Heyes et aL,
1997). Also, inhibitors of KAT and kynurenic acid synthesis have been 
identified. Isonicotinic acid hydrazide inhibits rat KAT in v ivo  (Shibata et aL,
1996) and kynurenic acid synthesis in  rat can be inhibited by L-a-aminoadipate 
(Chang et aL, 1997) and am m onia (Saran et aL, 1998). Stim ulators of kynurenic 
add  production also exist. 2-Oxoadds, such as pyruvate and a-keto-isocaproate, 
have been show n to elevate kynurenic add  levels in  rat brain, both in vitro  
and in vivo  (Hodgkins et aL, 1999).
Nicotinylalanine (Figure 1.12.) is an inhibitor of kynurenine-3-hydroxylase 
(Russi et aL, 1992). It is now widely understood that quinolinic add  treatm ent 
leads to neurodegeneration of nigrostriatal neurons. M iranda et al (1997) have 
reported that nigral infusion of quinolinic add  or NMDA results in a m arked
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decrease in striatal tyrosine hydroxylase activity (used biochemically as an 
indicator for dopaminergic neurons). A combination of nicotinylalanine w ith 
L-kynurenine and probenecid (the organic add  transport inhibitor) increased 
kynurenic add  levels three-fold in whole brain, and 1.5-fold in the substantia 
nigra alone (Miranda et aL, 1997). This prevented neurotoxicity and seizures 
induced by quinolinic add.
A lthough inhibitors of kynureninase have been developed, they have been 
show n not to be as successful at elevating the CNS endogenous kynurenic add  
concentration {via reduction of 3-hydroxykynurenine and 3-hydroxyanthranilic 
add  levels) as the kynurenine-3-hydroxylase inhibitors are (Chiarugi et aL, 
1996). m -Nitrobenzoylalanine inhibits kynurenine-3-hydroxylase, whereas the 
related compound, cr-methoxybenzoylalanine, preferentially inhibits 
kynureninase (Natalini et aL, 1995). The inhibition of kynurenine-3- 
hydroxylase by m -nitrobenzoylalanine substantially reduces 3- 
hydroxykynurenine levels. However, cr-methoxybenzoylalanine increases the 
levels of kynureninase substrate 3-hydroxykynurenine but does not decrease 
levels of the 3-hydroxyanthranilic add  product (see structures in Figure 1.13.), 
highlighting the possibility that different isoforms of kynureninase may exist.
73
NH
COOH
Nicotinylalanine
NH
COOH
NO,2
m-Nitrobenzoylalanine
(mNBA)
NH
COOH
OMe
a-Methoxybenzoylalanine
(cy-MBA)
Figure 1.13. Structures of inhibitors of kynurenine 3-hydroxylase and 
kynureninase.
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1.8. AIMS OF THIS PROJECT
The involvem ent of CS-lyase/GTK/KAT in  the metabolism of halogenated 
alkenes and the subsequent developm ent of nephrotoxicity has been discussed. 
Marked differences in the nephrotoxic effects of HCBD in  m ale and female rats 
have been reported (Hook et aL, 1983; Hook et aL, 1982). A dult females were 
found to be m ore sensitive to HCBD-induced nephrotoxicity than  adult m ales 
(Hook et aL, 1983; Hook et aL, 1982). In addition, HCBD has been show n to be 
slightly m ore nephrotoxic to young male mice than to adult males (Lock et aL, 
1984). From these studies it can be proposed that the differences in  
nephrotoxicity observed is due to the level of CS-lyase/GTK/KAT activity in  rat 
kidney in male and female, and young and adult rats. Similarly, in rat brain 
there is evidence that CS-lyase/GTK/KAT expression is developm entally 
m odulated w ith the finding that mRNA levels are m odulated in  rat brain 
during post-natal developm ent (Plant et aL, 1997; Tam burin et aL, 1999).
These clear dem onstrations of sex- and age-related differences in CS- 
lyase/GTK/KAT activity strongly indicate that this tri-functional enzym e 
m ight be horm onally regulated by sex horm ones and glucocorticoids. The 
predom inant aim of this research was to dem onstrate the effect of such 
horm ones on CS-lyase/GTK/KAT gene expression in  male rat brain and 
kidney and to determ ine its m olecular basis.
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CHAPTER 2 
MATERIALS AND METHODS
2.1. MATERIALS
All chemicals and general items used in this study are listed alphabetically, 
by supplier, below. Molecular biology kit components, restriction 
endonucleases, DNA molecular weight m arkers and cloning vectors used in 
the study are included in this section.
2.1.1. Chemicals and General Items
All chemicals purchased were of the highest purity available.
P^C] Autoradiographic microscales; Hyperfilm p-max; pS]-UTPaS 
(Amersham Pharmacia Biotech, UK). Optimal Cutting Tem perature (OCT) 
compound; poly-L-lysine-coated microscope slides; potassium  sodium  
tartrate; di-sodium hydrogen ortho-phosphate, anhydrous {BDH Chemicals 
Ltd, UK). Agarose MP (multi-purpose); proteinase K; Trisma base; tRNA 
(Boehringer M annheim, Germany). B iophenol/chloroform  w ith stabiliser 
{Camlab, UK). Acetic acid (glacial); chloroform; DPX m ountan t; 
formaldehyde solution; glycerol; hydrochloric acid; sodium  acetate; sodium  
carbonate; sodium  chloride; sodium  hydroxide; sucrose (Fisher Scientific, 
UK). Ethanol (Hayman Ltd, England). Kodak Developer D19; Kodak Rapid 
Fixer; Polaroid Film (Kodak, UK). Triethanolam ine (TEA) (Lancaster, UK). 
Bacteriological agar; phosphate-buffered saline (PBS); tryptone; yeast extract
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(Oxoid Ltd, UK). dNTPs (dATP, dCTP, dCTP, dTTP); isopropylthio-p-D- 
galactoside (IPTG); nuclease-free water; rNTPs (rATP, rCTP, rGTP, rUTP); 5- 
bromo-4-chloro-3-indolyl-P-D-galactoside (X-Gal) (Promega Ltd, UK). Acetic 
anhydride; 2-amino-2-methyl-l,3-propanediol; ampicillin; bovine serum  
album in (BSA) protein standard; corticosterone - water soluble; diethyl 
pyrocarbonate (DEPC); dextran sulphate; dithiothreitol (DTT); 
ethylenediaminetetraacetic acid (EDTA); P-oestradiol - water soluble; 
cyproterone acetate; eth idium  bromide (EtBr); Ficoll; Folin and Ciocalteu's 
phenol reagent; formamide; a-keto-y-methiolbutyric acid (a-KMB); 
L-kynurenine; mifepristone; L-phenylalanine; polyvinyl pyrrolidone; 
progesterone - water soluble; RNase A; sodium  citrate; testosterone {Sigma 
Chemical Company, USA). DE-81 filter paper (Whatman, UK).
2.1.2. Molecular Biology Kit Components
The kits used in this study, including their contents, are listed below. All 
kits were stored at -20°C, unless otherwise stated.
Rat GenomeWalker™ Kit (Clontech Laboratories Inc., USA)
• Five Genome W alker DNA Libraries, each consisting of rat genomic 
DNA (from Sprague-Dawley rats) digested w ith one of the restriction 
endonucleases; EcoRV, Sea I, Dra I, Pvu II, Sep I (lOOng each)
Adaptor Primer 1 (AP-1, lOpM)
Nested Adaptor Primer 2 (AP-2, lOpM)
Positive Control Primer 1 (PCP-1, lOpM)
Nested Positive Control Primer 2 (PCP-2, lOpM)
Tth PCR Reaction Buffer (lOx)
M agnesium Acetate (Mg(OAc)2 , 25mM)
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• Advantage® Genomic Polymerase Mix (50x)
Wizard® PCR Preps DNA Purification System {Promega Ltd, UK)
• PCR Preps DNA Purification Resin
• Wizard® PCR Preps M inicolum ns
• Wizard® PCR Preps Direct Purification Buffer (KCl (50mM); Tris-HCl 
(lOmM, pH 8.8); MgCl^ (l.SmM); Triton® X-100 (0.1%))
• Syringe barrels, 3 ml
• Stored at room  tem perature.
TOPO™ TA Cloning® Kit (Invitrogen BV, The Netherlands)
• pCR®2.1-TOPO Vector, linearised and topoisomerase I-activated 
(10ng/|il plasmid DNA in  glycerol (50%); Tris-HCl (50mM, pH 7.4); 
EDTA (ImM); DTT (ImM); Triton X-100 (0.1%); BSA (lOOpg/ml); 
phenol red)
• Sterile water
• M l3 Forward (-20) and Reverse Primers (0.1|ig/|il each in  Tris-EDTA 
(TE) buffer (Tris-HCl (lOmM); EDTA (lOmM))
The following four items constitute the One Shot™  kit reagents, and
were stored at -80°C.
• One Shot™  Competent TOPI OF' £. coli Cells (genotype F' {lacl^TnlO 
(Tet^)l mcrA A{mrr-hsdRMS-mcrBC) O80ZflcZAM15 AlacX74t recAl  
deoR aroD139 A{ara-leu)7697galU galK rpsL (Str^) endA1 nupG)
• Super Optimal Catabolite (SOC) Media (tryptone (2%); yeast extract 
(0.5%); NaCl (lOmM); KCl (2.5mM); MgCl^ (lOmM); MgSO  ^ (lOmM); 
glucose (20mM))
• pUC18 Supercoiled Control Plasmid DNA (lOng/pl)
• p-Mercaptoethanol (500mM)
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Wizard® Plus SV M inipreps DNA Purification System {Promega Ltd, 
UK),
• Wizard® Plus SV Cell Resuspension Solution (Tris-HCl (50mM, pH 
7.5); EDTA (lOmM); RNase A (lOOpg/ml))
• Wizard® Plus SV Cell Lysis Solution (NaOH (0.2M) and SDS (1%))
• Wizard® Plus SV N eutralisation Solution (guanidine hydrochloride 
(4.09M); potassium  acetate (0.759M); glacial acetic acid (2.12M); pH 4.2)
• Wizard® P/ms SV Colum n W ash Solution (potassium acetate (60mM); 
Tris-HCl (lOmM, pH 7.5); 60% ethanol)
• Wizard® Plus SV Minipreps Spin Colum ns
• Collection tubes, 2ml
• Alkaline Protease Solution
• Nuclease-Free W ater
All constituents stored at room  tem perature.
Riboprobe® Combination System {Promega Ltd, UK)
SP6/T7 RNA Polymerase (500 units each) 
pGEM® Express Positive Control Template (5pg) 
Transcription Optimised Buffer (5x)
Recombinant RNasin® Ribonuclease Inhibitor (2,500 units) 
DTT (lOOmM)
Nuclease-Free W ater
rNTPs (rATP, rCTP, rGTP, rUTP, lOmM each)
2.1.3. Restriction Endonucleases
All restriction endonucleases used in this study were purchased from  
Promega Ltd (UK) and were stored at -20°C. These are listed alphabetically 
w ith details of the source and the restriction endonuclease recognition site 
(vand a ) in  Table 2.1.
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Table 2.1. Restriction endonucleases
Restriction
Endonuclease Source Recognition site
Apa I Acetobacter pasteurianus G GGCG’ C 
GaCCGG g
BamH I Bacillus amyloliquefaciens H G’ GATG G 
G GTAGaG
EcoRI Escherichia coli RY13 G’ AATT G 
G TTAAa G
Nco I Nocardia corallina G’ GATG G 
G GTAGaG
Sal I Streptomyces albus G G’ TGGA G 
G AGGTa G
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2.1.4. DNA Molecular Weight Markers
Molecular weight m arkers (250-10,000bp) were purchased from Promega Ltd 
(UK) and were stored at -20°C.
2.1.5. Cloning Vectors
The cloning vectors used in this study are detailed below (including full 
vector maps in  Figures 2.1. and 2.2.) and were both stored at -20°C.
2.1.5.1. pGEM®-T Vector {Promega Ltd, UK)
The pGEM®-T vector (Figure 2.1.) exhibits a m ultiple cloning region w ith in  
an a-peptide coding region for the p-galactosidase enzyme. This m ultiple 
cloning region is flanked by T7 and SP6  RNA polymerase prom oters. There 
is an origin of replication from the filam entous phage fl and an am picillin 
resistance gene for selection in E. coli.
2.1.5.2. pCR®2.1-TOPO Vector {Invitrogen BV, The Netherlands)
The pCR®2.1-TOFO vector (Figure 2.2.) exhibits a m ultiple cloning region 
w ithin  an a-peptide coding region for the P-galactosidase enzyme. This 
m ultiple cloning region is flanked by a T7 RNA polymerase prom oter, and 
M13 forward and reverse prim er sites for sequencing. There is an origin of 
replication from the filam entous phage fl, and am picillin and kanam ycin 
resistance genes for selection in £. coli.
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Xmn
Sea
Nae I
f1 ori
Apa  I 
Aat II 
Sph  I 
BstZ I 
Nco  I 
Sac  II
Am p pGEIVI®-T
Vector
(3000bp)
iacZ
Spe  I 
Not I 
BstZ 
Pst I 
Sail 
Nde  
Sac  I 
Bsrx 
Nsi I
on
Î  SP6
Figure 2.1. Map of pGEM®-T cloning vector {Promega Ltd).
The map illustrates the m ultiple cloning region, w ith in  the a-peptide 
coding region for the P-galactosidase enzyme, flanked by T7 and SP6 RNA 
polymerase promoters. Restriction endonuclease sites are show n in 
addition to the origin of replication from the filam entous phage fl and the 
ampicillin resistance gene (AmpO-
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/acZaATG
M l3 R e v e r s e  Prim er Hind Kpn I S ac  I BarrH  I Spe  I
CAG GAA ACA GCT ATG AC ATG ATT ACG CCA AGC TTG GTA CCG AGC TCG GAT CCA CTA
G TC C TT TG T CGA TAG TG TAG TAA TGC GGT TCG AAC CAT GGC TCG AGC CTA GGT GAT
S sfX  I EcoR I
G TA ACG GCC GCC AGT GTG CTG GAA T T C  GCC C T T  
CAT TGC CGG CGG TC A CAC GAC C TT AAG CGG GA
E co R  I
AG GGC GAA TTC TGC  
T T C  CCG C T T  AAG ACG
E coR  V BstX I N ot I Xho  I N si I Xba  I Apa  I ,
I i l l  I I  I ^ __________
AGA TA T CCA TC A CAC TGG CGG CCG CTC GAG C A T GCA T C T  AGA GGG CCC A A T TCG CGC TA T  
T C T  A T A  GGT AG T GTG ACC GCC GGC GAG CTC G TA CG T AGA TC T CCC GGG T T A  AGC GGG ATA
1 7  Prom oter M 13 Forw ard (-2 0 ) P rim er M l 3 Forward (-4 0 ) Prim er
CTG GCC GTC G TT T T A  
GAC CGG GAG CAA A A T
AGT GAG TCG TAG AAT TC A
TC A CTC AGC A T A  AT T T A  AGT
pCR®2.1-T0P0  
3 .9  k b
'A  OGT CGT GAC TGG GAA AAC  
T GCA GCA CTG ACC C T T TTG
Comments for pCR®2.1-T0P0 
3908 nucleotides
L acZ a fragment: bases 1-571 
M l3 reverse priming site: bases 205-221  
M ultiple cloning site: bases 234-357  
T7 promoter/priming site: bases 364-383  
M 13 Forward (-20) priming site: bases 391-406  
M 13 Forward (-40) priming site: bases 411-426  
f l  origin: bases 548-962  
Kanamycin resistance ORF: bases 1296-2090  
Am picillin resistance ORF: bases 2108-2968  
C olE l origin: bases 3113-3786
Figure 2.2. Map of pCR®2.1-TOPO TA cloning® vector {Invitrogen BV).
The map illustrates the m ultiple cloning region, w ithin  the a-peptide 
coding region for the P-galactosidase enzyme, flanked by a T7 RNA 
polymerase prom oter, and M13 forward and reverse prim er binding sites. 
Restriction endonuclease sites, the origin of replication from the 
filam entous phage fl, and am picillin and kanam ycin resistance genes are 
also shown.
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2.2. METHODS
2 .2 .1 . Extraction and Purification of Plasmid DNA
The techniques described in the following sections include preparation of 
the pTA243 plasmid (pGEM®-T vector w ith insert of nucleotides 181 to 424 
from the CS-lyase/GTK/KAT cDNA sequence), extraction and purification 
of pTA243 from E. coli, quantitation, and the assessment of the purity and 
m olecular size of the plasmid DNA.
2 .2 .I.I. Small Scale Preparation of Plasmid DNA
Previously, a 243 base pair sequence, corresponding to nucleotides 181 to 424 
of the 5' region of CS-lyase/GTK/KAT cDNA, had been cloned into a 
pGEM®-T vector (Plant et al, 1997) for use as a probe for m RNA expression. 
Figure 2.3. shows the CS-lyase/GTK/KAT cDNA sequence highlighting 
nucleotides 181 to 424 (Perry et a l,  1993). Plant et al (1997) transform ed 
pTA243 into a JM109 strain of £. coli cells to allow larger quantities of the 
plasmid to be produced through replication w ith the host genome. Glycerol 
stocks were then prepared of the pTA243-containing JM109 bacteria (850jil of 
bacterial culture containing plasmid of interest, in  ISOpl of sterile glycerol 
(100%), vortexed to mix, and stored at -20°C w ith back-up stocks stored at 
-80°C).
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1 AAACT6ACCAAGGAGTATGATCMTCCC6TCCAGCCTCC6A6CC
45  TGCAGCCGnTGGTCATGGTGAGCTGCnCAGCTAACAAnGCACTGACAGTGCTCnGAGCCAAGnGCnCTGGGCGGAAGTAGTCCATCTAGGGGTC
145  GGCCTCTTTAAAGAAACAGACnCTGCAACCTTGGGACTACGTnGGGGTCGCCGGCTAnGGACGGAGCAGCGCAAnGnAGCTGAAGCAGCTCACC
Met T lr ly s Arp lew Gin Ala Arp Arp I w Aw Gly He A w Gin A w lew 17
2 4 4 ATG AGG AAA GGG GTG GAG GGT GGG AGG GTG GAG GGG A n GAT GAA AAG GTG
T n wal Glw Phe Gly ly s Lew H r ly s Glu Tyr Aw Hal Hal AW lew Gly 84
2 8 5 TGG GTG GAG T n GGG AAA GTG AGG AAG GAG TAT GAG GTG GTG AAG TTG GGT
Gin GIV Phe Pro ASP Phe S er Pro Pro Aw Phe Ala H r Gin Ala Phe Gin 51
8 4 6 GAG GGG TTG GGT GAG TTG TGG GGT GGG GAG T n GGA AGG GAA GGT T n GAG
Gin Ala H r Ser Gly Asn Phe Met lew Aw Gin Tyr H r Ara Ala Phe Gly 8 8
8 8 7 GAG GGT AGG AGT GGG AAG TTG ATG GTG AAG GAG TAG AGG AGG GGA T n GGT
Typ Pro Pro lew H r Asn Hal lew Ala S er Phe Phe Gly Lys i w lew Gly 85
4 4 8 TAG GGA GGA GTG AGA AAG GTG GTG GGA AGT TTG T n GGG AAG GTG GTG GGA
Gin Glu Met Asp Pro Lew H r A w Hal Leu Hal H r Hal Gly Ala Tyr Gly 102
4 8 8 GAG GAG ATG GAG GGA GTG AGG AAT GTG GTG GTG AGA GTG GGT GGG TAT GGG
Ala lew Phe H r Arp Phe Gin Ala lew Hal Aw Glu Gly Aw Glu Hal He 118
5 5 8 GGG TTG TTG AGA GGG T n GAG GGG GTG GTG GAT GAA GGA GAT GAG GTG ATG
We Met Glw Pro Ala Pbe Aw Gys Tyr Glu Pro Met H r Met Met Ala Gly 186
681 ATG ATG GAA GGT GGT T n GAG TGT TAT GAA GGG ATG AGA ATG ATG GGT GGA
Giv GVS Pro Hal Phe Hal H r Lew ly s Pro Ser Pro Ala l¥ o Lys Gly Lys 1 58
8 5 2 GGT TGG GGT GTG TTG GTG AGT GTG AAG GGG AGG GGT GGT GGT AAG GGG AAA
lew Gly Ala S er Asn A n Tw Ghi Lew Aw Pro Ala Glu lew Ala S er Lys 1 78
7 8 8 GTG GGA GGG AGG AAT GAT TGG GAA GTG GAT GGT GGA GAA GTG GGG AGG AAG
Pbe T lr Pro Arp H r Lys He Lew Hal lew Aw H r Pro A w AW Pro Lew 187
7 5 4 TTG AGA GGT GGG AGG AAG ATG GTG GTG GTG AAG AGA GGG AAG AAG GGT n A
Gly iv s Hal Phe S er Arp Met Glw Lew Glu lew Hal Ala A w Lew Gys Gin 2 0 4
8 85 GGA AAG GTA TTC TGT AGG ATG GAG GTG GAG GTG GTG GGT AAT GTG TGG GAG
Gin HIS ASP Hal Hal Gys He % r AW Glu Hal Tyr Ghi Tra i w Hal Tyr 221
8 5 8 GAG GAG GAT GTG GTG TGG ATG TCT GAT GAG GTG TAG GAG TGG GTG GTG TAT
Asa Gly HIS Gin HIS Hal S w He Ala Ser iw Pro Gly Met Tra Aw Ara 2 8 8
8 8 7 GAG GGG GAG GAG GAG GTG AGG ATG GGG AGG GTG GGT GGG ATG TGG GAT GGG
T lr lew H r He Gly Sn* Ala Gly ly s Ser Phe Ser Ala H r Gly Tra Lys 2 5 5
8 5 8 AGG GTG AGG ATG GGG AGT GGA GGG AAA AGG TTG AGT GGG AGT GGG TGG AAG
vai Gly Tpp Hal Met Gly Pro Aw Aw He Met ly s HIS lew Ara H r Hal 2 7 2
1 8 8 8 GTG GGG TGG GTG ATG GGT GGA GAT AAG ATG ATG AAG GAG GTG AGG GAG GTG
His Gin Asn Ser lie Phe His Gys Pro H r Gin Ala Gin Ala Ala Hal Ala 2 8 8
1 8 6 8 GAG GAG AAT TGT ATG TTC GAG TGG GGG AGG GAG GGG GAG GGT GGA GTA GGG
Gin Gys Phe Gin Arp Glu Gin Gin HIS Phe Gly Gin Pro S er SW Tyr Phe 8 0 6
1111 GAG TGG T n GAG GGG GAG GAG GAA GAG T n GGA GAA GGG AGG AGG TAG T n
lew Gin Lew Pro Gin Ala Met Glu lew Aw Arp Aw His Met He Ara s w 8 2 8
11 6 2 TTG GAG GTG GGA GAG GGG ATG GAG GTG AAG GGA GAG GAG ATG ATG GGT AGG
Lew Gin Ser Hal Gly Lew Lys lew Tro He S er Gin Gly S w Tyr Pbe lew 8 4 0
1 21 8 GTG GAG TGA GTG GGG GTG AAG GTG TGG ATG TGG GAG GGG AGG TAG TTG GTG
lie Ala ASP lie Ser Aw Phe ly s S er ly s Met Pro Aw lew Pro Gly Ala 8 5 7
1 26 4 A n GGA GAG ATG TGA GAG TTC AAG AGG AAG ATG GGT GAG GTG GGG GGA GGT
Gin Asa Gin Pro Tyr Asp Ara Arp Phe Ala ly s Tra Met He Lys Aw Met 8 7 4
18 1 5 GAG GAT GAG GGT TAT GAG AGA GGG T n GGG AAG TGG ATG ATG AAA AAG ATG
GIV lew Hal Gly He Pro Hal S er H r Phe Phe Ser Ara Pro HIS Gin ly s 881
1 86 6 GGG TTG GTG GGG ATG GGT GTG TGG AGA TTG TTC AGT GGG GGG GAT GAG AAG
ASP Phe ASP His Tyr He Arp Pbe Gys Phe Hal ly s Aw ly s Ala H r lew 4 8 8
1 4 1 7 GAG TU GAG GAG TAG ATG GGA TTG TGT T n GTG AAG GAG AAG GGG AGA GTG
Gin Ala Met Asp Gin Arp Lew Arp ly s Tra ly s Glu Lew Gin Pro ST8P 4 2 8
146 8 GAG GGG ATG GAT GAG AGA GTG GGG AAG TGG AAA GAG GTG GAA GGG TGA GGA
1 5 1 9  GGGTGCCCTCAGCCCCACCTGGAACACAGGGCTCAGCTATGCCTTAGCACAGGGATGGCAGTGGAGGGCCCAGCTGTGTGACTGCGCATGnTCCAGA
1 6 1 7  AAAGAGGGGATGTGTTGGGGGnGAAGGGATGGmGGGAGTGTGGATGTGGAGTAnGGGnGGGGGGGAGnGTGGGTGTGAGGGTAGTGGTGTGTAGG
1 7 1 8  TTGGGTGTAGGGTTTTGAnGTTTGTGGGGTGTGTGGGTGGGGGAGGAAAGGGTGGAATATGAGGGGGGGTAGGAGGTTAGGGGTGGGGAGGGTGTGTGGG
18 1 9  TTGTGTAGATGnGTGGTGTGAGGTGAGGATGnGGTAGTGnGGTAATAAAGnnAAGnAnAGGAGGGTGA,
Figure 2.3. Rat renal CS-lyase cDNA nucleotide and deduced amino acid 
sequences.
Nucleotides 1-1892 are illustrated, w ith nucleotides 181 to 424 highlighted 
(in red) to show the sequence which was inserted into the pGEM®-T vector 
to create pTA243 (Plant et ah, 1997). cDNA sequence taken from Perry et al 
(1993).
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Bacterial m inicultures of the JM109 E. coli cells, transform ed w ith pTA243, 
were prepared in Luria-Bertani (LB) media (tryptone lOg, yeast extract 5g, 
NaCl lOg, made up to 11 w ith milli-Q water and autoclaved to sterilise) 
containing SOpg/ml am picillin (made as a lOOmg/ml solution, filter- 
sterilised, and stored in 500pl aliquots at -20°C) and inoculated w ith either 
lOOjxl of glycerol stock, or a single colony from an LB agar plate (tryptone 5g, 
yeast extract 2.5g, NaCl 5g, made up to 500ml w ith milli-Q water, 7.5g 
bacteriological agar added, and autoclaved to sterilise). Mini cultures were 
then incubated overnight (12-16 hours) at 37°C w ith agitation.
pTA243 plasmid DNA was extracted from the m ini cultures using the 
Wizard® Plus SV Mini Prep DNA Purification System (section 2.1.2.) w hich 
relies on the ability of negatively charged DNA to adhere to the positively 
charged, silica-based resin, and is readily eluted w ith water due to a quick 
rehydration feature. By following the m anufacturer's recom m endations, 
this kit provided a straight-forward m ethod for obtaining substantial 
quantities of clean DNA which was free from protein or genomic DNA 
contam ination.
2.2.I.2. Purification of Plasmid DNA by PhenoLChloroform Extraction
and Ethanol Precipitation
Phenol : chloroform extraction and ethanol precipitation purifies DNA by 
rem oving all protein, lipid and carbohydrate from the preparation. Equal 
volum es of biophenoLchloroform (1:1 (v/v)) and plasm id DNA were 
aliquoted into a microfuge tube, vortexed to form an em ulsion, and then
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centrifuged at 10,840 xg for 5 m inutes to separate the em ulsion into organic 
and aqueous phases. Since DNA is insoluble in phenol, the aqueous phase 
was rem oved, transferred to a clean microfuge tube and an equal volum e of 
chloroform added. This was vortexed and centrifuged, as before. The 
aqueous phase was then rem oved, transferred to a clean microfuge tube and 
2 vols, ethanol (100%) and 1/10 vol. sodium  acetate (3M) were added. The 
DNA was stored at -80°C for 30 m inutes to allow precipitation of the DNA 
out of the ethanol solution.
The precipitated DNA was then  centrifuged at 18,320 xg for 30 m inutes to 
form a pellet, the ethanol rem oved, and the pellet washed in ethanol (70%) 
and centrifuged at 18,320 xg for 10 m inutes. The ethanol was rem oved and 
the pellet allowed to air dry for 5 m inutes. Finally, the pellet was 
resuspended in Tris-EDTA (TE) buffer (Tris-HCl (lOmM), EDTA (ImM) for a 
Ix solution) to concentrate the sample.
2.2.I.3. Determ ination of DNA Concentration by UV Spectrophotometry
DNA concentrations were quantified using the Genequant II D N A /R N A  
Calculator (Pharmacia Biotech). This programmable spectrophotometric 
apparatus measures the absorbance of the sample at a w avelength of 260nm 
and calculates the concentration of DNA (where the dilution factor of the 
sample was entered into the spectrophotometer prior to m easurem ent of 
the absorbance) where an optical density (OD) reading of 1 corresponds to 
50|ig/m l double stranded DNA. A further m easurem ent at 280nm allows 
the purity of the sample to be calculated spectrophotometrically using the
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ratio of A260nm/A280nm, where a pure preparation of DNA has a ratio of 
1.8 (Sambrook et al., 1989).
2.2.I.4. Assessment of DNA Purity and Size by Agarose Gel 
Electrophoresis
In order to gauge the purity of extracted DNA, samples were electrophoresed 
alongside know n molecular weight m arkers (Ikb DNA ladder, section 2.1.4.) 
on 1.2-1.5% (w /v) agarose gels in  Ix tris-acetate EDTA (TAE) buffer (trisma 
base 484g, EDTA (0.5M, pH 8.0) 200ml, acetic acid (glacial) 114.2ml, milli-Q 
water 500ml, pH adjusted to 8.3, m ade up to final volum e of 101 for a lOx 
solution) by applying a voltage of 80-120 volts (depending on the size of the 
gel) to separate the DNA according to m olecular size. The presence of 
eth idium  bromide (EtBr) in the gel (2^ g /m l) allowed the DNA to be 
identified, by fluorescence, w hen viewed under ultra-violet (UV) light. 
Consequently, an estim ation of the size of the DNA bands was m ade by 
direct comparison to the molecular weight markers, and the presence of 
contam ination ascertained.
2.2.2. Animal Experimentation
2.2.2.I. Animal Husbandry
Male W istar Albino rats (see section 222.1. for body weight ranges and age 
of animals) were housed in an air-conditioned un it to m ain tain  room  
tem perature at 20°C and relative hum idity  at 50-60%. Daily light exposure 
was regulated to 12 hours, between 0700h and 1900h, and anim als were
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perm itted access to food and water ad libitum (Universal feed, Bantin and 
Kingman, UK).
2.1.12. Dosing of Animals
Rats were purchased from Bantin and Kingman  (UK) as neonates, and 
arrived in cages each containing litters of 8  male pups w ith m others, to 
allow the rats at least one week acclimatisation period. Prior to dosing, rats 
were weighed and tail-marked into groups, according to com pound and 
dosage, where n=4. Com pounds were administered by i.p. injection and 
dosing was performed between lOOOh and llOOh at post-natal day 18 (body 
weight 26.3 to 29.8g), post-natal day 20 (30.2 to 35.6g), post-natal day 22 (36.3 
to 44.1g), post-natal day 24 (47.8 to 54.6g), and post-natal day 29 (70.3 to 84.3g). 
Rats were killed by decapitation 24 hours after dosing.
Rats were treated w ith dexamethasone (l.Omg/kg, lO.Omg/kg or lOO.Omg/kg) 
or corticosterone (0.3mg/kg, 3.0mg/kg or 30.0mg/kg) in water vehicle; 
m ifepristone (lO.Omg/kg) in 10% ethanol vehicle; |3-oestradiol (lO.Omg/kg) 
or progesterone (l.Omg/kg or lO.Omg/kg) in water vehicle; testosterone 
(lO.Omg/kg) or cyproterone acetate (lO.Omg/kg) in 10% ethanol vehicle. For 
each treatm ent group (dictated by the treatm ent age and test com pound 
dose) the appropriate water or 1 0 % ethanol controls were prepared.
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2.2.2.3. Preparation of Rat Kidney Tissue for Biochemical Assays 
Following decapitation, both kidneys were imm ediately rem oved from 
animals, decapsulated, and weighed. Both kidneys were placed in ice-cold 
sucrose (0.25M) containing Tris-HCl (lOmM, pH7.5) to produce a kidney 
hom ogenate of 25% (w/v). The kidney tissue was scissor-minced and 
hom ogenised on ice. The hom ogenate was then  centrifuged at 153,000 xg 
for 90 m inutes in a Beckman L7 centrifuge (70.1 TI rotor) to yield the 
cytosolic supernatant. The cytosolic fraction was stored in 1ml aliquots at 
-20°C for use in specific enzyme activity determ inations (section 2.2.3.).
2.2.2.4. Preparation of Rat Brain Tissue for Biochemical Assays 
Following decapitation, the whole intact brain was rem oved, weighed, and 
placed in ice-cold sucrose (0.25M) containing Tris-HCl (lOmM, pH7.5) to 
produce a brain hom ogenate of 25% (w/v). The brain tissue was then  
scissor-minced and hom ogenised on ice. The crude hom ogenate was stored 
at -80°C in 1ml aliquots for use in  specific enzyme activity determ inations 
(section 2.2.3.).
2.2.3. Assessment of the Effects of Sex Horm ones and Glucocorticoids on 
CS-Lyase/ Glutam ine Transam inase K /K ynurenine A m inotransferase 
Activity in  Rat Brain and Kidney
The aim of these studies was to determ ine the effects of P-oestradiol, 
progesterone, testosterone, cyproterone acetate (an anti-androgen), 
dexamethasone, corticosterone and m ifepristone (an anti-glucocorticoid) on 
the specific activity of GTK in rat kidney and brain.
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2.2.3.I. Protein Determination Assay
Protein concentrations of kidney cytosolic fractions and brain hom ogenates 
were determ ined by the m ethod of Miller (1959) which is adapted from the 
m ethod of Lowry (1951). Initially this involved the construction of a 
standard curve using bovine serum  album in (BSA) in  the range 0- 
200fig/ml. Standards were prepared using BSA protein standards in a final 
volum e of 1ml w ith milli-Q water. 1ml Solution A, (prepared as 1ml 
CUSO4.5 H2O (5%), 10ml potassium  sodium  tartrate (1%) and 100ml sodium  
carbonate, anhydrous (10%), prepared in NaOH (0.5M)) was added to each 
and incubated for exactly 10 m inutes at room  tem perature. 3ml Folin- 
Ciocalteu reagent (Ix) was then added to reactions, imm ediately vortexed to 
mix, and reactions were then incubated at 50°C for 10 m inutes to allow 
developm ent of colour. Reactions were stopped by transferring tubes to a 
cool water bath. The absorbance of the standards was read at 650nm on a 
Uvikon 932 spectrophotometer (Kontron Instruments) and the standard 
curve plotted. Kidney cytosol and brain hom ogenate samples were prepared 
and the absorbance m easured at 650nm. All protein assays were carried out 
in triplicate. The protein concentrations of the kidney and brain samples 
were read directly from the standard curve. By m easuring the concentration 
of protein in  the kidney and brain samples, the GTK assays could be 
standardised to enzyme activity per mg protein.
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2.2.S.2. Assay for the Determ ination of G lutam ine Transam inase K 
Activity in Rat Kidney and Brain
The m ethod of Cooper and Meister (1985) was employed to calculate the 
specific activity of GTK in kidney cytosol. This assay depends on the ability 
of GTK to catalyse the transam ination reaction between L-phenylalanine 
and a-keto-y -methiol-butyric acid (a-KMB) producing phenylpyruvate and 
L-methionine.
GTK
L-phenylalanine + a-KMB ----------► phenylpyruvate + L-methionine
The reactions were set up in triplicate in  a final volum e of lOOji/l consisting 
of 35^1 GTK reagent (ammediol buffer, made as 200mM solution w ith 2.1g 
2-amino-2-methyl-l,3-propanediol-HCl in 10ml milli-Q water, pH adjusted 
to 9.0 w ith concentrated HCl, and volum e m ade up to 20ml; L- 
phenylalanine (lOmM); a-KMB (5mM, prewarm ed to 37°C)), and kidney 
cytosol or brain hom ogenate (~100//g in 62.5frl milli-Q water). Following a 
10 m inute incubation at 37°C, the reactions were term inated by the addition 
of 0.9ml NaOH (3.33M). Since the phenylpyruvate product was stable for 
only 15 m inutes, the absorbance of phenylpyruvate was im m ediately 
m easured at 322nm and the enzyme activity calculated as shown.
Enzyme activity (nm ol/m in) = Absorbance 322nm
Molar extinction coefficient of pyruvate
(where the molar extinction coefficient of phenylpyruvate at 322nm = e = 24 OOOM'^ cm*^ )
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The specific enzyme activity was then calculated as follows.
Specific activity (nm ol/m in /m g protein) = Enzyme activity (nm ol/m in)
mg protein
2.2.3.S. Statistical Analysis
Statistical analysis of the GTK specific activities (of treated groups compared 
to the appropriate control groups) was carried out using one-way ANOVA, 
followed by the Bonferroni-Dunn post-hoc test for comparison of 
individual groups.
2.2.4. Isolation and Sequencing of the Upstream Regulatory Region from 
the CS-Lyase/Glutamine Transaminase K/Kynurenine Aminotransferase 
Gene
In order to attem pt isolation of the upstream  regulatory region from the CS- 
lyase/GTK/KAT gene, an adapted m ethod of long distance polymerase 
chain reaction (PGR) was employed (Siebert et ah, 1995). This technique 
provides a means of finding unknow n genomic DNA sequences w hich lie 
adjacent to a know n sequence, such as a cDNA sequence, and is also referred 
to as 'Genomewalking'. This approach requires two gene-specific prim ers 
(GSPs) which lie adjacent to one another (i.e. on the same DNA strand in  
the sequence, rather than on opposite DNA strands as in  the m ajority of 
PCR-based technologies) designed against the know n sequence, usually a 
cDNA sequence. Figure 2.4. illustrates the theory behind this technique.
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Genome DNA library diœi 
with restriction endonucTe,
sted
eases
V V V V
I
DNA fragments of various lengths 
present in each library
I
Adaptor sequences are ligated onto each 
rat genonic DNA fragment
4—  GSP (secondary)
N 4—  GSP (primary)
N  1
AP-1 _  
AP-2
GENOMIC D N A  ADAPTOR 
FRAGMENT
AP-1 
primary GSP
PRIMARY PGR
AP-2 
secondary GSP
SECONDARYOR  
'NESTED' PCR
I
Examine PCR products by 
electrophoresis on an 
agarose/EtBr gel
Figure 2.4. Flow diagram illustrating the Genome Walker™ procedure 
(Clontech Laboratories Inc.).
Genomic DNA is digested with restriction enzymes creating 5 genomic 
libraries. GenomeW alker adaptors are then ligated to the ends of each DNA 
fragment in each of the five libraries. The DNA of interest is amplified by 
primary PCR using the primary gene-specific prim er (primary GSP) and 
adaptor prim er 1 (AP-1). The secondary PCR uses the nested gene-specific 
prim er (secondary GSP) and adaptor prim er 2 (AP-2).
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The Rat Genom eW alker™  Kit (section 2.1.2.) provides five restriction 
endonuclease-digested rat genomic DNA libraries w ith a specific adaptor 
sequence ligated onto the ends of each fragment. A 'nested' pair of prim ers 
designed against this adaptor were also provided w ith the kit. Using these 
adaptor primers, and the GSPs designed against the CS-lyase/GTK/KAT 
cDNA sequence, the kit provided a m eans of isolating and amplifying the 
genomic regions between these two sets of prim ers to enable the cloning of 
prom oter regions and other upstream  regulatory elements.
2.2.4.I. Primer Design and Preparation
Using the know n cDNA sequence from the CS-lyase/GTK/KAT gene (Perry 
et al., 1993), a pair of GSPs were designed to 'walk' in  the unknow n 5' 
upstream  region from the rat CS-lyase/GTK/KAT gene. Figure 2.5. 
illustrates a small section of the 5' non-coding region of the CS- 
lyase/GTK/KAT cDNA sequence w ith the GSP binding sites highlighted. 
These GSPs were designed with 40-60% G-C content, as recom m ended for 
m ost PCR-based techniques, and were synthesised by Life Technologies 
(UK). All primers employed in this study are detailed in Table 2.2., and the 
percentage total G-C contents are also given.
95
AAACTBACCAAG6AGTATGATCAATCCCGTCCAGCCTCCGAGCCTGCAGCCGTTTGGTCATGGT6A6C
3 ’ ^4------------------------
3- GSP-4(44-62)
69 TGCTTCAGCTAACAATTGCACTGACAGTGCTCTTGAGCCAAGTTGCTTCTGGGGGGAAGTAGTCCATCT
 GSP-3(52-69) ♦ ---------------------------------------------
5' GSP-2(99-126)
138 AGGGGTCGGCCTCTTTAAAGAAACAGACTTCTGCAACCTTGGGACTACGTTTGGGGTCGCCGGCTATT
%  ^  GSP-K156-180)
206 GGAGGGAGGAGGGGAATTGTTAGGTGAAGGAGGTGAGG
Figure 2.5. The CS-lyase/GTK/KAT cDNA sequence 5’ non-coding region.
The prim ing sites and orientation of the gene-specific prim ers (listed in 
Table 2.2.) are highlighted. GSP-1 (156-180) and GSP-2(99-126) are show n as a 
'nested' pair of primers. GSP-3(52-69) and GSP-4(44-62) are an overlapping 
'nested' pair of primers.
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Table 2.2. Primers used in GenomeWalking experiments
Primer Name Nucleotide sequence %G:C
Content
GSP-1(156-180)
for primary PCR
CCCAAGGTTGCAGAAGTGTGTTTGT 48%
GSP-2(99-126)
for secondary PCR
TTGGGGGGAGAAGGAAGTTGGGTGAAGA 54%
ISP-1
for primary PCR
TGGGGTTGTGTGGAGAGGT 58%
ISP-2
for secondary PCR
AGGAGGGGTGGGGTATAGT 58%
GSP-3(52-69)
for primary PCR
AGGTGAGGATGAGGAAAG 50%
GSP-4(44-62)
for secondary PCR
GATGAGGAAAGGGGTGGAG 58%
AP-1
for primary PCR
GTAATAGGAGTGAGTATAGGGG 48%
AP-2
for secondary PCR
AGTATAGGGGAGGGGTGGT 54%
PCP-1
for primary PCR
GGAGAGTGAGGAATGTGGAGAAAGTGATATGG 47%
PCP-2
for secondary PCR
AGTAGGTTTGGGGAGTAGAGGTGATAGTGAGG 50%
Gene-specific prim ers (GSPs) designed for Genom eW alking experim ents are 
listed, showing the position of nucleotides in the cDNA sequence (Figure 
2.5., Perry et al, 1993) which they were designed against (in brackets). 
Intron-specific prim ers (ISPs) used in the second genom ewalk are also 
detailed. In addition, the nucleotide sequences of the nested pair of adaptor 
prim ers (AP-1 and AP-2) designed against the adaptor sequence are given. 
Finally, the positive control prim ers (PCP-1 and PCP-2) designed against the 
interleukin  6  (IL6 ) gene are listed.
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2.2.4.2. Long Range PCR from the CS-Ly ase/ GTK/K AT Non-Coding 
Sequence into the 5’ Upstream Regulatory Region
The GenomeW alking technique was employed to isolate the prom oter 
region of the CS-lyase/GTK/KAT gene by designing GSPs against the 5' non ­
coding region of the CS-lyase/GTK/KAT cDNA. Using the Rat 
GenomeW alker™  Kit {Clontech Laboratories Inc., USA), and following the 
m anufacturer's recom mendations, PCR amplifications were set up w ith 
each of five genomic libraries provided w ith the kit. These libraries 
contained an assortm ent of genomic DNA fragments, each of which was the 
product of digestion w ith one of five different restriction enzymes {Eco RV, 
Sea I, Dra I, Pvu II, Ssp I) which all recognise a 6  base pair sequence and leave 
blunt ends (Figure 2.4.).
Each primary PCR was set up to contain 0.2mM of each dNTP (dATP, dCTP, 
dGTP, dTTP), Mg(OAc)2 (l.lm M ), AP-1 (0.2jiM) and prim ary GSP (0.2jiM) 
m ade up to a total volum e of 50jil w ith buffer and nuclease-free water. 5ng 
of each digested genomic DNA library and Ijxl of Advantage® Polymerase 
mix were added to each reaction. The Advantage® Polymerase mix contains 
predom inantly Tth DNA polymerase, a proof-reading polymerase and a 
TthStart antibody which provides an easy, automatic form of 'ho t start' PCR. 
'H ot start' is a general term  referring to any m ethod of PCR that keeps one 
or m ore reactants functionally separate from the rest of the com ponents 
prior to the onset of therm al cycling (Kellogg et al., 1994). Positive and 
negative controls were also set up to check for contam ination in  the PCR. A 
positive control was prepared as for the samples (replacing the GSP w ith  the
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positive control primer; PCP-1) using one rat genomic DNA library selected 
at random . The nested pair of positive control primers, provided w ith the 
kit, were designed against the interleukin gene, IL6  (Table 2.2.). Similarly, a 
negative control was prepared, using the GSP and AP-1, but including 
nuclease-free water in the reaction instead of genomic DNA library.
The thermocycling program  for the prim ary PCR amplification was set up as 
show n in a DNA Engine, PTC-200 (MJ Research):
Primary PCR amplification thermocycling conditions
Step 1. 7 cycles 94°C 25 sec
72°C 4 m in
Step 2. 32 cycles 94°C 25 sec
67°C 4 m in  (adjusted to 53°C for later 
genomewalks)
Step 3. 67°C (adjusted to 53°C for later genomewalks) for an additional
4 m in following the final cycle
Primary PCRs were analysed on a 1.5% agarose/EtBr gel. The secondary or 
'nested' PCR amplifications were set up using either 1/zl of the prim ary PCR 
reaction or a plug sample taken directly from the band on the prim ary PCR
agarose/EtBr gel (using a sterile pipette tip). The concentrations of dNTPs,
Mg(OAc)2, secondary GSP and AP-2 were the same as for the prim ary PCR 
amplification. Secondary PCRs were analysed on a 1.2% agarose/EtBr gel.
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'Nested' secondary PCR amplification thermocycling conditions
Step 1. 5 cycles 94°C 25 sec
72°C 4 m in
Step 2. 18-22 cycles 94°C 25 sec
67°C 4 m in  (adjusted to 53°C for later 
genomewalks) i
Step 3. 67°C (adjusted to 53°C for later genomewalks) for an additional
4 m in following the final cycle
The Tth DNA polymerase produces fragments w ith 'A ' overhangs which 
can be ligated into a TOPO™TA cloning® vector w ith relative ease.
2.2.4.S. PCR Product Purification.
The Wizard® PCR Preps DNA Purification System {Promega Ltd, UK) was 
employed to purify the PCR product from the PCR reactants, contam inants, 
amplification primers and prim er-dim ers in preparation for cloning into a 
pCR®2.1-TOPO cloning vector. This kit uses a resin colum n which binds 
agarose gel-separated DNA of various fragment lengths. DNA of 500bp in 
length is 70-90% recovered from the resin, however, recovery declines w ith  
smaller fragment lengths and DNA which is over lOkb may be sheared 
through the column. The m anufacturer's recom m endations were followed 
to purify the PCR product from the agarose/EtBr gel using the vacuum  
manifold procedure.
2.2.4.4. Cloning of PCR Product into pCR®2.1-TOPO Vector
The TOPO™TA Cloning® Kit {Invitrogen BV, The Netherlands) provides a 
quick m ethod of introducing a PCR product into a TOPO™TA Cloning®
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vector. This kit is based on the heat-shock approach for the introduction of 
genetic m aterial into bacterial cells. The protocol provided w ith the kit was 
followed to ligate the PCR product into the vector, and subsequently 
transform  TOPlOF' One Shot™ E. coli cells w ith the vector. TOPO™ TA 
Cloning® is unusual because a DNA ligase is not used in the ligation 
reaction. The cloning relies on the 3'-A overhangs of the PCR product 
ligating to the 5'-T overhangs in the cloning vector. Fresh PCR products 
were used in the ligation reaction to ensure that no degradation of the 
single 3'-A overhangs occurred, which would prevent ligation into pCR®2.1- 
TOPO vector. Ligation reactions were set up w ith the purified PCR product 
(lOng//il) and the pCR®2.1-TOPO™ TA cloning vector (Figure 2.2.) (lOng//il) 
in  a final volum e of 5pl w ith nuclease-free water, and incubated for 5 
m inutes at room  tem perature.
The recom binant DNA was transform ed into competent TOPlOF' E. coli 
cells using the 'heat shock' m ethod. By heating the cells to 42°C, the cell 
surface was modified to be permeable to DNA. The transform ed bacteria 
were then spread onto LB agar plates containing ampicillin (50|xg/ml), X-Gal 
(40mg/ml), and IPTG (0.5mM), and incubated at 37°C overnight.
Single white colonies were picked from the agar plates, using a sterile 
toothpick, and m inicultures were prepared (section 2.2.I.I.) M inicultures 
were incubated at 37°C overnight (12-16 hours), w ith agitation. 100/i 1 of 
each m iniculture was rem oved to a microfuge tube and crude DNA extracts 
were prepared by adding an equal volum e of phenol, and vortexing for 15
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seconds. These extracts were then electrophoresed on a 1.2% agarose/EtBr 
gel (section 2.2.I.4.), providing a simple m ethod of determ ining which 
m ini cultures contained vector DNA with a successfully ligated PCR product 
insert. These cultures were then identified and the DNA extracted from 
them  (section 2.2.I.I.).
2.2.4.S. DNA Sequencing of Cloned PCR Product
DNA sequencing was performed by the autom ated fluorescence m ethod on 
PCR products (generated from GenomeW alking) which had been ligated 
into the pCR®2.1-TOPO cloning vector. DNA sequencing was perform ed 
using an Applied Biosystems 373A autom ated DNA sequencer by Mr Roy 
Jadhubanda (University of Surrey DNA Sequencing Department). This 
technique is based on a dideoxy sequencing reaction using fluorescent dye- 
labelled dNTPs and T7 DNA polymerase. Reactions were prepared using 
800ng sample DNA, 3.2pmol M13 forward (-20) or M13 reverse primers, in a 
final volum e of 12|il w ith nuclease-free water. The addition of T7 DNA 
polymerase allows the generation of a replica DNA sequence where each 
nucleotide is labelled w ith dye. The samples were then  electrophoresed 
through an acrylamide gel and separated according to size. W hen a 
fragment reaches a fixed position, above the lower buffer chamber of the 
apparatus, the fluorescence of the dyes is excited by light from a laser (which 
scans back and forth across the gel). A photo m ultiplier tube detects the 
fluorescent light and converts it into an electrical signal w hich is 
transm itted for processing into sequence data. The sequence of their colours 
directly yields the base sequence (Smith et al, 1986).
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2.2.5. Localisation of CS-Lyase/GIutamine Transaminase K/Kynurenine 
Aminotransferase mRNA in Rat Brain
To investigate the factors which regulate the expression of the CS- 
lyase/GTK/KAT gene in the rat, in situ hybridisation was utilised to 
provide quantitative localisation of CS-lyase/GTK/KAT m RNA in the 
brain. This was accomplished by transcribing cRNA, from tem plate CS- 
lyase/GTK/KAT cDNA, in both sense and antisense directions to generate 
pS]-labelled cRNA riboprobes. These riboprobes were then  hybridised to rat 
brain sections, and regional quantitation assessed by film autoradiography. 
To m inim ise contam ination by RNases in the m ethods which follow, all 
solutions were prepared w ith DEPC which is a strong, but not complete, 
inhibitor of RNases (Fedorcsak & Ehrenberg, 1966). Solutions were treated 
w ith DEPC (0.1%) for at least 12 hours at 37°C, then autoclaved, w ith the 
exception of solutions containing amines (such as Tris buffers), as DEPC 
reacts rapidly w ith amines (Sambrook et ah, 1989).
2.2.5.I. Preparation of Probe Template
Previously, a 243 bp sequence corresponding to nucleotides 181 to 424 of the 
5' region of CS-lyase/GTK/KAT cDNA had been cloned into a pGEM®-T 
vector (Plant et ah, 1997). JM109 E. coli cells transform ed w ith this plasm id 
were grown in a mini culture, overnight at 37°C w ith agitation. Plasmid 
DNA was extracted from the m ini culture (section 2.2.1.1.), and then  
precipitated in ethanol to further purify the DNA (section 2.2.1.2.).
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2.2.5.2. Linearisation of Probe Template DNA
In order to generate cRNA riboprobes in sense and antisense directions, the 
template DNA was linearised by two restriction enzymes {Sal I for the sense 
riboprobe, and Nco I for the antisense probe). Restriction digests were set up 
to contain 10 units restriction enzyme, -lOjug tem plate DNA, 2jul buffer 
(supplied w ith restriction enzyme), O.Sjul BSA (O.lmg/ml), and DEPC-treated 
water to a final volum e of 20/zl. Digests were incubated overnight at 37°C to 
ensure complete linearisation of tem plate DNA. To confirm that 
linearisation of the tem plate was complete, samples of digested and non ­
digested DNA were electrophoresed on a 1.2% agarose gel containing EtBr 
(section 2.2.1.4.) and observed under UV light.
2.2.5.3. Transcription of P®S]-Labelled cRNA Riboprobes
Using the Riboprobe® Combination System {Promega Ltd, UK) cRNA 
riboprobes were generated by SP6 and T7 RNA polymerases. SP6 
polymerase and T7 polymerase transcribe sense (non-specific) and antisense 
(specific) riboprobes, respectively. Initially, non-radiolabelled probes were 
transcribed from a positive control tem plate and pTA243 to ensure 
sufficient transcription. W hen a successful transcription was confirmed on a 
1.5% agarose gel (section 2.2.1.4.), pS]-labelled UTPaS was included in  the 
transcription reaction. Typical transcriptions were prepared in  a total 
volum e of 20jul as follows:
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2/il Transcription Optimised Buffer (5x)
2/il DTT (lOOmM)
0.5/il Recombinant RNasin Ribonuclease Inhibitor (20 units)
4/il rNTPs (rATP (25/iM), rCTP (25/iM), rCTP (25pM) and rUTP 
(10/iM))
2.5/il linearised DNA tem plate (0.2-1.0mg/ml in TE buffer) 
l/il SP6/T7 RNA polymerase (15-20 units)
3/il PS]-labelled UTPaS (30pCi)
5^1 DEPC-treated water
Transcriptions were incubated at 37°C for the sense probe (T7 RNA 
polymerase), and 42°C for the antisense probe (SP6 RNA polymerase). After 
one hour, an additional Ip l SP6 or T7 RNA polymerase was added to each 
transcription to increase the yield of riboprobe, and incubated for a further 
hour at the appropriate tem perature. The cRNA riboprobes were stable for 
two weeks prior to use in hybridisation, w hen stored in hybridisation buffer 
(formamide (50%), dextran sulphate (50%), Ficoll (0.02%), polyvinyl 
pyrrolidone (0.02%), BSA (0.02%), tRNA (500/ig/ml), DTT (lOmM), NaCl 
(0.3M), Tris (lOmM, pH8.0), EDTA (ImM, pH8.0), vortexed to mix) at -20°C.
2.2.S.4. Test of Incorporation of Radiolabel into cRNA Riboprobe
The efficiency of the 'ho t' transcription was tested by determ ination of the 
percentage of radiolabel which had been incorporated into the riboprobe. 
This involved spotting 0.5//1 of radiolabelled probe onto two halves of DE-81 
filter paper, and allowing them  to dry thoroughly. One half of the filter 
paper was then subjected to a series of washes ( 3 x 5  m ins NagHPO^ (0.5M), 
2 x 5  m ins milli-Q water, 100% ethanol rinse). A direct com parison was
105
then made of the radioactivity of the washed half to the unw ashed half as 
m easured on a Geiger counter in counts per second (cps), and the percent 
incorporation calculated as:
percent incorporation = cps washed filter paper x 100
cps unwashed filter paper
(where a percent incorporation of 60% or above is essential for hybridisation 
work).
2.2.5.5. Preparation of Rat Brain Tissue for Sectioning
Rats were killed by decapitation and intact, whole brains were rem oved 
immediately. Brains were rapidly frozen in isopentane at -20°C and stored 
at -80°C for up to one m onth  before tissue sectioning.
2.2.5.6. Cryostat Sectioning of Brain Tissue
Rat brains were m ounted in OCT com pound and secured into the cryostat 
{Zeiss M icrom ) . Adjacent 20jum coronal sections of rat brain, for sense and 
antisense binding of cRNA riboprobes, were cut at SOOjum intervals at -20°C 
and m ounted onto poly-L-lysine coated slides. Slides were stored for one 
week at-20°C prior to fixation in formaldehyde (4%), containing PBS (O.IM, 
pH 8.0), for one hour at room  tem perature. Following fixation, slides were 
washed 2 x 5  m ins in PBS (O.IM), air-dried, and stored at -4°C prior to in situ 
hybridisation.
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2.2.S.7. In situ  Hybridisation
All solutions involved in  the hybridisation steps were m ade w ith DEPC- 
treated milli-Q water to elim inate RNase contam ination and all incubations 
were carried out at room  tem perature, unless otherwise stated. Brain 
sections were allowed to warm  to room  tem perature before use.
(i) Pre-hybridisation
Pre-hybridisation prepares the tissue for hybridisation by partially digesting 
the cell structure allowing easier access of the cRNA riboprobe to CS- 
lyase/GTK/KAT m RNA in the tissue. The pre-hybridisation steps below 
were followed:
• proteinase K digestion (0.05/zg/ml) 10 m ins
(in O.IM Tris pH 8.0; 0.05M EDTA pH 8.0)
• milli-Q water rinse
• TEA wash (O.IM, pH 8.0) 2 m ins
• acetic anhydride (0.25%) in  TEA (O.IM) 10 m ins
(to remove positive charges)
• SSC (2x) washes 2 x 2  m ins
(Standard Saline Citrate (SSC) solution is prepared w ith  NaCl (175.32g) and 
Sodium citrate (88.23g) then made up to 800ml w ith  m illi-Q  H 2O, pH adjusted to 7.3 
w ith lOM NaO H  and volume adjusted to 11. Stored at room temperature).
Finally, the sections were dehydrated by washing in  ascending 
concentrations of freshly prepared ethanol (50%, 70%, 95%, 100%, 100%) for 
3 m inutes each, then air-dried.
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(ii) Hybridisation
The hybridisation solutions containing P^S]-UTPaS radiolabelled cRNA 
riboprobe (section 2.2.S.3) were heated to 65°C for 10 m inutes to m elt any 
annealed strands, then centrifuged at 1,500 xg for 10 m inutes to elim inate 
dextran sulphate precipitates. The hybridisation solutions were placed onto 
sections and sealed onto the slide with a coverslip, using DPX liquid 
m ountant. cRNA riboprobes were allowed to hybridise to m RNA in the 
sections, overnight (16-20 hours) on a slide warming tray preheated to 60°C.
(iii) Post-hybridisation
To rem ove any cRNA riboprobe, specific or non-specific, which had not 
bound to the section the post-hybridisation washing and digestion steps 
listed below were followed:
• SSC (4x) 30 m ins
• SSC (4x) 4x 5 m ins
• RNase A (20mg/ml) 30 m ins at 37°C
(in lOmM Tris pH 8.0; Im M  EDTA pH 8.0; 0.5M NaCl)
(to remove all non-specifically bound cRNA riboprobe, as RNase A is specific for 
ssRNA)
The following washing steps were included to gradually rem ove salt from  
the sections.
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• SSC (2x) + DTT (ImM) 2x 5 m ins
• SSC (Ix) + DTT (ImM ) 10 m ins
• SSC (0.5x) + DTT (ImM) 10 m ins
• SSC (O.lx) + DTT (ImM) 10 m ins at 62°C
The slides were then cooled in SSC (O.lx) and dehydrated in ethanol washes 
as listed, for 3 m inutes per wash.
• ethanol (50%) + SSC (0.08x) + DTT (ImM)
• ethanol (70%) + SSC (0.08x) + DTT (ImM)
• ethanol (95%)
• ethanol (100%)
• ethanol (100%)
Finally, slides were air-dried for 30 m inutes, then  apposed to p-max 
autoradiographic film for 7-10 days at 4°C. Following exposure, films were 
developed in D-19 developer w ith gentle agitation. The developing reaction 
was stopped, after 4 m inutes, w ith milli-Q water, containing glacial acetic 
acid, for 30 seconds. The images on the film were fixed in Kodak Rapid Fix 
for 4 m inutes, washed for 30 m inutes in  milli-Q water, w ith  gentle 
agitation, then left to dry prior to analysis.
2.2.5.S. Quantitation of CS-Lyase/GTK/KAT m RNA in Rat Brain
Sections using the M O D  Image Analysis System
An MCID Image Analyser (Imaging Research) was used to quantitate CS- 
lyase/GTK/KAT mRNA density (nCi/m g tissue) against a calibration curve 
derived from know n f^C] brain paste standards, which were laid dow n w ith
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each film. f^C] brain paste standards are preferable to P^S] brain paste 
standards due to their longer half-life (Clark & Hall, 1986). CS- 
lyase/GTK/KAT m RNA densities were calculated by subtracting sense 
values from antisense values, w ith m easurem ents being taken from regions 
on both sides of the brain section and across several sections, where 
required. The films were quantified at the same neuroanatom ical level by 
taking Bregma points from the rat brain atlas (Paxinos and W atson, 1986) for 
42 neuroanatom ical regions previously show n to contain CS- 
lyase/GTK/KAT mRNA (Plant et ah, 1997).
For each of the 42 neuroanatom ical regions quantified, the m ean and 
standard error of the m ean (s.e. mean) were calculated, for com parison 
between treated and untreated control groups using one-way analysis of 
variance (ANOVA).
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CHAPTERS
THE EFFECT OF GLUCOCORTICOIDS AND SEX 
HORMONES ON GLUTAMINE TRANSAMINASE K SPECIFIC 
ACTIVITY IN MALE RAT BRAIN AND KIDNEY
3.1. INTRODUCTION
The involvem ent of the glucocorticoids and sex steroid horm ones in  the 
regulation of several enzymes involved in xenobiotic metabolism has long 
been established (Honkakoski & Negishi, 2000). Glucocorticoids bind to 
cytoplasmic receptor proteins, know n as glucocorticoid receptors (GRs), 
which act as ligand-dependent transcription factors. Following dim érisation 
of two horm one /  horm one-receptor complexes, they bind to specific 
palindrom ic DNA sequences (Beato et al., 1989) and can induce or inhibit 
gene expression through a process called frans-activation or trans- 
repression, respectively. During frans-activation, the horm one-activated 
GR binds to a regulatory sequence called a glucocorticoid response elem ent 
(GRE) (Beato & Sanchez-Pacheco, 1996).
Glucocorticoids have been reported to be involved in the frans-activation of 
the tyrosine aminotransferase gene (Jantzen et al., 1987). Also, the ability of 
glucocorticoids and sex horm ones to induce cytochrome P450s, such as 
CYP2B, has been extensively studied (Corcos, 1992; Dannan et al., 1986; 
Gonzalez, 1988; Jarukam jorn et ah, 2001; Nem oto & Sakurai, 1995; W hitlock, 
1986). The sex steroid horm ones have also been reported to affect the
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expression of enzymes, such as CYP2D, in various brain regions (Bergh & 
Strobel, 1996).
Following ontogeny studies, it was hypothesised that these horm ones may 
also be involved in the physiological m odulation of the CS-lyase/GTK/KAT 
gene (Plant et al., 1997). Using in situ hybridisation techniques and cRNA 
riboprobes prepared from a 243bp sequence (nucleotides 181-424) specific to 
the 5' region of the cDNA (Perry et al., 1993), Plant et al (1997) m apped and 
quantified the levels of CS-lyase/GTK/KAT mRNA in the male rat brain 
during post-natal development. Plant et al (1997) reported that the levels of 
CS-lyase/GTK/KAT mRNA were m odulated during developm ent 
according to neuroanatom ical region. In many regions, such as the anterior 
commissure and corpus callosum, the CS-lyase/GTK/KAT m RNA levels 
increased gradually from post-natal day 14 to adult levels by post-natal day 
35. In some regions (medial forebrain bundle, lateral septal nuclei, cerebral 
penduncle, granular retrosplenial cortex and tem poral cortex) a higher level 
of mRNA expression was found, w ith adult levels detected by post-natal day 
28. A very different pattern of expression was shown in the fronto-parietal 
cortex and the basoamygdaloid nuclei, where a m aximal level was reached 
at post-natal day 28 which then decreased back to adult levels by post-natal 
day 42.
The ability of glucocorticoids and sex horm ones to m odulate GTK activity in 
male rat brain and kidney will be examined, utilising the established GTK 
assay of Cooper and Meister (1985).
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3.2. THE EFFECT OF GLUCOCORTICOID HORMONES ON THE SPECIHC 
ACTIVITY OF GLUTAMINE TRANSAMINASE K IN MALE RAT BRAIN 
AND KIDNEY
The effects of the glucocorticoids; dexamethasone and corticosterone, and 
the anti-glucocorticoid; m ifepristone (RU-486), on the specific activity of 
GTK in rat kidney and brain were determined. Corticosterone (Figure 3.1.) 
is the m ain endogenous glucocorticoid in the rat (Henning, 1978). It is 
produced from the hydroxylation of progesterone in the zona fasciculata of 
the adrenal cortex, following secretion of adrenocorticotrophic horm one 
(ACTH) from the anterior pituitary gland. ACTH stimulates the conversion 
of cholesterol into pregnenolone, the precursor of all steroid horm ones, via 
steroidogenic acute regulatory (StAR) protein (Cherradi et al., 1998). The 
pharmacology of the glucocorticoids is reviewed in Meaney et al (1993).
Dexamethasone (Figure 3.1.) was also studied as a potential m odulator of 
GTK activity as it is a synthetic glucocorticoid which is know n to be a potent 
inducer of many enzymes involved in xenobiotic metabolism (Jarukam jorn 
et al., 1999; Jarukam jorn et al., 2001; M eehan et al., 1988). M ifepristone 
(Figure 3.1.) was also used to determ ine the effect of an anti-glucocorticoid 
(Spitz & Bardin, 1993) on the specific activity of GTK in male rat kidney and 
brain. In addition to it's anti-glucocorticoid properties, m ifepristone has 
also been show n to inhibit the growth of breast cancer cell lines via the 
progesterone receptor (Bardon et al., 1985). By studying the effect of 
mifepristone on GTK specific activity, the ability of glucocorticoids and sex
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steroid horm ones to m odulate CS-lyase/GTK/KAT levels in rat brain and 
kidney can be evaluated further.
It was decided to use post-natal day 21 rats for the prelim inary experiments 
since it is after this age that endogenous levels of glucocorticoids rise 
(Henning, 1978). This m inim ised the effects of endogenous glucocorticoids 
and sex horm ones on the specific activity of GTK.
3.2.1. Prelim inary Experiments
Preliminary experiments were carried out to establish the effects of 
dexamethasone, corticosterone and m ifepristone on the specific activity of 
GTK in post-natal day 21 male rat brain and kidney. Following segregation 
into groups of four, rats were treated w ith water vehicle controls, 
dexamethasone (lOO.Omg/kg) or corticosterone (30.0mg/kg). The 
dexamethasone and corticosterone doses used have both been show n to 
induce the activity of metabolic enzymes in the kidney (Jarukam jorn et al., 
2001) and also serotonin S-HTj^ receptors in brain (Gur et al., 2001). Also, in  
separate groups, rats were adm inistered 10% ethanol vehicle control and 
m ifepristone (lO.Omg/kg) in 10% ethanol vehicle. H orm ones were
administered in a volum e of 4pl per gm anim al weight. The range of 
injected volum es was from lOOpl to 350pl.
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Figure 3.1. Structures of the glucocorticoid, corticosterone; synthetic gluco­
corticoid, dexamethasone; and anti-glucocorticoid, m ifepristone (RU-486).
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3.2.1.1. The Effect of Dexamethasone, Corticosterone and Mifepristone 
on Glutamine Transaminase K Specific Activity in Post-Natal Day 21 
Male Rat Kidney
As illustrated in Figure 3.2., dexamethasone treatm ent (lOO.Omg/kg) 
significantly increased the specific activity of GTK in post-natal day 21 male 
rat kidney, w hen compared to the water vehicle control. Corticosterone 
(30.0mg/kg) increased the GTK specific activity in m ale rat kidney to a 
greater extent than following dexamethasone treatm ent. Conversely, the 
anti-glucocorticoid, m ifepristone (lO.Omg/kg), was found to have no effect 
on the specific activity of GTK.
3.2.1.2. The Effect of Dexamethasone, Corticosterone and Mifepristone 
on Glutamine Transaminase K Specific Activity in Post-Natal Day 21 
Male Rat Brain
In post-natal day 21 male rat brain, i.p. adm inistration of dexam ethasone 
resulted in a significant induction of GTK specific activity, w hen compared 
to the water control (Figure 3.3.). An elevation of GTK specific activity was 
also produced in the brains of the corticosterone-treated group, where a 
significant increase was observed. A lthough induction of GTK in  brain was 
observed w ith both glucocorticoids, the effect of dexam ethasone was m ore 
pronounced in the brain than in the kidney, whereas the effects of 
corticosterone were similar in both tissues. The lack of effect of 
mifepristone (lO.Omg/kg) on rat brain GTK specific activity was consistent 
w ith the studyn in the kidney. Mifepristone failed to influence the specific 
activity of GTK in either a stimulatory or an inhibitory m anner.
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Figure 3.2. Effect of glucocorticoids on glutamine transaminase K 
specific activity in post-natal day 21 male rat kidney.
Glutamine transaminase K specific activity in kidney cytosolic extracts 
from post-natal day 21 male rats treated with glucocorticoids; 
dexamethasone (Dex., lOOmg/kg) or corticosterone (Cort., 30mg/kg); or 
antiglucocorticoid, mifepristone (lOmg/kg). Results are expressed as the 
mean (± s.e. mean) where n=4 for each treatment group. *P < 0.005, 
**P < 0.01,***P < 0.001.
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Figure 3.3. Effect of glucocorticoids on glutamine transaminase K 
specific activity in post-natal day 21 male rat brain.
Glutamine transaminase K specific activity in brain homogenates from 
post-natal day 21 male rats treated with glucocorticoids; dexamethasone 
(Dex., lOOmg/kg) or corticosterone (Cort., 30mg/kg); or 
antiglucocorticoid, mifepristone (lOmg/kg). Results are expressed as 
the mean (± s.e. mean) where n=4 for each treatment group. *P < 0.005, 
**P < 0.01, ***P < 0.001.
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3.2.2. The Effect of Dexamethasone on Glutam ine Transam inase K Specific 
Activity in Male Rat Kidney
Having observed an increase in specific enzyme activity of GTK in post­
natal day 21 male rat kidney, following i.p. adm inistration of 
dexamethasone (lOO.Omg/kg), in the prelim inary experiments the effect of 
two lower doses of dexamethasone (1.0 and lO.Omg/kg), in the same age rats, 
was examined to determ ine if this induction was dose-dependent.
On comparison w ith the results of the prelim inary experiment, the specific 
activities of the groups treated w ith l.Omg/kg and lO.Omg/kg 
dexamethasone (Figure 3.4.) were both higher than  the induction in  specific 
activity observed with lOO.Omg/kg. In fact, the induction observed was 
higher in the kidney of rats in the lO.Omg/kg dexamethasone-treated group, 
where a significant elevation was seen. The GTK specific activity in  the 
l.Omg/kg dexamethasone-treated group was lower than that observed w ith 
lO.Omg/kg dose, but still significantly higher w hen compared to the water 
control. Since the inductions observed w ith the lower doses of 
dexamethasone were greater than  w ith the lOO.Omg/kg dose, it was decided 
to use 1.0 and lO.Omg/kg doses of dexamethasone for subsequent studies.
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As the initial study involved only post-natal day 21 male rats, it was decided 
to examine the effect of dexamethasone at various post-natal ages around 
this day to determ ine whether different patterns of induction occurred. 
Using l.Omg/kg and 10.0 m g/kg doses of dexamethasone, the effect on the 
GTK specific activity on post-natal days 19, 23, 25 and 30 was therefore 
studied.
At post-natal day 19, dexamethasone treatm ent did not significantly increase 
or decrease the specific activity of GTK in male rat kidney at either 
l.Omg/kg or lO.Omg/kg (Figure 3.4.). Similarly, following the same 
dexamethasone treatm ent at post-natal days 23, 25 and 30 there was no 
significant m odulation of GTK specific activity observed.
Additionally, Figure 3.4. clearly shows that the specific activity of GTK in  the 
male rat kidney of the control groups, was observed to rem ain level at 
around lOOnm ol/m in/m g at post-natal day 19 and 21, double by post-natal 
day 23, and fall again to llO nm ol/ m in / mg at post-natal days 25 and 30.
3.2.3. The Effect of Dexamethasone on G lutam ine Transam inase K Specific 
Activity in Male Rat Brain
Since the prelim inary experiments on post-natal day 21 male rat brain 
revealed a significant increase in GTK specific activity using a lOO.Omg/kg 
dose of dexamethasone, the brain hom ogenates from rats treated w ith the 
lower doses of l.Omg/kg and lO.Omg/kg dexamethasone (see section 3.2.2.),
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were used to determ ine the specific activity of GTK in post-natal day 19, 21, 
23, 25 and 30 male rat brain.
In Figure 3.5. it can clearly be seen that, as observed in the kidney, 
dexamethasone does not affect GTK specific activity at post-natal day 19 at 
either dose, l.Omg/kg or lO.Omg/kg. The results for post-natal days 23, 25 
and 30, were also similar to that observed for the kidney. No induction or 
suppression of GTK specific activity was apparent in male rat brain 
following l.Omg/kg or lO.Omg/kg dexamethasone treatm ent.
However, at post-natal day 21, both i.p. doses of dexamethasone (l.Omg/kg 
and lO.Omg/kg) significantly up-regulated GTK specific activity in brain, 
where the lO.Omg/kg dose increased the specific activity by two-fold greater 
than w ith l.Omg/kg. These observed effects m irrored the pattern of 
induction observed in the kidney, to a greater absolute level.
Changes in the GTK specific activities of the brain control groups followed a 
different pattern to that seen in the kidney. W hereas kidney activities 
peaked around day 23, the brain activities progressively increased from  post­
natal day 19 through to 30, from 20nm ol/m in /m g protein to over 
70nm ol/ m in /m g  protein.
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3.2.4. The Effect of Corticosterone on G lutam ine Transam inase K Specific 
Activity in Male Rat Kidney
Since the two lower doses of dexamethasone (l.Omg/kg and lO.Omg/kg) 
were capable of inducing GTK in kidney and brain, it was decided to use 10- 
and 100-fold lower doses of corticosterone also, 3.0mg/kg and 0.3mg/kg, 
respectively. Using the same dosing criteria as the dexam ethasone study, 
the effects of 0.3mg/kg and 3.0mg/kg corticosterone were studied in rat 
kidney at post-natal day 19,21,23,25 and 30.
The pattern of induction of GTK specific activity following corticosterone 
treatm ent was very different to that observed w ith dexam ethasone 
treatm ent in the age-matched male rats (Figure 3.6.). M odulation of the 
specific activity of GTK was apparent at all ages studied, w ith one or both of 
the doses administered. At post-natal day 19, corticosterone treatm ent 
significantly increased specific activity w ith the 0.3mg/kg dose, but failed to 
induce at the 10-fold higher dose. A very sim ilar pattern was seen w ith  days 
23, 25 and 30, where the lower dose of 0.3mg/kg induced GTK to a greater 
extent than the higher dose of 3.0mg/kg. At post-natal day 23, GTK specific 
activity was increased significantly w ith the 0.3mg/kg dose. As w ith  the day 
19 results, no significant increase was found in the 3.0mg/kg corticosterone- 
treated group. At post-natal day 25, 0.3mg/kg corticosterone treatm ent lead 
to a highly significant increase in specific activity, w ith the 3.0mg/kg 
treatm ent group displaying some induction in kidney GTK specific activity. 
In the older age group of post-natal day 30 rats, some induction at both doses 
was observed. The pattern of m odulation differed markedly in the post-
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natal day 21 group, as the 3.0mg/kg dose enhanced specific activity of GTK to 
a greater extent than the lower dose.
3.2.5. The Effect of Corticosterone on G lutam ine Transam inase K Specific 
Activity in  Male Rat Brain
At post-natal day 19, an increase in  GTK specific activity was observed in the 
0.3mg/kg corticosterone-treated group, w ith no induction in the group 
adm inistered the glucocorticoid at a 10-fold higher dose (Figure 3.7.). On 
post-natal day 21, induction was observed with both doses of corticosterone, 
but the pattern differed to that on post-natal day 21 in kidney. On post-natal 
day 23 in rat brain, induction in specific activity was observed w ith both 
doses. Similarly, on post-natal day 30, GTK specific activity was induced at 
both dose levels. The data for post-natal day 25 failed to show any 
significant change in specific activity of GTK, at either dose administered.
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3.3. THE EFFECT OF SEX HORMONES ON THE SPECIFIC ACTIVITY OF 
GLUTAMINE TRANSAMINASE K IN MALE RAT BRAIN AND KIDNEY
The effects of the sex horm ones P-oestradiol, progesterone, testosterone and 
the anti-androgen cyproterone acetate (Figure 3.8.), on the specific activity of 
GTK in rat kidney and brain, were determined. Secretion of the steroid 
horm one progesterone is stim ulated following secretion of gonadotrophin 
releasing horm one (GnRH) from the hypothalam us. This, in  turn, triggers 
the release of follicle-stimulating horm one (FSH) and luteinising horm one 
(LH) from the anterior pituitary which target the female gonads. The 
synthesis of androgens begins w ith hydroxylation of progesterone at C-17 to 
produce 17a-hydroxyprogesterone. Following cleavage of the side chain, 
androstene-dione is generated, which undergoes reduction of the 17-keto 
group to yield testosterone. Testosterone can be further metabolised to 
produce p-oestradiol. The actions of progesterone are m ediated via 
progesterone receptors (PRs). In rat, two forms of PR exist; PR-B, a full 
length form (110 kDa), and PR-A, an N -term inus truncated form (86 kDa) 
(Camacho-Arroyo et aL, 1995).
To m aintain  consistency w ith the glucocorticoid experiments, the effects of 
p-oestradiol, progesterone, testosterone, and the anti-androgen cyproterone 
acetate, were examined to determ ine w hether these steroid horm ones could 
m odulate the specific activity of GTK in  male rat brain and kidney.
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Figure 3.8. Structures of the sex hormones; p-oestradiol, progesterone and 
testosterone; and the anti-androgen, cyproterone.
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3.3.1. Preliminary Experiments
Preliminary experiments were carried out to determ ine w hether any of the 
com pounds above could alter GTK specific activity in post-natal day 21 male 
rats. Rats were treated w ith water vehicle controls, p-oestradiol (lO.Omg/kg) 
or progesterone (lO.Omg/kg), or 10% ethanol vehicle control, testosterone 
(lO.Omg/kg) or cyproterone acetate (lO.Omg/kg). These doses have 
previously been reported to m odulate other renal and brain enzymes.
3.3.I.I. The Effect of P-Oestradiol, Progesterone, Testosterone and 
Cyproterone Acetate on Glutamine Transaminase K Specific Activity in 
Day 21 Male Rat Kidney and Brain
As show n in Figure 3.9., the only com pound capable of upregulating the 
specific activity of GTK in post-natal day 21 male rat kidney was 
progesterone. Figure 3.10. clearly shows that the same effect was found in  
the brain.
Future work w ith sex steroid horm ones was therefore focused on the effect 
of progesterone, to determ ine any dose- or age-dependency. GTK specific 
activity was examined in  post-natal day 19, 21, 23, 25 and 30 m ale rats 
following i.p. adm inistration of progesterone.
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Figure 3.9. Effect of sex hormones on glutamine transaminase K 
specific activity in post-natal day 21 male rat kidney.
Glutamine transaminase K specific activity in kidney cytosolic extracts 
from post-natal day 21 male rats treated with sex hormones; P -oestradiol 
(P"Oestr., lOmg/kg), progesterone (Prog., 1 Omg/kg), testosterone 
(Testost., 1 Omg/kg), or anti-androgen, cyproterone acetate (Cyp. Ac., 
1 Omg/kg). Results are expressed as the mean (± s.e. mean) where n=4 
for each treatment group. *P < 0.005, **P < 0.01, ***P < 0.001.
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Figure 3.10. Effect of sex hormones on glutamine transaminase K 
specific activity in post-natal day 21 male rat brain.
Glutamine transaminase K specific activity in brain homogenates 
from post-natal day 21 male rats treated with sex hormones; 
p-oestradiol (p-Oestr., 1 Omg/kg), progesterone (Prog., 1 Omg/kg), 
testosterone (Testost., lOmg/kg), or anti-androgen, cyproterone 
acetate (Cyp. Ac., 1 Omg/kg). Results are expressed as the mean (± s.e. 
mean) where n=4 for each treatment group. *P < 0.005, **P < 0.01, 
***P < 0.001.
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3.3.2. The Effect of Progesterone on Glutamine Transaminase K Specific 
Activity in Male Rat Kidney
The dose-related effects of progesterone at different post-natal ages are 
show n (Figure 3.11.). It is quite clear that the only age of rats in  which 
progesterone was found to m odulate GTK specific activity in kidney is at 
post-natal day 21. At post-natal days 19, 23, 25 and 30, no significant 
alteration of activity was found.
3.3.3. The Effect of Progesterone on Glutamine Transaminase K Specific 
Activity in Male Rat Brain
As show n in Figure 3.12., at post-natal days 19 and 30 there was no 
significant m odulation of GTK specific activity following adm inistration of 
l.Omg/kg or lO.Omg/kg progesterone. At post-natal day 21, a dose of 
l.Omg/kg was capable of upregulating specific activity but lOmg/kg had no 
significant effect. Conversely, at post-natal day 25, l.Omg/kg progesterone 
failed to m odulate the specific activity, however, the 10-fold higher dose did 
increase specific activity.
The age group where the largest induction was observed was at post-natal 
day 23. This was the only age where both doses of progesterone significantly 
elevated the specific activity of GTK.
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3.4. DISCUSSION
3.4.1. The Effect of Glucocorticoids on the Regulation of Glutamine 
Transaminase K in Male Rat Brain and Kidney
In the prelim inary experiments, both corticosterone and the synthetic 
glucocorticoid dexamethasone successfully m odulated the specific activity of 
GTK in post-natal day 21 male rat kidney and brain (Figures 3.2. and 3.3.). 
The anti-glucocorticoid, m ifepristone (RU-486), failed to induce or suppress 
this activity in either kidney or brain. On reflection, the lack of any 
stimulatory or inhibitory response following m ifepristone treatm ent was to 
be expected. During the first two weeks, post-natal days 3 to 14, the limbic- 
hypothalamic-pituitary-adrenal axis stress system is inactive and the 
developing rat is hyporesponsive to stress (Sapolsky & Meaney, 1986). At 
this time the rat m aintains very low levels of circulating corticosterone, 
even under conditions of stim uli which cause a response in  adults. In 
addition, there are low levels of GR in  brain during this post-natal period 
(Rosenfeld et al., 1998). The levels of circulating corticosterone do not rise 
until the weaning period (around post-natal day 25) under a stress response 
(Goldman et al., 1973); (Vazquez & Akil, 1993). This stress response is 
mimicked in anim als who are m aternally deprived earlier than  the natural 
weaning period (Levine, 1994; Rosenfeld et al., 1991).
Therefore, w hen using post-natal day 21 male rats, at an age prior to the 
endogenous generation of glucocorticoids, the intra-peritoneal
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adm inistration of mifepristone would have very little endogenous 
glucocorticoid activity to inhibit.
On analysis of the data for corticosterone treatm ent at post-natal day 21, the 
extent of induction was effectively the same in  kidney and brain. It can be 
concluded from this that corticosterone m ight play a role in  regulating the 
expression of GTK in both of these tissues. As the levels of endogenous 
glucocorticoids increase after post-natal day 21 (Henning, 1978; Vazquez & 
Akil, 1993), so the levels of CS-lyase/GTK/KAT m RNA found in  brain also 
rise (Plant et al., 1997), which reinforces the hypothesis that glucocorticoids 
m ight influence GTK expression.
The effects of both dexamethasone and corticosterone on the GTK specific 
activity in male rat kidney and brain at post-natal days 19, 21, 23, 25 and 30, 
demonstrated that the com pounds induced GTK activity w ith  varying 
patterns. W ith dexamethasone treatm ent, an induction in  specific activity 
of GTK in kidney and brain was observed only on day 21 (Figures 3.4. and
3.5.) suggesting that in male rat kidney and brain, there is a w indow  on post­
natal day 21 where GTK levels are susceptible to m odulation  by the 
synthetic glucocorticoid.
W ith corticosterone the induction pattern was very different. In kidney and 
brain, m odulation of the level of GTK was apparent at all ages studied (with 
the exception of post-natal day 25 in brain). However, the highest induction 
was again at post-natal day 21. Compared w ith the dexam ethasone results.
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the period during which GTK is open to corticosterone m odulation appears 
m uch broader. This may be explained at the receptor level for these 
agonists. In the central nervous system, corticosterone binds to two types of 
receptors; type I, which is structurally sim ilar to the renal mineralocorticoid 
receptor (MR) and type 11, which is identical to GRs found in non-neural 
corticosteroid target tissues (De Kloet et ah, 1990; Funder & Sheppard, 1987; 
McEwen et al., 1986; Reul & De Kloet, 1986). Both MR and GR share nearly 
identical DNA binding domains, and very sim ilar horm one binding 
domains, but they differ in  their affinity for corticosterone, where the 
affinity for MR is higher than  for GR (Lim-Tio et al., 1997). GR has the 
highest affinity for synthetic glucocorticoids such as dexam ethasone (De 
Kloet et al., 1975; Reul & De Kloet, 1985). It is possible that the expression of 
MR and GR plays a part in the observed pattern of induction of GTK activity 
observed. However this would require more in depth study.
A nother possible explanation for these differences is that the m easurem ent 
of GTK specific activity in kidney and brain is made using whole kidney 
cytosol or whole brain homogenate. It is feasible that GTK levels are 
induced or suppressed differentially in various regions of the kidney or 
brain, but as micro-dissection techniques were not employed here, these 
differences could not be detected. In order to determ ine the effects of 
dexamethasone and corticosterone on individual neuroanatom ical regions, 
in situ hybridisation techniques could be employed to locate, quantitate and 
compare CS-lyase/GTK/KAT mRNA expression w ith the GTK specific 
activity levels in this study.
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3.4.2. The Effect of Sex Hormones on the Regulation of Glutamine 
Transaminase K in Male Rat Brain and Kidney
From the sex horm one prelim inary studies (Figures 3.9. and 3.10.) it was 
clear that only progesterone was capable of upregulating GTK expression in  
post-natal day 21 male rat kidney and brain. In kidney, the induction pattern 
followed a sim ilar profile as for dexamethasone treatm ent, w ith an effect 
seen only at post-natal day 21 (Figure 3.11.). Interestingly, in  the brain, the 
induction pattern differed, w ith post-natal days 21, 23, and 25 showing 
induction such that the age range where GTK could be induced was broader 
w ith progesterone than  w ith dexamethasone, but was narrow er than  that 
observed w ith corticosterone.
It is not surprising that the effect of progesterone treatm ent on GTK specific 
activity closely reflects the effects observed w ith both glucocorticoids. The 
DNA binding dom ains for each of these nuclear receptor families are highly 
conserved, and can all recognise horm one response elem ents in  the m ouse 
m am m ary tum our virus (MMTV) prom oter and induce its transcription 
(Thackray et al., 1998).
The sensitivity of GTK to m odulation by these horm ones m ight be due to 
the expression of GR, MR and PR in kidney and brain during this stage of 
post-natal development. Further study into receptor binding of these 
horm ones, at the post-natal ages studied, would help to clarify how  these 
horm ones induce GTK activity in  the patterns observed.
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From these results it can be concluded that the glucocorticoids; 
dexamethasone and corticosterone, and the sex horm one progesterone, are 
all able to m odulate the specific activity of GTK. In each case, the GTK 
specific activity was increased, although the level of induction differed 
depending on the age of rats and the dose of horm one administered. The 
finding that GTK can be induced by these horm ones also provides 
supportive evidence for the possible involvem ent of CS-lyase/GTK/KAT in 
certain neurodegenerative disorders. For example, increased endogenous 
cortisol production has recently been reported in hum an  subjects w ith m ild 
to m oderate Alzheim er's Disease (Rasmuson et al., 2001). This may provide 
a new strategy for the developm ent of therapy for such neurodegenerative 
disorders.
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CHAPTER 4
CLONING AND ANALYSIS OF THE UPSTREAM REGULATORY 
REGION FROM THE RAT CS-LYASE GENE
4.1. INTRODUCTION
During the last decade several innovative PGR technologies have been 
introduced to aid the isolation of new sequences of genomic DNA. In 
particular, these tools have been used for the sequencing of unknow n 
genomic DNA from regions of know n sequence, usually a cDNA sequence. 
This technique is commonly referred to as 'Genome walking'. 
Methodologically, there are three approaches to Genomewalking; inverse 
PGR (Ochman et ah, 1988), adaptor ligation PGR (Parker et al., 1991) and 
random ly prim ed PGR (Rosenthal & Jones, 1990). However, these m ethods 
have proved very complex and not effective for 'walks' in  uncloned 
genomic DNA (Siebert et al., 1995). The technique employed in  this study is 
an im proved m ethod based on long and accurate PGR using a modified 
version of the adaptor ligation PGR m ethod (section 2.2.4.). 
Genomewalking experiments were performed to walk from know n 
sequences of the CS-lyase gene into unknow n upstream  regulatory regions, 
with the objective of identifying regulatory sequence motifs.
The cDNA has been cloned and sequenced for rat (Perry et al., 1993) and 
hum an (Perry et al., 1995) renal cytosolic CS-lyase. On analysis of the rat 
nucleotide sequence. Perry et al (1993) proposed that the 5' non-coding
141
region of the m RNA may be involved in regulating CS-lyase expression by 
the form ation of a secondary loop structure. They reported that this may 
influence progression of the ribosome along the m RNA during translation. 
Figure 4.1. shows the rat kidney cytosolic CS-lyase cDNA sequence (Perry et 
al., 1993). Nucleotides 18-87 and 218-287 (highlighted in blue. Figure 4.1.) are 
the inverted repeats which the authors proposed as form ing the secondary 
loop structure. In addition, the am ino acid residues 244-249 (Ser-AIa-Gly- 
Lys-Ser-Phe), deduced from nucleotides 973 to 990, are highlighted in green 
and represent the PLP binding site (Figure 4.1.). The cryptic branch site and 
splice acceptor regions are underlined (Figure 4.1.).
The cDNA sequence was used as the tem plate for the design of gene-specific 
prim ers (GSPs) to walk into the unknow n upstream  region. The design of 
GSPs for this type of PGR m ust consider the annealing tem peratures of the 
adaptor primers. If the annealing tem peratures of the GSPs do not comply 
w ith the annealing tem peratures of the adaptor primers, the generation of a 
PGR product is unlikely. All prim ers used in this study are detailed in  Table 
2.2.
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1 AAACTGACCAA6GAGTATGATCAATCCC6TCCAGCCTCCGA6CC
4 5  TGCAGCCGTTTGGTCATGGTGAGCTGCTTCAGCTAACAATTGÇAÇIGAÇAGTGCTCTTGA6CCAAGTTGCTTCTGGGCGGAAGTAGTCCATCTAGGGCTC
1 4 5  GGCCTCmAAAGAAACAGACTTCTGCAACCTTGGGAGTACGTTTGGGGTCGCCGGCTATTGGACGGAGCAGCGCAATTGTTAGCTGAAGCAGCTCACC
Met T lr Lys Am Leu Gin Ala Am Am Leu Asn Gly He Asn Gin Asn Leu 17
2 4 4 ATG AGG AAA GGG GTG GAG GGT GGG AGG GTG GAC GGG A n GAT GAA AAG GTG
Tin Val Glu Phe Gly Lys Leu H r Lys Glu TVr Asn Val Val Asn Leu Gly 34
2 8 5 TGG GTG GAG Tn GGG AAA GTG AGG AAG GAG TAT GAG GTG GTG AAG TTG GGT
Gin Gly Phe Pro Asn Phe Sh * Pro Pro Asn Phe Ala H r Gin Ala Phe Gin 51
3 4 8 GAG GGG TTC GGT GAG TIG TGG GGT CCG GAG Tn GGA AGG GAA GGT Tn GAG
Gin Ala T lr S er Gly Asn Phe Met Leu Asn Gin TVr H r Am Ala Phe Gly 66
3 8 7 GAG GGT AGG AGT GGG AAG TTC ATG GTC AAG CAG TAG AGG AGG GGA Tn GGT
TVn Pro Pro Leu H r Asn Val Leu Ala Ser Phe Phe Gly Lys Leu Leu Gly 85
4 4 8 TAG GGA GGA GTG AGA AAG GTG GTG GCA AGT TTC Tn GGG AAG CTG GTG GGA
Gin Glu Met Asn Pro Leu H r Asn Val Leu Val H r val Gly Ala TVr Gly 102
4 8 8 GAG GAG ATG GAG GGA GTG AGG AAT GTG GTG GTG AGA GTG GGT GCC TAT GGG
Ala Leu Phe H r Am Phe Gin Ala Leu Val Asn Glu Gly Asn Glu Val He 1 1 8
5 5 0 GGG TTG TTC AGA GGG Tn GAG GGG CTG GTG GAT GAA GGA GAT GAG GTG ATG
lie Met Glu Pro Ala Phe Asn Gys Tyr Glu Pro Met H r Met Met Ala Gly 1 36
601 ATG ATG GAA GGT GGT Tn GAG TGT TAT GAA CCC ATG AGA ATG ATG GGT GGA
GIV GVS Pro Val Phe val H r Leu Lys Pro S w Pro Ala Pro Lys Gly Lys 153
6 5 2 GGT TGG GGT GTG TTC GTG AGT GTG AAG GGG AGC GGT GGT GGT AAG GGG AAA
Leu Gly Ala Ser Asn Asn Tin Gin Leu Asn Pro Ala Glu Leu Ala So* Lys 170
7 0 3 GTG GGA GGG AGG AAT GAT TGG GAA GTG GAT GCT GGA GAA GTG GGG AGG AAG
Phe T lr Pro Am H r Lys lie Leu Val Leu Asn H r Pro Asn Asn Pro Leu 187
7 5 4 TTG AGA GGT GGG AGG AAG ATG GTG GTG GTG AAG AGA GGG AAG AAG GGT n A
GIV Lys Hal Phe Ser Am Met Glu Leu Glu Leu Val Ala Asn Leu Gys Gin 2 0 4
3 0 5 GGA AAG GTA TTG TCT AGG ATG GAG GTG GAG GTG GTG GGT AAT GTG TGG GAG
Gin His Asn Val val Gys He Ser Asn Glu Val Tyr Gin Tin Leu Val TVr 221
8 5 6 GAG GAG GAT GTG GTG TGG ATG TCT GAT GAG GTG TAG GAG TGG GTG GTG TAT
Asn Gly HIS Gin His Val Ser He Ala Sh ' Leu Pro Gly Met Tin Am Am 2 3 3
8 0 7 GAG GGG GAG GAG GAG GTG AGG ATG GGG AGG GTG GGT GGG ATG TGG GAT GGG
H r Leu T lr lie Gly Ser Ala Gly Lys Ser Phe Ser Ala H r Gly Trn LVS 2 5 5
8 5 6 AGG GTG AGG ATG GGG AGT GGA GGG AAA AGG n c AGT GGG AGT GGG TGG AAG
Val Gly Tin Val Met Gly Pro Asn Asn He Met Lys HIS Leu Am H r Val 2 7 2
1 0 0 8 GTG GGG TGG GTG ATG GGT GGA GAT AAG ATG ATG AAG GAG GTG AGG GAG GTG
HIS Gin Asn Ser He Phe HIS Gys Pro H r Gin Ala Gin Ala Ala Val Ala 2 6 8
1 0 6 0 GAG GAG AAT TCT ATG TTG GAG TGG GGG AGG GAG GGG GAG GGT GGA GTA GGG
Gin Gys Phe Glu Am Glu Gin Gin His Phe Gly Gin Pro Ser S er TVr Phe 3 0 6
1111 GAG TGG Tn GAG GGG GAG GAG GAA GAG m GGA GAA GGG AGG AGG TAG m
Leu Gin Leu Pro Gin Ala Met Glu Leu A »i Am Asn HIS Met He Am S er 3 2 3
11 6 2 TTG GAG GTG GGA GAG GGG ATG GAG GTG AAG GGA GAG GAG ATG ATG GGT AGG
Leu Gin Ser Val Gly Leu Lys Leu Tin He S er Gin Gly Ser TVr Phe Leu 3 4 0
121 3 GTG GAG TGA GTG GGG GTG AAG GTG TGG ATG TGG GAG GGG AGG TAG nc GTG
lie Ala Asn He Ser Asn Phe Lys Ser Lys Met Pro Asn Leu Pro Gly Ala 3 5 7
1 2 6 4 A n GGA GAG ATG TGA GAG TTG AAG AGG AAG ATG GGT GAG GTG GGG GGA GGT
Glu Asn Glu Pro IVr Asn Am Am Phe Ala Lys Tin Met He Lys Asn Met 3 7 4
1 31 5 GAG GAT GAG GGT TAT GAG AGA GGG Tn GGG AAG TGG ATG ATG AAA AAC ATG
GIV Leu Val Gly He Pro Val Sh > H r Phe Phe So* Am Pro HIS Gin LVS 381
136 6 GGG TTG GTG GGG ATG GGT GTG TGG AGA TTC TTG AGT GGG GGG GAT GAG AAG
Asn Phe Asn His Tyr He Am Phe Gys Phe Val Lys Asn Lys Ala H r Leu 4 0 8
14 1 7 GAG Tn GAG GAG TAG ATG GGA TTC TCT Tn GTG AAG GAG AAG GGG AGA GTG
Gin Ala Met Asn Glu Am Leu Am Lys Trn Lys Glu Leu Gin Pro STOP 4 2 3
1 46 8 GAG GGG ATG GAT GAG AGA GTG CGC AAG TGG AAA GAG GTG GAA GGG TGA GGA
1 5 1 9  GGCTGCCCTCAGCCCCACCTCGAACACAGGCCTCAGCTATGCCTTAGCACAGGGATGGCACTGGAGGGCCCAGCTGTGTGACTGCGCATGmCCAGA
1 6 1 7  AAAGAGGCCATGTGTTGGGGGTTGAAGCCATCCTTTCCCAGTGTCCATGTGGACTATTGGGTTGGGGGCCAGTTCTGGGTCTCAGCCTACTCCTCTGTAGG
1 7 1 8  TTGGGTGTAGGGTTTTGAnGTnGTGGGGTGTGTGGGTGGGGGAGGAAAGGGTGGAATATGAGGGGGGGTAGGAGGnAGGGGTGGGGAGGGTGTGTGGG
1 8 1 9  nGTGTAGATGnGTGGTGTGAGGTGAGGATGnGGTAGTGnGGTAATAAAGTnTAAGnAnAGGAGGGTGA,
Figure 4.1. The nucleotide and deduced am ino acid sequences of rat renal 
CS-lyase cDNA.
Nucleotides 1-1892 are illustrated. In blue, the two 70-nucleotide inverted 
repeats (nucleotides 18-87 and 218-287). In green, the region of PLP binding 
(residues 244-249). In red, cDNA sequences against which the prim ers GSP- 
1(156-180) and GSP-2(99-126) were designed. Underlined nucleotides, cryptic 
branch site (single) and splice acceptor nucleotide sequences (double). Figure 
adapted from Perry et al (1993).
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4.2. ISOLATION OF THE CS-LYASE GENE UPSTREAM REGULATORY 
REGION SEQUENCES USING PRIMERS GSP-ia56-180) AND GSP-2(9M26>
The nested pair of primers; GSF-1(156480) and GSF-2(99-126), were designed 
against the CS-lyase rat kidney cDNA (priming sites in red. Figure 4.1.) to 
attem pt isolation of the upstream  regulatory region. Five prim ary FCR 
reactions were prepared using GSF-1(156-180) and AF-1 w ith each of the rat 
genomic DNA libraries; RDL-1 (Eco RV), RDL-2 (Sea I), RDL-3 (Dra I), RDL-4 
(Pvu II) and RDL-5 (Ssp I), as described as in section 2.2.4.2. A negative 
control was prepared, using GSF-1(156-180) and AF-1, w ith no genomic 
library present. Finally, a positive control was prepared, using the prim ers 
FCF-1 and AF-1, and genomic library RDL-2 (which was selected at random ).
Electrophoresis of the primary FCR's on a 1.5% agarose/EtBr gel showed the 
successful amplification of a 600bp fragm ent from rat genomic library RDL-2 
(lane 3, Figure 4.2.). A faint 600bp band was present in  the FCR from  the 
Pvu 1 library, RDL-4 (lane 5, Figure 4.2.). FCR's using the genomic libraries 
RDL-1, RDL-3 and RDL-5 were all unsuccessful. As expected, no bands were 
present in the negative control (lane 7, Figure 4.2.) as this reaction contained 
no genomic library. Multiple, slightly smeared, bands were present in  the 
positive control w ith RDL-2 (lane 8, Figure 4.2.).
Subsequently, secondary FCR's were prepared using Ipl of the prim ary FCR 
as a template, for each respective genomic library (section 2.2.4.2.). In 
addition, five separate secondary FCR's were prepared using a plug sam ple 
taken directly from the 600bp band in  the 1.5% agarose/EtBr gel (from lane 3,
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Figure 4.2.), instead of Ijxl from the primary reactions. Analysis of the 
secondary PCR's, on a 1.2% agarose/EtBr gel, revealed that the reactions 
prepared w ith plug samples, taken directly from 600bp band on the primary 
PCR gel, were more successful than those prepared using Ijil of primary 
FCR reaction. The 600bp band was re-amplified in three of the former five 
FCR's prepared (lanes 2, 3 and 4, Figure 4.3.). However, in  the latter 
secondary FCR's, prepared w ith Ip l of primary FCR, only library RDL-2 
produced a faint 600bp band (lane 8, Figure 4.3.). The secondary FCR 
successfully amplified a 2.6kb band for the positive control, which was the 
expected positive control product size for genomic library RDL-2 (lane 13, 
Figure 4.3.).
The 600bp fragments were purified from lanes 2, 3 and 4 (Figure 4.3.) of the
1.2% agarose/EtBr gel, as described in section 2.2.4.3. The purified 600bp 
fragments were then cloned into the pCR®2.1-TOFO cloning vector (vector 
map. Figure 2.2.), and introduced into competent One Shot™  TOFIOF' 
E. coli cells (section 2.2.4.4.). Six cloning reactions were prepared for each of 
the three purified samples, and six separate cloning reactions were prepared 
using Ip l of secondary FCR's represented in each of the lanes 2, 3 and 4 
(Figure 4.3.).
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1 2 3 4 5 6 7 8
750bp
600bp
Figure 4.2. Photograph of 1.5% agarose/EtBr gel of prim ary PCR products 
obtained with prim ers GSP-K156-180) and AP I.
Lane 1 Ikb DNA ladder
Lane 2 primary PCR products from genomic library RDL-1
Lane 3 primary PCR products from genomic library RDL-2
Lane 4 primary PCR products from genomic library RDL-3
Lane 5 primary PCR products from genomic library RDL-4
Lane 6 primary PCR products from genomic library RDL-5
Lane 7 negative control containing no genomic library
Lane 8 positive control using primers PCP-1 and AP-1 w ith  genomic library RDL-2
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f -  2.6kb
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Figure 4.3. Photograph of 1.2% agarose/EtBr gel of secondary PCR products 
obtained w ith primers GSP-2(99-126) and AP-2.
Lane 1 Ikb DNA ladder
Lanes 2 -6  secondary PCR products generated using direct plug sample of 600bp primary 
PCR product band (lane 3, Figure 4.2.)
Lanes 7 -1 1  secondary PCR products generated using Ipl of primary reaction (for each of the 
five genomic libraries)
Lane 12 negative control
Lane 13 positive control using PCP-2 and AP-2
Lane 14 Ikb DNA ladder
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Phenol extraction of the pCR®2.1-TOPO vectors, from the TOPlOF’ E. coli, 
was performed (section 2.2.4.4.). The extracts were electrophoresed on a 1.2% 
agarose/EtBr gel to determ ine which E. coli m inicultures had been 
transform ed w ith pCR®2.1-TOPO vector containing the 600bp insert (Figure 
4.4.). Of the cloning reactions prepared using Ip l of the secondary PCR's, no 
reactions were successful (upper gel, lanes 2 to 19, Figure 4.4.). However, in 
the cloning reactions prepared using the purified 600bp product, nine E. coli 
m ini cultures contained pCR®2.1-TOPO vector w ith 600bp insert (lower gel, 
lanes 2 to 3,5 to 7 and 9 to 12, Figure 4.4.). These clones were simply nam ed 
clones 1 through 9, respectively. The nine successful clones all contained 
E. coli genomic DNA, rRNA and tRNA, as w ith the failed cloning reactions. 
The vector bands for these clones were approximately 600bp larger in  size 
than  the equivalent band in the failed cloning reactions. The vectors 
containing insert were purified from the E. coli m inicultures (section 
2.2.I.I.).
To determ ine more accurately the size of insert in the pCR®2.1-TOPO vector 
for each of the nine clones, restriction digest analysis was employed (section
2.2.I.5.). Digests were prepared for each clone using Apa I (to linearise the 
vector) or Eco RI (to excise the insert from the vector) and were 
electrophoresed on a 1.2% agarose/EtBr gel alongside non-digested vector. 
The expected product sizes for the Apa I digests were 3.9kb (representing the 
vector) or 4.5kb (vector plus 600bp insert). For the Eco RI digests, a band of 
3.9kb size (vector) and a 600bp band (insert) were expected. For each of the 
nine clones, the Apa I digests produced a 4.5kb linearised vector band only
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(Figure 4.5.). The Eco RI digests, for each of the nine clones, produced a 3.9kb 
vector band and a 600bp insert band, confirming that the cloning reactions 
had been successful.
To further confirm the size of the insert in  the pCR®2.1-TOPO vector, and 
specificity as the original 600bp product, clone 6 was selected, as the 600bp 
band was strongest in this clone, and a PCR analysis perform ed (section
2.2.I.6.). The reaction was prepared using the pCR®2.1-TOPO TA vector plus 
insert, and gene-specific prim er GSP-2(99-126) and adaptor prim er AP-2, 
since these prim ers were responsible for the amplification of the 600bp 
secondary PCR product (Figure 4.3.). On analysis of the PCR on a 1.5% 
agarose/EtBr gel, a 600bp fragment was successfully amplified from the 
vector (Figure 4.6.).
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1 3 5 7 9 11 13 15 17 19
UPPER GEL 
3.9kb
LOWER GEL 
4.5kb ^
E. coli genomic DNA 
pCR®2.1-T0P0 vector
rRNA
tRNA
2 4 6 8 10 12 14 16 18 20
Figure 4.4. Photograph of 1.2% agarose/EtBr gel of phenol extraction of 
pCR®2.1-TOPO vector DNA from competent TOPlOF' E. coli m inicultures.
UPPER GEL
Lane 1 Ikb DNA ladder
Lanes 2 -7  cloning reactions w ith Igl of secondary PCR from lane 2, Figure 4.3.
Lanes 8-13  cloning reactions w ith Ijil of secondary PCR from lane 3, Figure 4.3.
Lanes 14 -19 cloning reactions w ith  Igl of secondary PCR from lane 4, Figure 4.3.
Lane 20 Ikb DNA  ladder
LOWER GEL
Lane 1 Ikb DNA ladder
Lanes 2 -7  cloning reactions from plug sample of 600bp band from secondary PCR from
lane 2, Figure 4.3.
Lanes 8-13 cloning reactions from plug sample of 600bp band from secondary PCR from
lane 3, Figure 4.3.
Lanes 14-19 cloning reactions from plug sample of 600bp band from secondary PCR from 
lane 4, Figure 4.3.
Lane 20 Ikb DNA ladder
The successful cloning reactions are in  low er lanes 2 and 3, 5 to 7 and 9 to 12. 
These have been nam ed clones 1 to 9, respectively.
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600bp —>
600bp
LOWER GEL
UPPER GEL
MIDDLE GEL
600bp
Figure 4.5. Photograph of 1.2% agarose/EtBr gel of restriction digest analysis 
of TOPO™ TA cloning®.
N on-digested sam ples were electrophoresed alongside Apa  1 digests to show  
vector linearisation, and alongside Eco RI digests to show  the 600bp insert 
and the linearised vector.
UPPER GEL
Lane 1 Ikb DNA ladder
Lane 2 non-digested DNA from clone 1
Lane 3 A pa  I-digested DNA from clone 1
Lane 4 Eco Rl-digested DNA from clone 1
Lanes 5 - 7  non-digested, A pa  I-digested and 
respectively  
Lanes 8 - 1 0  digests as before, DNA from clone 3
Lanes 11 -13  digests as before, DNA from clone 4
Lane 14 Ikb DNA ladder
Eco Rl-digested DNA from clone 2,
MIDDLE GEL
Lane 1 Ikb DNA ladder
Lanes 2 -4  digests as before, DNA from clone 5
Lanes 5 - 7  digests as before, DNA from clone 6
Lanes 8 - 1 0  digests as before, DNA from clone 7
Lanes 11 -13  digests as before, DNA from clone 8
Lane 14 Ikb DNA ladder
LOWER GEL 
Lane 1 
Lanes 2 -4  
Lane 5
Ikb DNA ladder
digests as before, DNA from clone 9 
Ikb DNA ladder
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750bp
500bp
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Figure 4.6. Photograph of 1.5% agarose/EtBr gel of PCR analysis for 600bp 
insert in pCR®2.1-TOPO vector.
Lane 1 Ikb DNA ladder
Lane 2 PCR product from reaction w ith DNA from clone 6 as template, using primers GSP-
2(99-126) and AP-2
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Having verified that the insert in  the pCR®2.1-TOPO vector was 600bp in 
size, clone 6 was sent for autom ated DNA sequencing (section 2.2.4.5.). On 
analysis of the DNA sequence, regions of the pCR®2.1-TOPO vector 
surrounding the m ultiple cloning site were identified (in green. Figure 4.7.). 
The restriction sites surrounding the vector m ultiple cloning site; Bam HI 
and Eco Rl, were also present (underlined. Figure 4.7.). In addition, the 
prim ing site of the gene-specific prim er GSP-2(99-126) was located in the 
sequence (in red. Figure 4.7.). The CS-lyase sequence was traceable from the 
GSP-2(99-126) binding site, upstream  to nucleotide 84 of the cDNA sequence 
in Figure 4.1. This related to nucleotides 511 to 554 (Figure 4.7.). The DNA 
sequence of clone 6 could not be traced to CS-lyase cDNA sequence beyond 
nucleotide 84. Instead, the sequence featured several regions of long 
nucleotide repeats, characteristic of intronic material.
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fmMI CcoRI
1 nCGCA6CTC6eflTC C «CTAGTnACG6CC6CCM6T6TGCTeeiU\TTCeCCC
5 1  TTACTATAGGGCACGCGTGGTCGACGGCCCGGGCTGGTACTAGGGGAGCG
1 0 1  CGCCGGGGAGCTGTCCAGAGAACGCCAGGGTGGAACCTCTGGGTAGGGGG
1 5 1  CGAGTGCGCGGAGGAGCGCGGATCTGCCAGGACAAGTGCAGCCTGGGGAC
2 0 1  CGTGGCGGAGACTCAAGTGAAAGGCACGCACGGAAGCCGGGCGCGCGTGA
2 5 1  TTGGGTTCAGTGAGGTGACAGCGGGCGTCCCTTTTTATACTCGAGCCACT
3 0 1  GAAGAAGGGGGGGGGGTGTGGGGGGGAGGGAGGGAGGGGTAGTGGTGTTT
3 5 1  GTGGGTAGGGAGAGGGAGTGGGGGGGTGGGTGTTTGGGGGGTTGTTTTGT
4 0 1  GGGTGAGGGTAGGGGTTTTAGGTGTGGGGGGGGAAGTGATATAGGGAGGG
4 5 1  GAAAGGGGGGGGTGGGTAAGGGTGGGGGGGGGGGGGGGGTGTTTAAAGGG
5 0 1  AAGTGGGAGGTTTGGAGTGACAGTGGTGTTGAGGGAAGTTGGTTGTGGGG
£ e o R I
5 5 1  GGAAAAGGGGGAATTGTGGAGATATGGATAGAGTGGGGHGGHTGGAGGAT
0 0 1  GGATGTAGAGGGGGAATTGGGGTATATGAGTGGTATTAGAATTAAGTGGN
Figure 4.7. DNA sequence of Clone 6.
In red, prim ing site of GSP-2(99-126). In green, regions corresponding to 
pCR®2.1-TOPO vector. Restriction sites of Bam HI and Eco RI are underlined  
(single! for comparison with the vector map in Figure 2.2. Sequence 
matching the 5' non-coding region of CS-lyase cDNA (nucleotides 511 to 
554) is underlined (double).
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4.3. ISOLATION OF CS-LYASE GENE UPSTREAM REGULATORY REGION 
USING PRIMERS ISP-1 AND ISP-2
W ith the discovery of the presence of an intron, new prim ers were designed 
against the intronic sequence obtained from the first genom ewalk (Figure 
4.7.), in  order to 'walk' further upstream  into the in tron  and eventually 
return  into the know n sequence (Figure 4.8a.). The intron-specific primers; 
lSP-1 and lSP-2, were designed as a nested pair at positions 109-127 and 53-71 
in the intronic sequence, respectively (Figure 4.8b.).
Primary PCR's were prepared, as for the first genomewalking experiment, 
using the rat genomic libraries RDL-1 to 5 and the prim ers lSP-1 and AP-1. 
No products were generated from these PCR's (photograph of agarose/EtBr 
gel not shown).
155
ISP-1
ISP-2
/
intronic sequence (in 
genomic DNA)
nucleotide 84 
(in known CS-lyase 
cDNA sequence)
nucleotides 1-83 
(in known CS-lyase 
cDNA sequence)
Figure 4.8a. Diagrammatic representation of strategy for design of primers; 
ISP-1 and ISP-2, against intronic sequence.
The diagram  represents CS-lyase m R N A  prior to splicing and rem oval of 
in tronic m aterial. G reen represents k n o w n  sequence (from  the cDNA). 
Blue represents in tron ic  sequence (reported in  the sequence in  Figure 4.7.). 
The prospective positions of ISP-1 and ISP-2 are show n to enable a 
genom ew alk fu rther upstream  to re tu rn  in to  know n  sequence and 
eventually  in to  the regulatory region.
5 1  TTACTATA6GGCACGCGTG6TCGACGGCCC6GGCTGGTACTAGGG6AGCG
1 0 1  CGCCGGGGAGCTGTCCAGAGAACGCCAGGGTGGAACCTGTGGGTAGGGGG
1 5 1  CGAGTGCGCGGAGGAGCGCGGATCTGCCAGGACAAGTGCAGCCTGGGGAC
2 0 1  CGTGGCGGAGACTCAAGTGAAAGGCACGCACGGAAGCCGGGCGCGCGTGA
Figure 4.8b. Nucleotides 51 to 250 of DNA sequence of Clone 6.
In red, the p rim ing  site of ISP-1 in  the in tron ic  sequence. In light blue, the 
ISP-2 prim ing site.
156
4.4. ISOLATION OF THE CS-LYASE GENE UPSTREAM REGULATORY 
REGION SEQUENCES USING PRIMERS GSP-3(52-69) AND GSP-4(44-62)
Following the failure of the second genomewalking experiment, it was 
decided to re-design the gene-specific primers. In order to avoid 'walking' 
into intronic sequence again, the nested pair of prim ers were designed 
against the 5' non-coding region of the CS-lyase cDNA sequence located 
further upstream  from the original primers; GSP-1 (156-180) and GSP-2(99- 
126). Primers GSP-3(52-69) and GSP-4(44-62) were designed as an 
overlapping, nested pair (Figure 4.9.) to bypass the intronic m aterial and 
'walk' into the upstream  regulatory region.
The annealing tem perature of the new GSP's; GSP-3(52-69) and GSP-4(44-62), 
could not be ideally matched to the adaptor primers; AP-1 and AP-2, and the 
positive control primers; PCP-1 and PCP-2. Therefore, prim ary PCR's were 
prepared as for the first genomewalking experiment, but the annealing 
tem perature was adjusted to find an optim um  tem perature for binding of 
both AP-1 and GSP-3(52-69). After several attempts, primary PGR products 
were obtained w hen the annealing tem perature was adjusted to 53°C. 
A lthough definite bands were not generated from the prim ary reactions, 
smears were present on the 1.5% agarose/EtBr gel in all five of the libraries 
used which was acceptable for a prim ary genomewalk (Figure 4.10.). As 
expected, no bands were apparent in the negative control (lane 7). Also, the 
positive control reaction (using RDL-4) failed to yield any products. This 
was also to be expected as the annealing tem perature was reduced 
dramatically from 67°C to 53°C.
157
1 AAACTGACCAAGGA6TATGATCAATCCCGTCCAGCCTCCGAGCCTGCAGCCGTTTGGTCATGGTG4-----------------
6 6  AGCTGCTTCAGCTAACAATTGCACTGACAGTGCTCTTGAGCCAAGTTGGTTCTGGGCGGAAGTAGT 
1 3 2  GGATGTAGGGGTGGGGGTGTTTAAAGAAAGAGAGTTGTGGAAGGTTGGGAGTAGGTTTGGGGGGG
1 9 9  GGGTATTGGAGGGAGGAGGGGAATTGTTAGGTGAAGGAGGTGAGG
Figure 4.9. The 5’ non-coding region of rat renal CS-lyase illustrating 
prim ing sites of GSP-3(52-69) and GSF-4(44-62).
N ucleotides 1 to 243 are illustrated, w ith  the p rim ing  site of GSP-3(52-69) 
indicated hy4— , and the p rim ing  site for GSP-4(44-62) is h igh ligh ted  by 4— .
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Figure 4.10. Photograph of 1.5% agarose/EtBr gel of prim ary PCR products 
obtained w ith prim ers GSP-3(52-69) and AP-1.
Lane 1 Ikb DNA ladder
Lane 2 primary PCR products from genomic library RDL-1
Lane 3 primary PCR products from genomic library RDL-2
Lane 4 primary PCR products from genomic library RDL-3
Lane 5 primary PCR products from genomic library RDL-4
Lane 6 primary PCR products from genomic library RDL-5
Lane 7 negative control containing no genomic library
Lane 8 positive control using primers PCP-1 and AP-1 w ith genomic library RDL-2
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Secondary PCR's were prepared using Ip l of the primary reaction as in the 
first genomewalking experiments, as a distinct band was not present after 
electrophoresis of the prim ary reactions to take a direct plug sample from 
the gel. No positive control was prepared as the annealing tem perature was 
too low for the binding of PCP-2. Following electrophoresis on a 1.2% 
agarose/EtBr gel, faint bands were found w ith all five libraries, however, in 
RDL-1, a strong band of Ikb was found ( lane 2, Figure 4.11.). No band was 
found in the negative control. The Ikb band was excised from the gel and 
purified (section 2.2.4.S.).
N ine cloning reactions were then set up using the pCR®2.1-TOPO vector and 
the purified Ikb fragment, as before. The pCR®2.1-TOPO vector was phenol 
extracted from the competent One Shot™  TOPlOF' E. coli cells, and the 
extracts electrophoresed on a 1.2% agarose/EtBr gel, to determ ine which E. 
coli m ini cultures contained pCR®2.1-TOPO vector successfully cloned w ith  
the Ikb insert. Only two of the nine m inicultures contained pCR®2.1-TOPO 
vector w ith Ikb insert (Figure 4.12.). These clones were nam ed clone 10 and
11. In all of the lanes, the vector DNA electrophoresed at a sm aller size than  
expected, which was explained by supercoiling of the DNA. In lanes 2 and 3, 
the DNA was clearly larger than that of the other m inicultures, so these 
were selected as containing the Ikb insert.
The pCR®2.1-TOPO vector DNA containing insert was purified from the 
TOPlOF' E. coli cells (section 2.2.1.1.) of clones 10 and 11. To confirm  that the 
inserts in the two purified pCR®2.1-TOPO vectors were Ikb in  size, PCR
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reactions were prepared using GSP-4(44-62) and AP-2, as these primers were 
responsible for the amplification of the Ikb fragment in the secondary PCR 
(Figure 4.11.). Electrophoresis of these analytical PCR's on a 1.5% 
agarose/EtBr gel revealed that, in both, a Ikb fragment was greatly amplified 
from the vector (Figure 4.13.).
The DNA derived from cloning reaction 10 (lane 2 of Figures 4.12. and 4.13.) 
was sent for autom ated DNA sequencing. In the sequence obtained, the 
binding site of prim er CSP-4(44-62) was identified at nucleotides 115-134 
(Figure 4.14.). A short sequence (nucleotides 103-114, Figure 4.14.), 
corresponding to pCR®2.1-TOPO vector DNA (in the m ultiple cloning site 
(nucleotides 283-294, Figure 2.2.), was also present. In addition, a TATA box 
was present in the sequence (nucleotides 235 to 239) and also a CAAT box 
further upstream  at nucleotides 297 to 300 (Figure 4.14.).
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Figure 4.11. Photograph of 1.2% agarose/EtBr gel of secondary PCR products 
obtained w ith prim ers GSP-4(44-62) and AP-2.
Lane 1 Ikb DNA ladder
Lane 2 secondary PCR products generated using Ipl of primary reaction from genomic
library RDL-1
Lane 3 secondary PCR products generated using Ipl of primary reaction from genomic
library RDL-2
Lane 4 secondciry PCR products generated using Ipl of primary reaction from genomic
library RDL-3
Lane 5 secondary PCR products generated using Ifil of primary reaction from genomic
library RDL-4
Lane 6 secondary PCR products generated using Ipl of primary reaction from genomic
library RDL-5
Lane 7 negative control
Lane 8 Ikb DNA ladder
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Figure 4.12. Photograph of 1.2% agarose/EtBr gel of phenol extraction of 
pCR®2.1-TOPO vector DNA from TOPlOF’ E. coli m inicultures.
The successful cloning reactions are in  lanes 2 and 3 (clones 10 and 11).
Lane 1 Ikb DNA ladder
Lanes 2 - 1 0  cloning reactions w ith purified Ikb product from secondary PCR (lane 2, Figure
4.11.)
Lane 11 Ikb DNA ladder
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Figure 4.13. Photograph of 1.5% agarose/EtBr gel of PCR analysis for Ikb 
insert in pCR®2.1-TOPO vector.
Lane 1 Ikb DNA ladder
Lane 2 PCR product from reaction using DNA  from clone 10 and primers GSP-4(44-62) and 
AP-2
Lane 3 PCR product from reaction using DNA from clone 11 and primers GSP-4(44-62) and 
AP-2
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4.5. DISCUSSION
The first genomewalking experiment (section 4.2.) involving the gene- 
specific primers; GSP-1 (156-180) and GSP-2 (99-126), failed to isolate the 
upstream  regulatory region of the CS-lyase gene. Instead, the genom ewalk 
entered into intronic m aterial after nucleotide 84 in  the cDNA sequence 
(Figure 4.1.). This is in agreement w ith the proposals of Perry et al (1993) 
who postulated that w ithin the 5' non-coding region, there was a region of 
intronic material, due to the cryptic branch site and splice acceptor 
nucleotide sequences found during the cloning and expression of the rat 
kidney cDNA. The authors hypothesised that in expression of the gene this 
region of intronic sequence was rem oved, possibly by alternative pre- 
mRNA splicing.
The isolation of intronic material from genomewalking procedures is 
common, since the generation of cDNA replicas is reliant on the retrovirus 
enzyme, reverse transcriptase, producing DNA copies from an m RN A  
template. Since mRNA is free from intronic material, the positions of 
introns are not highlighted in the resulting cDNA sequence. Therefore, 
w hen carrying out a genomewalk, using genomic libraries as employed in  
this study, it is a possibility that intronic sequence may be amplified.
Having unsuccessfully 'walked' through the intronic m aterial and back in to  
exon sequence (section 4.3.), new primers GSP-3(52-69) and GSP-4(44-62) 
were designed. The resulting Ikb sequence, generated from this th ird
166
genomewalk, was shown to possess some key features of an upstream  
regulatory elem ent (section 4.4.). Both of the prom oter sequence motifs; the 
TATA box and the CAAT box, were present in the DNA sequence isolated 
(Figure 4.14.). In addition, the prim ing site of the gene specific prim er GSP-4 
(44-62) was also identified. Flowever, a 'BLAST' search revealed that no 
other regulatory sequence motifs were present in the isolated genomic DNA 
sequence.
4.5.1. The H um an CS-Lyase Gene Sequence
Since this work was performed, the full hum an  genome sequence has been 
published (International H um an Genome Sequencing Consortium, 2001). 
The CS-lyase gene has been located to nucleotides 89567 to 78581 (reverse 
strand) of Contig: NT 023921 from chrom osome 9q 34.1. The positions of the 
eleven introns and twelve exons are illustrated (Figure 4.15.). The 
definitive assignment of the CS-lyase gene to chrom osome 9 confirms the 
prediction of Perry et al (1995). Using genomic DNA from somatic cell 
hybrids, they searched for the presence of hum an  renal CS-lyase sequences 
by PCR approaches. They reported a Ikb band in the hybrid containing 
hum an  DNA where chromosome 9 was the only genetic contribution to the 
hybrid (Perry et al., 1995).
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Figure 4.15. H om o sapiens renal cytoplasmic CS-lyase gene.
Regions in  blue are introns. Regions in  red are exons. The hu m an  CS-lyase 
mRNA is located on chrom osom e 9, 89567 to 78581 bp (reverse strand). 
Contig. NT 023921. Inform ation from website:-
h ttp :/ /  www.ncbi.nlm .nih.gov:80/AceView/hs.cgi?l=CCBLl& v=3& p=0
1 6 8
From a search of the hum an  CS-lyase gene upstream  region, the sequence 
m otif for the oestrogen receptor (ER) has been identified at position 2830 
upstream  from the transcription start site. TATA and CAAT boxes have 
also been highlighted in the sequence. W ith the exception of the TATA box 
and CAAT box, the rat genomic sequence isolated from the genom ewalk 
w ith prim ers GSP-3(52-69) and GSP-4(44-62) did not show any regulatory 
sequence motifs for horm one receptors or other transcription factors, such 
as API. The TATA and CAAT boxes were of similar distance apart for both 
the hum an  and rat sequence isolated, -60 nucleotides apart for each, 
how ever in the hum an  these were located m uch further upstream  than  in 
the rat. A lthough the deduced am ino acid sequences for the h um an  and rat 
enzyme are 82% similar (Perry et al., 1995), and there is pressure to conserve 
exon sequences, there is no such pressure to conserve in trons and upstream  
regulatory regions (except the regulatory protein binding motifs). Therefore, 
the sequence data published for the hum an  regulatory region of the CS-lyase 
gene may not apply for the rat.
It can be concluded that the regulatory motifs in the rat sequence m ust be 
located further upstream  from the sequence isolated in this study. Future 
studies would involve designing a new 'nested' pair of GSPs against the 
sequence from clone 10 (Figure 4.14.) to allow another section of upstream  
sequence to be isolated and regulatory motifs could then be identified by 
combining sequence data generated from m ultiple genomewalks.
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This work provides an opening for further research into the upstream  
regulatory region of the CS-lyase gene in the r a t  A lthough the hum an  
genome sequence is now  known, and with this has come the knowledge of 
regulatory motifs for specific genes, the regulatory signals for m ost genes 
rem ain to be characterised. The comparison of genome sequences for 
m ultiple vertebrates is the best m ethod of identifying these regulatory sites 
on a larger scale (W asserman et al., 2000). Therefore, rat models are still 
im perative for the broadening of our knowledge of the regulation of this 
enzyme by transcription factors, such as ER, and our understanding of the 
sex-specific and development-specific expression of this gene.
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CHAPTERS 
LOCALISATION AND QUANTITATION OF 
CS-LYASE/GTK/KAT mRNA EXPRESSION IN RAT BRAIN
5.1. INTRODUCTION
Previous research has indicated that CS-lyase/GTK/KAT is m odulated in rat 
brain during post-natal developm ent (Plant et al., 1997). CS- 
lyase/GTK/KAT of the CNS has already been discussed (section I.5.2.3.). 
Early studies on nephrotoxicity in rodents provide evidence for regulation 
of CS-lyase/GTK/KAT during developm ent (Lock et al., 1984). They 
reported that the kidney of young male mice (21 days) is m ore susceptible to 
damage after exposure to HCBD than  in the m ature animals. A sim ilar 
pattern of toxicity was observed in male rat kidney where nephrotoxicity 
was apparent in day 21 rats following 25mg/kg dose of HCBD (Hook et ah, 
1983). However, in the m ature rats a dose of 200mg/kg was required to 
produce the same degree of damage (Hook et al., 1983). This was postulated 
as being due to the fact that HCBD readily distributes into body fat (Davis et 
al., 1980). Since younger anim als have a lower percentage body fat, HCBD 
would not be sequestered into adipose tissue to the same extent as in  the 
adult, leaving higher levels of com pound to travel directly to the kidneys 
(Hook et al., 1983). Also, the conjugating enzyme systems which play a role 
in detoxification have not m atured at day 21 and, in  the case of GST, activity 
in  the younger rat is only 60% of the activity observed in the adult (Hales & 
Neims, 1976).
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There have also been several reports on the activity of CS-lyase/GTK/KAT 
in brain, and altered levels of activity during development. By quantifying 
kynurenic acid as a m easurem ent of KAT activity, levels have been show n 
to increase 20-fold from the first post-natal week to three m onths (Moroni et 
ah, 1988b). From three m onths to 18 m onths, kynurenic acid levels 
increased further by a factor of 2.5 (Moroni et al., 1988b). KAT activity has 
been reported to increase specifically in the cortex, hippocampal, striatal, 
thalamic and cerebellar regions from three m onths to 24 m onths 
(Gramsbergen et al., 1992). Levels of kynurenic acid have also been studied 
in fetal and neonatal whole rat brain. Prior to birth, kynurenic acid levels 
have been reported to increase dramatically, then fall to basal levels on post­
natal day 1 (Beal et al., 1992). Kynurenic acid has been proposed as being 
involved in the regulation of neural developm ent of excitatory synapses 
(Beal et a l, 1992).
In 1992, the activity of CS-lyase/GTK/KAT was studied in six 
neuroanatom ical regions (parietal cortex, caudate nucleus, hippocam pus, 
olfactory bulb, substantia nigra and cerebellum) during the post-natal period 
(Baran & Schwarcz, 1993). CS-lyase/GTK/KAT was reported to increase in 
all six brain regions of rats aged between post-natal day 3 and 3 m onths. 
Generally, enzyme activity^ increased w ith the age of the animals, how ever, 
the rate of this increase differed between brain regions. Relatively small 
increases were observed in the substantia nigra and cerebellum w ith three- 
to five-fold increases observed from post-natal day 3 to 3 m onths, compared 
to a 34-fold increase in activity in the parietal cortex during the same tim e
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period. A similar approach was taken by Ceresoli et al (1996). They 
m easured the activity of 3-hydroxyanthranilic acid oxygenase and KAT in 
the brain of post-natal day 7 ,14, 21 and 28 and 2.5 m onth-old rats, following 
striatal injury caused by ibotenate injection into the striatum , to determ ine 
the effect of neural injury on the kynurenine pathway during ontogeny. 
Increases in the activity of both enzymes were observed in all ages studied 
(Ceresoli et al., 1996). However, the 3-hydroxyanthranilic acid oxygenase 
activity (which leads to quinolinic acid production) was increased to a 
greater extent in the older anim als w ith the effect observed being 
progressively reduced through to the younger anim als which had the 
lowest increase in enzyme activity. KAT activity followed a different 
pattern w ith the younger anim als having the highest increase in KAT 
activity, and the effect decreasing through to the older rats. This w ork 
indicated that younger animals m ight preferentially synthesise kynurenine, 
w ith adult rats synthesising the neurotoxin, following excitotoxic events 
(Ceresoli et al., 1996). In order to provide direct evidence for these ontogenic 
changes, in response to neuronal damage, pH]-kynurenine was injected 
intrastriatally into post-natal day 7, 14 and young adult male rats and, in 
separate groups, in conjunction w ith ibotenate (Ceresoli et al., 1997). They 
then m easured the levels of tritiated kynurenine pathway metabolites and 
reported a shift towards kynurenic acid production in the lesioned striata of 
all ages studied. However, at later post-lesion stages, the conversion of 
kynurenine towards 3-hydroxykynurenine and quinolinic acid production 
was observed in the young adult rats (Ceresoli et al., 1997).
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The previous findings on the m odulation of enzyme activity in rat brain 
during developm ent have led to research on localisation of CS- 
lyase/ GTK/KAT mRNA levels in rat brain. Plant et al (1997) located and 
quantitated CS-lyase/GTK/KAT mRNA levels in male rat brain during 
post-natal developm ent and found that, in  many of the 42 brain regions 
studied, a steady increase in mRNA to adult levels was observed. In some 
regions, including the cerebral penduncle and medial forebrain bundle, 
adult levels were rapidly reached by post-natal day 35, and in other regions, 
such as the fronto-parietal cortex and basolateral amygdaloid nuclei, the 
levels reached higher than adult levels by post-natal day 28, and then  
returned to adult levels by post-natal day 32 (Plant et al., 1997). It has also 
been reported that CS-lyase/GTK/KAT m RNA is expressed throughout 
adult rat brain w ith particularly high levels found in  the hippocampus, 
piriform  cortex and choroid plexus (Tam burin et al., 1999). The high levels 
of CS-lyase/GTK/KAT in the choroid plexus are in accordance w ith the high 
activity of GTK reported in this region (Cooper et al., 1993).
W ith the above evidence suggesting physiological m odulation of CS- 
lyase/ GTK/KAT mRNA in rat brain during post-natal developm ent, the 
effects of the sex horm ones and glucocorticoids (administered as before in 
Chapter 3) on mRNA levels in rat brain at post-natal days 19, 21, 23, 25, 30 
and 42 were studied to determ ine w hether CS-lyase/GTK/KAT expression is 
horm onally m odulated and to identify the stages of post-natal developm ent 
where the enzyme is susceptible to regulation by horm ones.
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5.2. THE EFFECT OF SEX HORMONES AND GLUCOCORTICOIDS ON CS- 
LYASE/GTK/KAT m RNA IN MALE RAT BRAIN
5.2.1. Transcription of cRNA Riboprobes
To locate and quantify CS-lyase/GTK/KAT mRNA levels in rat brain, 
cRNA riboprobes specific to nucleotides 181 to 424 from the CS- 
lyase/GTK/KAT cDNA sequence (Perry et al., 1993), which had previously 
been inserted into a pGEM®-T vector (kind donation from Dr Nick Plant) to 
generate plasmid pTA243, were transcribed. Plasmid DNA was prepared 
and linearised using restriction endonucleases Sal I and Nco I to generate 
cRNA riboprobes in sense and anti-sense directions, respectively (section
2.2.1.). Linearisation of the plasmid DNA was confirmed by electrophoresis 
on a 1.2% agarose/EtBr gel (Figure 5.1.). As shown, the digested samples 
have electrophoresed to over 3kb in size which is correct as the pGEM®-T 
vector is 3kb and, including the 243bp insert, the actual plasm id size is over 
3.2kb.
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Figure 5.1. Photograph of 1.2% agarose/EtBr gel of restriction endonuclease 
digests of pTA243.
Lane 1 Ikb DNA ladder
Lane 2 Non-digested pTA243
Lane 3 Sal 1-digested pTA243
Lane 4 Nco 1-digested pTA243
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Restriction endonuclease-digested pTA243 samples were purified by 
phenolrchloroform  extraction and ethanol precipitation, then  
electrophoresed on a 1.2% agarose gel to confirm the purity of the digested 
samples (Figure 5.2.). Linearised pTA243 samples were then  used as 
tem plates for the cRNA riboprobe transcriptions. Prior to the transcription 
of radio-labelled cRNA riboprobes, transcriptions containing non ­
radiolabelled UTP were prepared, then electrophoresed on a 1.5% 
agarose/EtBr gel to confirm successful transcripts had been transcribed 
(Figure 5.3.). Subsequently, radioactive transcriptions were prepared. 
Several problems were experienced w ith the riboprobe transcriptions in  
obtaining an anti-sense riboprobe {Nco I-digested pTA243 template) w ith 
sufficient percent incorporation of P^S]-labelled UTPaS. However, by 
increasing the quantity of P^S]-labelled UTPaS in the transcription from 
30jiCi to 50pCi and om itting non-labelled UTP from the reaction, an 
incorporation of 68% was achieved for the anti-sense riboprobe, and 72% for 
the sense riboprobe.
The in situ hybridisation technique was initially worked up using adult 
male rat brain (9 weeks) which had been previously frozen, sectioned and 
m ounted onto poly-L-lysine coated microscope slides to hybridise the cRNA 
riboprobes to CS-lyase/GTK/KAT m RNA in the rat brain sections (section
2.2.5.). After exposure of the sections to p-max hyperfilm for seven days, the 
hyperfilm was developed and regional quantitation assessed by film  
autoradiography.
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Figure 5.2. Photograph of 1.2% agarose/EtBr gel of purified digested pTA243.
Lane 1 Ikb DNA ladder
Lane 2 purified Sal I-digested pTA243
Lane 3 purified Nco I-digested pTA243
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Figure 5.3. Photograph of 1.5% agarose/EtBr gel of cRNA riboprobe 
transcriptions.
Lane 1 Ikb DNA ladder
Lane 2 SP6 RNA polym erase positive control transcrip tion
Lane 3 T7 RNA polym erase positive control transcrip tion  
Lane 4 transcrip tion  from  N co  I-digested pTA243 using SP6 RN A
polym erase
Lane 5 transcrip tion  from Sal I-digested pTA243 using T7 RN A
polym erase 
Lane 6 Ikb DNA ladder
179
5.3. DISCUSSION
Several problems were experienced w ith this technique, which resulted in 
no films being suitable for analysis. Initial complications were faced at the 
first stage, being the transcription of cRNA riboprobes, where there was 
difficulty in obtaining a cRNA riboprobe w ith a sufficiently high percent 
incorporation of radiolabel into the riboprobe. This was repeatedly 
experienced w ith the transcription of the anti-sense probe, whilst the sense 
riboprobe consistently yielded satisfactory incorporations of above 70%.
In order to determ ine if the problems encountered w ith the transcriptions 
were due to the template DNA, new glycerol stocks were prepared from the 
original stock of pTA243. Having used the new pTA243 stock for restriction 
digests and subsequent transcriptions, the same result was observed w here 
the anti-sense riboprobe did not yield a satisfactory incorporation of f^S]- 
UTPaS.
Since the transcriptions including only non-radiolabelled nucleotides had 
been successful (Figure 5.3.), it was highly likely that the radiolabelled 
UTPaS was interfering in the transcription. The possibility that the 
problems encountered were due to the first step of the synthesis of the anti­
sense riboprobe being the addition of p^S]-UTPaS was elim inated by 
checking back over the sequence which had previously been inserted in to  
the pGEM®-T vector itself (i.e. from nucleotides 181-424 of the rat renal
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The data showed no significant difference in binding between the positive 
and negative strand probes. This indicated that the occasional patchy 
binding observed was non-specific and did not represent differential 
expression of CS-lyase mRNA.
cytosolic CS-lyase/GTK/KAT cDNA sequence (Perry et al., 1993)) and this 
was confirmed not to be the case.
The quantity of P^S]-labelled UTPaS included in the transcriptions and the 
ratio of this to the non-radiolabelled ribonucleotides was then considered. 
Having increased the quantity of pS]-labelled UTPaS in the transcription to 
SOjxCi, an anti-sense cRNA riboprobe was transcribed w ith 68% 
incorporation.
Using the anti-sense riboprobe (68% incorporation of pS]-labelled UTPaS) 
and the sense riboprobe (72% incorporation of P^S]-labelled UTPaS) the in 
situ hybridisation steps were performed according to the protocol (section
2.2.5.). However, CS-lyase/GTK/KAT mRNA on the autoradiograms could 
not be quantified due to insufficient specific binding of riboprobe to the 
brain sections and surrounding microscope slide (Figure 5.4a.). A 
representative image from a successful in situ  hybridisation for CS- 
lyase/GTK/KAT mRNA in adult rat brain is show n (Figure 5.4b.) for 
comparison and to illustrate the results which can be achieved w ith this 
technique (Dr N. Plant, personal communication). As uneven  areas were 
observed on both the sections and the microscope slides, despite the strict 
washing procedures in the post-hybridisation steps, a problem w ith the 
hybridisation buffer was considered. Following preparation of fresh 
solutions used in each step of the in situ  hybridisation procedure, the 
problem persisted.
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Future attempts to determ ine the effect of horm ones on CS- 
lyase/ GTK/KAT mRNA levels during post-natal developm ent, using in 
situ hybridisation, could involve the use of a different restriction 
endonuclease for linearisation of the pTA243 DNA template, to rule out the 
possibility of problems transcribing a particular ribonucleotide at the 
beginning of the transcription. Failing this, the template could be prepared 
again by repeating the cloning of the 243bp sequence into the pGEM®-T 
vector. A lthough tim e-consum ing, this may prevent any future difficulties 
w ith this initial stage of the technique.
Tam burin et al (1999) successfully localised KAT I m RNA in  rat brain using 
the in situ hybridisation technique and reported it to be present at high 
levels in the hippocampus, piriform  cortex and the choroid plexus. The 
riboprobes used were 596 nucleotides in length, over double the length of 
the riboprobes used in this study. This may be a further factor to consider in 
the localisation of CS-lyase/GTK/KAT mRNA in the future.
This work did not yield any conclusions regarding the m odulation  of CS- 
lyase/GTK/KAT levels during post-natal developm ent and following 
horm onal treatment. However, future study in this area would broaden 
knowledge of the regulation of CS-lyase/GTK/KAT, and help to understand 
the molecular basis of the action of the enzyme giving the potential for the 
developm ent of therapeutics against the neurotoxicity and 
neurodegeneration linked to its activity.
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Image a. Autoradiographic image of unsuccessful in situ 
hybridisation. The image shows regions of non-specific 
binding of p^S]-UTPaS-labelled cRNA riboprobe.
Image b. Autoradiographic image of successful in situ 
hybridisation showing regions of specific binding of p^S]- 
UTPaS-labelled cRNA riboprobe to CS-lyase/GTK/KAT 
mRNA (Dr N Plant, personal communication).
Figure 5.4. Autoradiographic images of CS-lyase/GTK/KAT mRNA in male rat 
brain (9 weeks) following in situ hybridisation with [^^S]-radiolabelled UTPaS 
riboprobe.
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CHAPTER 6 
GENERAL DISCUSSION
6.1. DISCUSSION
The sex- and age-related differences in the activity of CS-lyase/GTK/KAT, 
previously reported (Beal et al., 1992; Ceresoli et al., 1996; Ceresoli et al., 1997; 
Gramsbergen et al., 1992; Hook et al., 1983; Hook et al., 1982), have strongly 
suggested that this enzyme m ight be regulated by sex horm ones and 
glucocorticoids. The general objective of this research was to determ ine 
w hether CS-lyase/GTK/KAT expression was indeed horm onally regulated 
and further to establish the m olecular basis of the m odulation.
The GTK specific activity assays have show n that progesterone, 
dexamethasone (synthetic glucocorticoid) and corticosterone (endogenous 
glucocorticoid) are all capable of increasing the activity of this enzyme in  
male rat brain and kidney (Chapter 3). However, this m odulation  was 
observed only at certain post-natal ages, in kidney and brain. The pattern of 
induction, at the post-natal ages studied, was similar following progesterone 
and dexamethasone treatm ent, where induction was restricted to post-natal 
days 21, including days 23 and 25 for the progesterone-treated rat brain. 
However, w ith corticosterone treatm ent, induction of CS-lyase/GTK/KAT 
activity was observed at all ages. These results support the w ork of Plant et 
al (1997) who proposed that CS-lyase/GTK/KAT expression is m odulated 
during post-natal development, following in situ hybridisation studies to
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localise the mRNA in rat brain. The enzyme assay data obtained shows that 
the susceptibility of GTK to m odulation by horm ones is restricted to 
particular post-natal days, suggesting that there is a w indow where the 
enzyme is open to m odulation by sex horm ones and glucocorticoids.
The precise control of gene expression by horm ones plays a pertinent role 
during developm ent in the rat. Levels of GTK activity have been 
demonstrated to follow distinct patterns in chick brain prior to hatching 
(Makar et al., 1994). The activity was reported to be relatively high at 
gestation day 5, decreased between gestation days 15 to 17 and then  
dramatically increased at day 23 (day of hatching), illustrating the 
susceptibility of GTK to m odulation during pre-natal developm ent.
Also, in the pre-natal rat, tyrosine am inotransferase (TAT) activity has been 
reported to be 10- to 15-fold lower than in adult rat liver, a developm ental 
change which has been linked to the responsiveness of this enzyme to 
glucocorticoids in the m ature anim al (Perry et al., 1983). Later studies on the 
effect of dexamethasone on TAT expression in foetal rat hepatocytes in vitro  
have supported this (Shelly et al., 1989). Using hepatocyte cultures derived 
from gestation day 15 rats. Shelly et al (1989) showed that dexam ethasone 
treatm ent increased TAT activity by the third day in  culture, where the 
activity was not detected on the first day. In gestation day 19 hepatocytes, 
activity was observed at both days 1 and 3 in culture. However, in the 
younger, day 13 hepatocytes, expression of TAT was only detected at barely 
m inim al levels even by the third day in culture. Following sim ultaneous
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treatm ent w ith dexamethasone and cAMP, the induction observed at 
gestation days 15 and 19 was further enhanced, and expression was detected 
by day 3 of culture of gestation day 13 hepatocytes (Shelly & Yeoh, 1991). 
This provides evidence to suggest that glucocorticoids can induce the 
expression of the aminotransferase TAT at specific periods of developm ent 
in rat liver in vitro. This indicates that glucocorticoids may induce the 
expression of other aminotransferases, which is supported by the findings of 
this study where dexamethasone and corticosterone induce activity in rat 
kidney and brain tissue.
It is widely understood that horm ones exert their physiological effects via 
horm one receptors, of which m any have been cloned and expressed in vitro  
(reviewed in Sladek & Giguere, 2000). The ability of horm ones to influence 
gene expression is m ediated through the presence of horm one receptor 
response elements (REs) located in the upstream  regulatory regions of m any 
genes for enzymes involved in xenobiotic metabolism. Generally, 
glucocorticoid and mineralocorticoid receptors are translocated to the 
nucleus, following the binding of the horm onal ligand (Lombes et al., 1994) 
and bind as heterodim ers to the palindrom ic RE. Nuclear horm one 
receptor regulation, specifically induction, of the cytochrome P450 genes is 
well documented (Honkakoski & Negishi, 2000). This glucocorticoid 
induction has been reported to be involved in the regulation of GYP 3A23 in  
rat hepatocytes (Huss & Kasper, 2000).
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The genomewalking experiments in rat genomic DNA did not show any 
regulatory sequence motifs, however, potential TATA and CAAT boxes 
were identified (Chapter 4). Therefore, the regulatory elem ents in  the 
prom oter region from the CS-lyase/GTK/KAT m ust be located further 
upstream  from the sequence obtained in this study. This is not unusual as 
horm one REs have been located as far a 8kb upstream  from the 
transcription start site for the GYP 3A4 gene (Goodwin et aL, 1999). Towards 
the end of this research, the sequence of the hum an  genome was published 
by the International H um an Genome Sequencing Consortium  (2001). The 
prom oter region from the hum an  CS-lyase/GTK/KAT gene was found to 
possess an oestrogen RE, indicating that this horm one m ight m odulate 
expression of the hum an  enzyme. In this rat study, p-oestradiol failed to 
induce the enzyme activity in post-natal day 21 male rat brain and kidney. It 
would appear that the m odulation in the rat, observed in this research, may 
be governed by different factors to the potential role of P-oestradiol in  
m odulation of the hum an  enzyme, suggested by the prom oter sequence 
(International H um an Genome Sequencing Consortium, 2001). This is 
feasible since the prom oter regions can differ remarkably, despite sharing 
82% identity between species at the am ino acid level (Perry et al., 1995). 
A lthough similarities may be present in these am ino acid sequences, the 
am ino acids which differ m ight introduce subtle conform ation changes in  
the secondary and tertiary protein structures, which could influence the 
factors regulating activity of the enzyme. Also, P-oestradiol was only tested 
in this study on post-natal day 21 male rats and, due to the differential
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developm ental m odulation discussed above, it can not be ruled out that this 
horm one may m odulate CS-lyase/GTK/KAT in the rat.
Since the experiments in this study involved in v ivo  horm one treatments, 
rather than in vitro  cultures, it is possible that additional factors affect the 
expression of CS-lyase/GTK/KAT. In hum ans, it has been reported that GR 
can induce levels of PXR mRNA in addition to up-regulation of CYP 3A 
expression (see Honkakoski & Negishi, 2000). It has not been ruled out that 
this may also occur in rat kidney and brain following horm onal induction 
of CS-lyase/GTK/KAT expression.
Due to the failure of the in situ hybridisation work in  this study, no 
autoradiographic images were available for analysis, and so no conclusion 
could be drawn as to the effects of post-natal developm ent and the sex and 
glucocorticoid horm ones on the expression of CS-lyase/GTK/KAT. 
However, the region-specific induction of RGS4 mRNA (Regulator of G- 
Protein-Signaling Protein Type 4) has been reported in the brain using in 
situ  hybridisation following corticosterone treatm ent (Ni et al., 1999) 
showing the capability of this technique to detect changes in the m RN A  
level in specific brain regions following even subtle induction by 
corticosterone. Also, the recent work of Tam burin et al (1999) has clearly 
localised KAT I mRNA in rat brain. Since the riboprobe tem plate used was 
596 nucleotides in length, compared to 243 bp in this study, this m ight also 
be a point to consider in relation to the problems encountered w ith  n o n ­
specific binding.
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6.2. FUTURE WORK
The conclusions draw n from this study have given an insight into the 
factors which m ight influence CS-lyase/GTK/KAT gene expression in the 
young rat. Both corticosterone and progesterone have been reported to 
m odulate CS-lyase/GTK/KAT activity in  male rat brain and kidney, but 
how  do these horm ones affect expression in the female? A lthough adult 
males have been show n to be less responsive to HCBD treatm ent than  the 
younger males (Lock et al., 1984), nephrotoxicity has been observed in the 
adult female rat (Hook et al., 1983; Hook et al., 1982). Therefore, it is possible 
that these horm ones could also affect activity of CS-lyase/GTK/KAT in the 
m ature female. Certainly, in the m ature female where there are differences 
in the levels of endogenous sex horm ones compared to the younger anim al, 
it is conceivable that a different enzyme activity response to exogenous 
progesterone would be observed.
In addition, the enzyme assays perform ed in this research used whole brain 
hom ogenate or whole kidney cytosol, such that any m odulation  of CS- 
lyase/GTK/KAT activity in individual brain or kidney regions could not be 
identified. By employing micro-dissection techniques, the effects of 
progesterone and corticosterone on CS-lyase/GTK/KAT activity could be 
assessed in individual regions. M odulation of enzyme activity m ight then  
be observed at post-natal days where previously no effect was apparent. 
Indeed, it is a distinct possibility that the horm ones examined in this w ork 
which failed to induce CS-lyase/GTK/KAT activity, such as testosterone and 
(5-estradiol, may actually affect individual areas of brain and kidney w hich
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were no t detected w hen  the w hole organ was used. H ow ever, for a fully 
quan tita tive technique, in s i tu  hybridisation should  be persevered w ith.
The patterns of responsiveness of CS-lyase/GTK/KAT to progesterone and 
corticosterone reported in  th is thesis cannot be fully confirm ed w ith o u t a 
determ ina tion  of the levels of progesterone and glucocorticoid receptors in  
rat brain  during  post-natal developm ent, and the effect of these h o rm o n es  
on  these levels. It has already been stated tha t the levels of GR in  the post­
natal rat brain  are low  (Rosenfeld et al., 1998) which, taking in to  account the 
findings of th is study, w ould  u ltim ately  affect the m o d u la tio n  of CS- 
lyase/G TK/KAT. A n im m unocytochem istry  technique using  an antibody 
specific for PR or GR w ould  allow  the detection of in tracellu lar h o rm o n e  
receptor in  tissue sections to indicate the levels of receptor p ro te in  p resen t 
in  in d iv id u al brain  and  kidney regions. This technique has been em ployed 
for the localisation of ER (N um an  et al., 1999).
A lternatively, cRNA riboprobes specific for the in tracellu lar PR or GR 
w ould  allow the levels of receptor m R N A  to be quantitated  by in s i tu  
hybridisation, as an indication  of levels of receptor p ro te in  presen t in  
in d iv id u a l brain  and kidney regions. Indeed, the localisation of 
in tracellu lar GR and MR in  the b rain  of m aternally  deprived  young rats has 
been reported (Vazquez et al., 1996). M ore complex studies could include 
locating PXR in  these tissues also. A com parison could th en  be m ade 
betw een the enzym e activity in  separate brain  and kidney regions w ith  
levels of receptor in  those regions.
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Since the sequencing of the h u m an  genom e this year, and the isolation of 
the upstream  regulatory region from  the CS-lyase/GTK/KAT gene, the area 
of ho rm onal regu lation  of the h u m an  enzym e has been enlightened. The 
identification of an oestrogen RE in  the p rom oter region suggests tha t 
oestrogen m ay influence expression of the enzym e in  hum ans. A lthough  
the h u m an  and ra t enzym es are 82% hom ologous at the p ro te in  level (Perry 
et ah, 1995), the expression of CS-lyase/GTK/KAT in  the ra t could be 
governed by very different factors. Using the sequence isolated in  this study 
(section 4.4.), a new  nested pair of prim ers could be designed against his 
sequence to assist in  genom ew alking fu rther in to  the  upstream  regulatory 
region from  the rat CS-lyase/GTK/KAT gene. This could allow h o rm o n e  
REs to be identified in  this p rom oter region shedding fu rther light onto  the 
regu lation  of this tri-functional enzym e.
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